Volume 29, issue 2 by Canadian Medical Association
Western University
Scholarship@Western
Canadian Journal of Surgery
3-1-1986
Volume 29, issue 2
Canadian Medical Association
Follow this and additional works at: https://ir.lib.uwo.ca/cjs
Part of the Surgery Commons
This Book is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Canadian Journal of Surgery by an
authorized administrator of Scholarship@Western. For more information, please contact tadam@uwo.ca, wlswadmin@uwo.ca.
Recommended Citation
Canadian Medical Association, "Volume 29, issue 2" (1986). Canadian Journal of Surgery. 172.
https://ir.lib.uwo.ca/cjs/172

why Coated vicryl* 
(polyglactin 910) suture 
is selected more than 
any other synthetic absorbable
For one thing, Coated VICRYL suture has a coating 
that's actually impregnated into the suture. It stands 
up to the wet environment of surgery better than 
soluble coatings.
And Coated VICRYL suture has many other 
important properties: Smooth passage through tis­
sue, ease of handling, knot security, and the ability 
to adjust knot tension for precise placement.
That is why you, our customers, have decided that 
Coated VICRYL suture is the best. After all, who 
knows better than you?
Coated vicryl Suture
E T H  I C O N  L T D .
Trodemork
a company
PETERBOROUGH, ONTARIO K9J 7B9
VOLUME 29, NUMBER 2 MARCH 1986 MARS
ISSN 0008-428XLe 
journal 
canadien
de chirurgie
LIST OF CONTENTS
QUILL ON SCALPEL
Gastric Cancer: Seeking the Chance to Cure
M.M. Cohen
77
A Tale of Two Women: the Concept of Good and Bad Disease in Breast Cancer
P.J. Fitzpatrick
78
CORRESPONDENCE
Acalcuious Cholecystitis in Burned Patients
M.J. Girotti; C.H. Scudamore
81
The Death of G.B.S.
B. Plewes; C. Sorbie
82
Radiation Exposure to the Surgeon During Ender’s Nailing
J.P. Moreau, J.P. Ashmore
82
Splenic Abscess — Percutaneous Drainage
V.K. Kapoor
82
SURGEONS’ UPDATE
Liability Insurance: the Costs; Malawi Orthopedic Project Seeks Volunteers
A. Chouinard
85
ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA
Transluminal Angioplasty: Indications and Overview
T.K. Scobie
90
Cardiac Mortality and Morbidity After Vascular Surgery 93
J.E. Calvin, T.M. Kieser, V.M. Walley, N.V. McPhail, G.G. Barber, T.K. Scobie
VOLUME 29, NO. 2, M ARCH  1986 / THE CANADIAN JOURNAL OF SURGERY 73
Strike First 
w ith
Bactrim ’ I.V.
Proven empiric therapy in moderate and severe 
infections
□  in penicillin/cephalosporin sensitive patients
□  in patients at risk of aminoglycoside nephrotoxicity
“ ...TMP-SMX would appear to be an exceptional 
drug combination for treatment of infections 
caused by most enteric Gram-negative bacilli, 
many clinically important Gram-positive 
bacteria, and certain intracellular organisms.” 1
□  Can achieve high serum and tissue levels1
□  Proven efficacy in many problem nosocomial 
infections2'34
□  Established safety profile with few serious side 
effects15'6
□  Up to 12-hour dosing interval
□  Available in parenteral and oral forms
Bactrim™ Rochei
(trimethoprim plus sulfamethoxazole)
Solution for Infusion
Original Research in Medicine and Chemistry
For prescribing information see page 101
LIST O F  C O N T E N T S  C o n t ’d
O R IG IN A L  A R TIC LE S
S e n s it iv ity  o f th e  H e m o c c u lt  II S lid e  T e s t  in D e te c t in g  C o lo n ic  N e o p la s m s
M .H. Poleski, P.H. G ordon
9 9
C h o n d ro m a la c ia  o f th e  F a b e lla : a  C a s e  R e p o rt
P. Legendre, J .V . Fow les, C. G od in
1 0 2
P o s te r io r  S te rn o c la v ic u la r  D is lo c a t io n s
R.K. Le igh ton , A .J . Buhr, A .M . S in c la ir
1 0 4
N o n tra u m a tic  S p o n ta n e o u s  R u p tu re  o f th e  U rin a ry  B la d d e r
A. Shaked, S. M eretyk, D. Pode, M. C aine
1 0 7
A n e u ry s m a l B o n e  C ys t: a  R e v ie w  o f  2 6  C a s e s
K.S. M orton
1 1 0
T e tra c y c lin e  In s tilla t io n  fo r  R e c u rre n t  C y s tic  T h y ro id  N o d u le s
J.P . DeYoung, A. Kahn, S. Le rm an , A.S. F erenczy
1 1 8
W h ite  C lo t S y n d ro m e : a R a re  C o m p lic a tio n  o f H e p a rin  T h e ra p y
J.R . Tanner, A .R . Downs
1 2 2
C h ro n ic  Ile a l O b s tru c t io n  in A d u lts  D u e  to  P e r i- i le a l V ite l lin e  V a s c u la r  R e m n a n ts
M .M. S ilver, T.A. Jory, J.C . W a lton , D .M . M ills
1 2 5
E ffe c ts  o f C o d -L iv e r  O il o n  In tim a l H y p e rp la s ia  in  V e in  G ra fts  U s e d  fo r  A rte r ia l B y p a s s
R.W . Landym ore, M .A. M acA u lay, J.H . C ooper, B.L. S heridan
1 2 9
R ig h t H e m o th o ra x : an  U n u s u a l P re s e n ta tio n  o f R u p tu re d  In fra re n a l A b d o m in a l A o r t ic  A n e u ry s m
P.G. Karam , R.J. N ovick, L.T . G lickm an , P.E. B lunde ll
1 3 3
C o n tr ib u tio n  o f Im m u n o h is to c h e m is try  to  th e  D ia g n o s is  o f B re a s t C a n c e r  in M e n
D.C. Aziz, C. M ilne, S. S o lom on , S.P. Jo thy
1 3 5
B o o k s  R e c e iv e d 8 6
S E S A P  IV  Q u e s tio n 9 2
N o tic e s 101
S E S A P  IV  C ritiq u e 1 0 6
B o o k  R e v ie w s 1 3 7
C la s s ifie d  A d v e rt is in g 1 3 9
A d v e r t is e rs ’ In d e x 1 4 0
VOLUME 29, NO. 2, M ARCH  1986 / THE CANADIAN JOURNAL OF SURGERY 75
m.
Power Plus generator
Incomparable safety
performance
precision
versatility
reliability
The powerful force in electrosurgery
Bard Canada Inc.
2345 Stanfield Road, Mississauga, Ontario L4Y 3Y3 
Telephone (416) 275-8000
/*$ " a
V
%
k
QUILL ON SCALPEL
This section provides a medium through which Canadian 
surgeons can declare themselves, briefly and informally, on 
the day-to-day affairs of surgery.
Gastric Cancer: Seeking the 
Chance to Cure
The diagnosis of cancer of the stomach 
generally causes despair in the heart of the 
victim and despondency and a sense of 
futility in the mind of the physician. Few 
cancers are viewed with such overriding 
gloom. The reasons for this endemic pes­
simism are clear: 30% of patients are not 
even surgically explored; in only one third 
will a curative resection be feasible, and 
even for this less-unfortunate minority the 
5-year survival is, at best, only 30%. 
These depressing figures are made even 
more discouraging by the widely held opi­
nion that none of our efforts over the past 
few decades has made the slightest 
impression on the ultimate outcome.
Cady and associates,1 describing the 
Lahey Clinic experience with 403 patients 
seen during the period 1957 through 1966, 
reported that although 44% had a cura­
tive resection, only 24% of this group sur­
vived 5 years, and of these long-term sur­
vivors about 25% died of disease in the
ensuing 10 years. They concluded that no 
progress in the surgical management of 
this disease had been made since 1950 
despite a generally aggressive surgical 
approach. They recommended more con­
servative management of focal gastric 
cancer, rejected routine total gastrectomy 
and advised that subtotal gastrectomy be 
performed taking “ a modest amount of 
surrounding omentum and whatever 
adjacent tissue is required to encompass 
gross tumour” . More recently, Diehl and 
colleagues2 reported on 164 patients seen 
during the period 1970 to 1980 at the 
Cleveland Clinic. Except for a reduction 
in operative mortality (from 10.3% to 
4%), there was no change in overall prog­
nosis compared with that achieved at the 
same institution during the period from 
1950 to 1972. They therefore “ do not 
recommend radical resections for small 
favorable cancers” . The very large series 
of 1024 cases seen in Montreal between
1941 and 1983 reported by Moore (Can 
J  Surg 1986; 29: 25-28) provides a strik­
ingly similar picture: 81% of patients 
underwent laparotomy, but only 24% of 
the 1024 patients underwent curative 
resection; of these, 34% survived 5 years 
and only 21% survived 10 years. Despite 
a substantial increase in overall resecta­
bility (from 47% in the first decade to 
65% in the third decade) there was no 
change in the survival rate. Moore con­
cluded that possible improvement will 
come only from other treatment modal­
ities.
Are we condemned to rely on improve­
ments in radiotherapy and chemotherapy 
(neither notably effective in gastric 
cancer) for future advances? The future 
may not be quite so bleak as it appears. 
There are two glimmers of hope. The first 
relates to etiology and the second to diag­
nosis. Moore reported a decline in the 
number of cases seen at the Royal Vic-
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toria Hospital during the study period. 
While this may, in part, be explained by 
a change in referral pattern, it also reflects 
a real decline in the incidence of gastric 
cancer on this continent. This is in con­
trast to areas of high prevalence (e.g., in 
Japan, where cancer of the stomach is the 
cause of almost half of all cancer deaths) 
where the incidence remains quite 
steady.3 Other changes are occurring 
too. There is a relatively greater reduc­
tion in antral cancers (especially in men) 
compared with proximal tumours, the age 
at diagnosis has increased and, perhaps 
most interestingly, there appears to be a 
substantial increase in the number of 
signet-ring carcinomas.4 These changes 
may provide important clues to the etiol­
ogy of gastric cancer and certainly merit 
closer study.
Second, why are the Japanese able to 
report5 that early gastric cancer 
represents about one third of their cases 
and that the 5-year survival rate is greater 
than 90%. It is unlikely that early gastric 
cancer is different in Japan. Those few 
cases that are recognized in North 
America (5% of all cases) appear to be 
indistinguishable in terms of histologic 
characteristics, growth patterns, co­
existent lesions in the stomach and cura­
bility by surgical resection6 from those 
reported by the Japanese. The explana­
tion for the discrepancy clearly lies in 
earlier diagnosis.
Perhaps we cannot hope to find gas­
tric cancer as early as Japanese physicians 
do. In a society in which gastric cancer
is substantially less common and is also 
on the decline, it would not be cost- 
effective to mount mass endoscopic 
screening programs. But there seems lit­
tle doubt that earlier and more ready 
recourse to endoscopy in symptomatic 
patients would identify many more cases 
of early gastric cancer. The accuracy of 
endoscopy has improved greatly. Moore 
reported only 76% accuracy in the 
30-years ending in 1970, but current tech­
niques would yield a tissue diagnosis in 
more than 95% of patients.7 This means 
that we have an obligation to identify 
high-risk patients and to investigate them 
aggressively for even minor gastric symp­
toms. Such patients include those with 
atrophic gastritis, pernicious anemia and 
hypergastrinemia from any cause. If gas­
tric polyps are found they should be 
removed and regular surveillance estab­
lished. The finding of intestinal metapla­
sia or severe dysplasia also merits care­
ful observation and regular reassess­
ment.8 It is doubtful if the suggested 
regular endoscopie examination of all 
patients following gastric surgery for 
benign disease would be cost-effective. 
What is desperately needed is a reliable 
serologic tumour marker.
As long as we continue to see gastric 
cancer at a stage when only 30% of 
patients can undergo resection for cure, 
arguments about the best operation are 
senseless. But if we can learn to detect 
gastric cancer early — and a group at 
McMaster University has shown that we 
can do much better9 — then as surgeons
we can return to the challenging question 
of what is the most effective curative 
operation.
M a x  M . Co h e n , m b , frcs(ed in ), frcsc
Member,
Editorial Board
Professor of Surgery,
University o f Toronto,
Toronto, Ont.
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A Tale of Two Women: the Concept 
of Good and Bad Disease in Breast Cancer
To know the natural progress o f disease is to 
know more than half of medicine.
Armand Trousseau
The treatment of breast cancer remains 
one of today’s greatest medical controver­
sies, and clinicians are in a state of great 
uncertainty about proper treatment. If 
cancer statistics are to be improved then 
the riddle of breast cancer must be solved. 
The disease has a thousand different 
faces, and no two patients suffer in 
exactly the same way. How do we sort out 
the different kinds of cancer and assess 
our results? It is insufficient to measure 
the quantity of life using 5 or 10-year 
yardsticks. The quality of life is equally 
important, but it is difficult to measure 
and is rarely reported.
The medical literature contains more 
reports on breast cancer than on any 
other tumour. Imhotep wrote the first 
treatise on breast cancer in 3000 BC. In 
the last 5 years there have been 13 662 
publications on breast cancer, with 5175 
discussing treatment and 2197 experimen­
tal approaches. Overall, they have done 
little to help the clinician in deciding how 
to investigate and treat his next new 
patient. Many reports relate to what hap­
pened to patients in a clinical trial, but 
provide little guidance as to whether the 
findings can be extrapolated to practice.
Over the years I have participated in 
both retrospective studies and prospective 
randomized controlled clinical trials.1'3 
Twenty years ago, I knew, or thought that
I knew, how to manage the disease. There 
have been many changes and advances in 
investigation and treatment, but I am now 
at a greater loss than ever to define 
optimal care in the many different phases 
of the illness. Improved survival rates are 
reported with more conservative local 
treatment and aggressive adjuvant ther­
apies.2'4,5 A patient’s problems, how­
ever, and what can be done to alleviate 
them, have not changed. Where should 
I put my efforts in the next decade? What 
constitutes optimal cost-effective investi­
gation and treatment? What about clini­
cal trials? What research should I do?
A recent mini-sabbatical gave me the 
opportunity to shift my mental gears and 
to review my own frontline oncologic
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practice. Experienced clinicians have 
always known that they can learn more 
about life and death from their patients 
than from any book or lecture. Glancing 
through old notes, I became aware of the 
importance of the natural history of the 
disease. It was exemplified by tjie histo­
ries of two women. Survival, whatever the 
treatment, was clearly related to the 
tumour’s degree of malignancy, or 
growth rate. From my records I rediscov­
ered the concept of “ good” and “ bad” 
breast cancer (not that there is such a 
thing as good cancer). Bad tumours are 
highly malignant and metastasize early; 
all treatments fail and the patient dies 
usually within a few months. Good 
tumours are of low-grade malignancy and 
metastasize only months or years after 
their initiation. The disease follows a 
chronic course during which the patient 
lives a relatively normal life with little or 
no treatment.
The first patient, with bad breast 
cancer, was a 28-year-old nurse who had 
had a complete physical examination just 
2 months earlier. She found a large lump 
in her left breast while bathing, and 
immediately sought medical advice. A 
mass- measuring 8 cm was present in an 
inflamed breast with peau d ’orange skin. 
The axillary nodes were not palpable and 
distant metastases were not detected. Fol­
lowing a course of irradiation to the 
breast and regional nodes, the tumour 
resolved. Widespread bone metastases 
developed, however, and she died within 
5 months of her first symptom. The 
second woman, illustrating good breast 
cancer, was 37 years old when she noticed 
a thickening in her left breast. A partial
mastectomy was performed, but 8 months 
later the tumour recurred at the primary 
site and was treated with a radium 
implant. For the next 32 years the patient 
was lost to follow-up. Then, she came 
back complaining of “ spots on the chest” 
and backache (Fig. 1). The chest wall 
showed recurrent nodules and roentgeno­
grams revealed widespread osteolytic and 
osteoblastic bone metastases. Palliative 
irradiation and hormones were given, but 
she died 2 years later aged 72 years, 35 
years after diagnosis. Both women died 
of breast cancer, but one lived with the 
cancer and without symptoms for half of 
her life.
The influence of treatment on survival 
can only be truly assessed in the light of the 
natural history of breast cancer.6 When 
did the cancer really start and is it “good” 
or “ bad” ? Since survival is intimately 
related to the degree of malignancy or 
growth rate, the length of history, the 
clinical stage and especially the status of 
the axillary lymph nodes, and the 
presence or absence of estrogen and 
progesterone receptors provide the best 
clues to its malignant potential. Estimates 
of tumour growth from serial measure­
ments of cutaneous nodules and pulmo­
nary metastasis suggest that fast-growing 
tumours double within 90 days, but slow- 
growing ones take more than 450 days. 4-7 
Such tumours might have originated from 
a single cell 8 and 42 years before diag­
nosis. An average tumour would appear 
to have a doubling time of 100 days, and 
so when the tumour is 1 cm in diameter 
and barely palpable it would contain 109 
cells and have been present for 10 years.4 
My two patients had very different 
tumours (Fig. 2). It seems reasonable to 
assume that the woman with bad breast 
cancer had a very short preclinical phase 
with metastases seeded almost immedi­
ately. In the other woman with good 
breast cancer, the tumour probably 
started some 15 years earlier, with
GOOD DISEASE BAD
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FIG. 1—Local recurrence in 70-year-old FIG. 2—Chronologic course of breast cancer 
woman 33 years after primary treatment. Dis- in two women, one with “ good” , the other
tant metastases were also present. with “ bad” disease.
metastases developing 6 years before diag­
nosis. Alternatively, the metastases may 
have been seeded 20 to 30 years after 
treatment or at the time of the local recur­
rence. But what factors controlled the 
tumour for so many years, and what 
other factors upset the balance and 
unleashed overt disease?
Breast cancer is a biologically predeter­
mined disease. Its characterization is 
essential in order to determine optimal 
treatment. The growth rate and metastatic 
potential vary enormously and depend on 
numerous tumour-host variables. About 
one third of patients, those who live 
longer than 5 years, could be considered 
to have good breast cancer. The spectrum 
of disease makes it difficult to assess 
treatment, and as any stratification will 
contain good and bad tumours a bias one 
way or another could account for the 
differences in the reports of clinical trials. 
Current research on treatment is being 
directed along biologic concepts rather 
than anatomic or mechanistic ones, which 
formed the basis for radical mastectomy 
and other aggressive treatment.5
Toronto can be proud of the major role 
that it has played in the now gold- 
standard treatment for stage I and II 
breast cancer, segmental mastectomy fol­
lowed by breast irradiation .1-2 This 
philosophy was developed from clinical 
observation and careful retrospective 
studies and, as already stated, the 
experienced clinician knows that his 
patients teach him more than he can learn 
from any other source.
P.J. Fitzpatrick, mb, bs, frcpc, frcr
Professor of Radiology (Oncology),
The Princess Margaret Hospital,
University of Toronto,
500 Sherbourne St.,
Toronto, Ont.
M4X 1K9
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Acalculous Cholecystitis 
in Burned Patients
To the editors.—The recent report by 
M.W. McDermott and colleagues (Can J 
Surg 1985; 28: 529-533) on the occurrence 
of acute acalculous cholecystitis in burned 
patients prompts me to make several com­
ments regarding this insidious and poten­
tially lethal condition in critically ill 
patients with no gastrointestinal disease.
Acalculous cholecystitis is common to 
all patients receiving intensive care regard­
less of the admitting diagnosis. Invaria­
bly, in my experience and that of 
others,' these patients have a number of 
factors in common. They are: prolonged 
narcotic requirements, mechanical venti­
lation, recent surgery, multiple blood 
transfusions, a source of sepsis remote 
from the gallbladder and hyperalimenta­
tion. Certainly these factors were present 
in all the patients described by 
McDermott.
The diagnosis of acalculous cholecysti­
tis is not as straightforward as McDer­
mott and colleagues suggest. I disagree 
with their summary, regarding diagnosis. 
This is a slowly progressive disease with 
abdominal findings that are nonspecific 
and invariably misleading. These critically 
ill patients often have local injuries (such 
as a burn), have been given narcotics 
intravenously, have incisions, have 
enlarged livers due to intravenous alimen­
tation and have altered mentation secon­
dary to sepsis, all of which make the 
interpretation of any finding almost 
impossible.
The biochemical picture is similarly 
confusing, especially in the patient with 
sepsis receiving intravenous hyperalimen­
tation. Radiologic investigations provide 
the only reliable method of making the 
diagnosis. In critically ill patients, bedside 
ultrasonography should be the initial 
investigation. If an abnormality is found 
(transverse diameter of the gallbladder 
greater than 5 cm, wall thickness greater 
than 4 mm, presence of sludge or stones, 
or air in the gallbladder wall),2 then 
there are several options for either treat­
ment or further investigation. Stones or 
emphysematous findings within the gall­
bladder wall require surgical therapy. The 
remaining nonspecific ultrasonographic 
findings common to patients with acal­
culous cholecystitis are consistent with 
either a diagnosis of acalculous chole­
cystitis or the fasting state. Hydroxydia- 
minoacetic acid (HIDA) or paraisopropy- 
liminodiacetic acid (PIPIDA) scanning 
should then be performed. If positive (no 
gallbladder visible in 2 hours) then surgi­
cal intervention is again required. I recog­
nize that the patient must be moved to the 
nuclear medicine department for this 
procedure, but this can be done safely if 
certain physical and staff requirements 
are met.3 The morbidity and mortality 
associated with this trip out of the inten­
sive care unit are far less than those of 
an unwarranted surgical exploration of 
the right upper quadrant either under 
local or general anesthesia. In some cases 
the radioisotope for these scans can be 
injected into the patient in the intensive 
care unit and the patient transported some 
time later.
Acalculous cholecystitis is lethal if left 
untreated. Acute awareness of the con­
dition and appropriate investigations are 
needed for early diagnosis and manage­
ment. I agree with the suggestions made 
by McDermott and colleagues regarding 
the surgical therapy.
Murray J. Girotti, md, frcsc
Co-director,
Surgical Intensive Care Unit,
Toronto General Hospital,
Toronto, Ont.
M5G 2C4
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To the editors.—We thank Dr. Girotti 
for his comments on our article. Dr. 
Girotti makes the statement that “ this is 
a slowly progressive disease with non­
specific abdominal findings” . We think 
this disease is likely a part of the syn­
drome of multisystem organ failure and 
usually presents as other organs fail. 
Acalculous cholecystitis may have a more 
acute course in patients suffering from 
multiple trauma or when oral feeding is 
reinstated.1-3
With reference to the investigation of 
the condition, Dr. Girotti states, “ Radi­
ologic investigations provide the only 
reliable method for making the diagno­
sis...” . We believe that the development 
of the new finding of tenderness in the 
right upper quadrant that is localized to 
the region of the gallbladder should alert 
the clinician to the possibility of acute 
acalculous cholecystitis. One of our 
patients had in fact been burned in this 
area, but this did not obscure the fact that 
right upper-quadrant tenderness did 
develop and did lead us to the diagnosis. 
Others3,4 have found that most patients 
with the diagnosis of acalculous 
cholecystitis who are able to respond have 
right upper-quadrant tenderness. Ultra­
sonography and HIDA scanning are good 
aids in diagnosis. But they, too, have their 
sources of error.
It is well known that total parenteral 
nutrition and alcoholic liver disease can 
affect the results of HIDA scanning.5 In 
one of our patients the diagnosis of acal­
culous cholecystitis was made from the 
findings of ultrasonography alone. After 
exploration of the gallbladder through a 
3.5-cm incision under local anesthesia, the 
gallbladder was judged to be normal. 
There was no morbidity attached to the 
procedure.
With respect to patients with small 
localized burns, we agree that movement 
of these patients from the specialized 
burn-care unit does not jeopardize the 
patient’s welfare. In our series, patients 
with acalculous cholecystitis tended to be 
those with severe, extensive burns. These 
patients often have limbs suspended for 
skin grafting and burn-wound care and 
are often intubated, compounding the 
difficulty and risk of transporting them 
out of the special care unit.
We agree with Dr. Girotti that 
ultrasonography and HIDA scanning 
should be done rather than “ an unwar-
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ranted surgical exploration” , but explo­
ration under local anesthesia should be 
done if acalculous cholecystitis is 
definitely suspected despite negative 
results of ultrasonography or HIDA 
scanning.
Charles H. Scudamore, md, frcsc
Assistant Professor of Surgery,
University of British Columbia,
3rd Floor,
910 West 10th Avenue,
Vancouver, BC 
V5Z 4E3
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The Death of G.B.S.
To the editors.—In his editorial on the 
broken hip (Can J  Surg 1985; 28: 
385-386), Sorbie refers to the terminal ill­
ness of George Bernard Shaw.
My brother, L.W. Plewes, FRCS, 
CBE, was Shaw’s orthopedic surgeon 
after he was admitted to the Luton and 
Dunstable Hospital in September 1950, at 
the age of 94 years, with a broken hip, 
chronic retention of urine and a 
hemoglobin value of 250 g/L  (he was a 
strict vegetarian all his life). A genitouri­
nary surgeon arranged treatment for an 
enlarged prostate. The fracture was 
reduced and fixed with a pin and plate. 
He was allowed limited weight bearing the 
following day and made steady progress. 
When he returned home, he removed the 
urinary catheter and refused further treat­
ment. He realized what was happening 
and said, “The great G.B.S. was gone 
and merely the shell remained.”
George Bernard Shaw did not die of a 
broken hip, but of chronic urinary reten­
tion, anemia and his own refusal to toler­
ate an indwelling catheter.
Burns Plewes, md, ms, frcsc,
FRCS(EDIN)
245 Beech Ave.,
Toronto, Ont.
M4E 3J1
To the editors.—I was very interested to 
read Dr. Plewes’ letter. It reveals infor­
mation to which I had no access. 1 am 
grateful for the correction and pleased to 
have first-hand knowledge. The 
newspapers at the time ascribed Shaw’s
death to the consequences of a fractured 
hip. It is usual, when compiling statistics 
for most clinical reviews, to list all deaths 
within 3 months of a fractured hip as 
relating to, if not resulting directly from 
it. The immediate cause may be, for 
example, pulmonary embolism. Jensen 
and Tetndevold1 list death rates of 17% 
at 3 months and 21.5% at 6 months after 
hip fracture.
In the case of G.B.S., I am reliably 
informed the sequence of events was as 
follows: Sept. 6, 1950 — broken hip, 
internal fixation; Sept. 22 — surgery to 
urinary tract; Oct. 5 — discharged from 
hospital; Nov. 2 — died.
I was a teenager when G.B.S. died and 
time can distort memories. I recall that 
his hip broke when he fell from a step lad­
der while pruning his apple trees. I hesi­
tate to repeat this, however, as I risk a 
letter from his gardener who may have 
more reliable information!
Charles Sorbie, md, frcsc
Professor and Head,
Department of Surgery,
Queen’s University,
Kingston, Ont.
K7L 3N6
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Radiation Exposure to the Surgeon 
During Ender’s Nailing
To the editors.—Thurlow’s remarks (Can 
J  Surg 1986; 29: 9) concerning the need 
to keep radiation exposure to a minimum 
in the operating room are well taken. A 
conventional nail and plate can certainly 
be used to treat all intertrochanteric frac­
tures, and the procedure does not require 
the use of an image intensifier.
Many surgeons now use image intensi- 
fiers during hip nailing. Our purpose was 
to quantify the exposure the hands of 
members of the operating team receive 
during Ender’s nailing. The operation 
must be done with two image intensifiers 
and the hands can’t easily be shielded.
Individual judgement must be used in 
deciding whether the operating team can 
accept that Ender’s nailing will probably 
entail the following exposure: 9 to 20 
mrem for the surgeon, 1.3 to 1.7 mrem 
for the instrument nurse and 2.8 to 3.0 
mrem for the anesthetist.
The 5000 mrem figure quoted by 
Thurlow is the annual occupational limit 
for exposure to the whole body. The cur­
rent limit used by Canadian authorities 
for extremities such as the hands is 75 000 
mrem/yr. This is the figure that should 
be used to put our paper (Can J  Surg
1985; 28: 25-26) and Thurlow’s com­
ments into perspective.
We did not propose to support or to 
challenge the adequacy of the interna­
tional standards and those used by Cana­
dian authorities.
J.P. Moreau, md, facs, frcsc
Division of Orthopedic Surgery,
University of Alberta,
Edmonton, Alta.
J.P. ASHMORE, PH D
Radiation Protection Bureau,
Department of National Health and Welfare, 
Ottawa, Ont.
Splenic Abscess — 
Percutaneous Drainage
To the editors.—I read with interest the 
report of Stringel and associates (Can J  
Surg 1985; 28: 269-270), describing suc­
cessful operative drainage of a splenic 
abscess. Although splenectomy and 
antibiotics are the treatment of choice for 
a splenic abscess,1 drainage of the 
abscess has been tried in an attempt to 
preserve splenic function and thus prevent 
overwhelming post-splenectomy infec­
tion. Percutaneous drainage of splenic 
abscesses is a theoretical option and can 
be performed safely using ultrasonogra­
phy and computed tomography for 
guidance. It results in decreased mor­
bidity and shorter hospital stay. Lerner 
and Spataro2 successfully managed four 
cases of splenic abscess by percutaneous 
drainage and referred to four more cases 
reported earlier.3,4 Kreel5 reported 
another case of splenic abscess treated 
successfully by this method.
Percutaneous catheter drainage under 
radiologic guidance is a safe and effec­
tive method for treating splenic abscess 
and is recommended, especially for debili­
tated patients.
vinay Kumar Kapoor, mb, bs, ms
Senior Resident,
Department of Surgery,
All India Institute of 
Medical Sciences,
New Delhi — 110029,
India
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SURGEONS’ UPDATE
What's new in surgery is the subject of this column. The short items are designed to let readers know 
who's doing what and why. Surgeons are interested in what other surgeons are doing in 
research, education, practice and administration. Surgery is a vibrant specialty, and, as 
its practitioners, you must be the source as well as the readers of this column.
Liability Insurance: the Costs
While most surgeons in Canada have to 
dig into their wallets for almost 100% 
more money than last year to cover their 
fees for liability insurance, their primary 
workplace — the hospital — is searching 
its budget for as much as 1000% more.
The increases, according to the insur­
ance companies, are simply a reflection 
of the rising numbers of writs against doc­
tors and hospitals, the increasing dollar 
values of awards to patients who can con­
vince the courts that someone was to 
blame for their injury, and the ever­
growing legal fees that accompany actions 
no matter what the outcome.
In 1984, the Canadian Medical Protec­
tive Association (CMPA) recorded an 
increase of about two new actions per 
month over the year before, while 
monthly payments for damages increased 
an average of about $100 000. What’s 
more, the CMPA had to pay out about 
$150 000 per month more in legal costs 
to defend its members. Although tabula­
tions for 1985 are not yet complete, says 
CMPA associate secretary Stuart Lee, 
FRCSC, the trend continues in all the 
provinces.
The picture for hospitals is similar: the 
Ontario Hospital Association’s Compre­
hensive Insurance Programme reported 
that for every claim lodged against a 
member in 1978 there were 4.5 in 1984, 
and awards increased six times during the 
same period. Jean-Claude Martin, presi­
dent of the Canadian Hospital Associa­
tion, says that a survey of brokers is under 
way to collect, if possible, nationwide 
figures on not only the claims and awards 
but also the risks attached to different 
types and locations of hospital. “ We are
Contributions to this column are welcome. 
Please send your material to: Mrs. Amy 
Chouinard, Canadian Journal o f  Surgery, PO 
Box 8650, Ottawa, Ont. K1G 0G8.
trying to gather the information but 
hospitals are not like the doctors who 
have only the CMPA; we are dealing with 
many insurance brokers. Some of the 
hospitals are grouped by region, some by 
provincial association and some are deal­
ing directly with brokers. Most of the 
western provinces — BC, Alberta, 
Manitoba — and Ontario are grouped 
under the hospital association and they 
deal with one broker; in Quebec, they 
deal with a consortium of brokers; the 
maritime provinces vary. But the legal 
contract is with the institution.”
Hospitals are only one area where the 
public purse is involved, as liability costs 
and insurance coverage have been front­
page news since the beginning of the year 
when many school boards and municipal­
ities attempted to renew their policies and 
were faced with unprecedented increases.
Compensating the injured patient
Government intervention is only a mat­
ter of time and the medical profession 
would like to have some input into the 
direction of change, says Richard Railton, 
FRCSC, a general surgeon from Welland, 
Ont., who chairs the Canadian Medical 
Association’s political action committee 
and serves on both the CMA Board of 
Directors and the Council on Economics.
Railton spoke to CJS after a meeting 
on Jan. 26 in which the economics coun­
cil heard from a government consultant 
on liability, Frank J. Sellers, FRCPC, and 
F. Norman Brown, FRCPC, secretary- 
treasurer of the CMPA. He acknowl­
edged both speakers as providing infor­
mation that allowed the council to focus 
on what can be done to improve the sys­
tem and fashion some recommendations 
for action by the CMA board and the 
medical profession in general.
Some weaknesses, said Railton, lend 
themselves readily to change, such as the
amount of time allowed for a patient to 
lodge a legal complaint, lump sums as 
payments instead of annuities for 
damages, rules on taxation and uses of 
awards, and the current arrangements for 
legal aid. Other weaknesses, such as the 
emphasis on finding someone at fault for 
the injury and the inadmissibility of other 
compensation as part of the payment for 
damages, are entrenched in the tort 
system.
“ Statutes of limitations have been 
around since the 1500s at least but are 
increasingly being affected by the ‘discov­
ery principle’. This means that the 
patient’s time limit in bringing an action 
against a physician for some alleged 
wrongdoing begins at the time that the 
person knows or ought to have known 
there was a problem. The time limit 
doesn’t start running if the person is 
under a disability, including being a 
minor. So you have the possibility of an 
obstetrician being sued for negligence 20 
or 30 years after delivering a baby. By this 
time, people have forgotten what really 
happened, records have disappeared, wit­
nesses have moved away or died, and it 
becomes terribly difficult to defend an 
action.
“ The statute of limitations we feel 
should have an absolute cap on it of 6 
years as is the case in British Columbia.” 
Otherwise, the circumstances are difficult 
to reconstruct as are the practices, 
knowledge and equipment that were stan­
dard at the time. In other words, the 
grounds for negligence are no longer firm.
“ Another problem is that a large 
amount of the money awarded to a per­
son goes to the provincial health plan. In 
Ontario, for example, if a court awards 
$2 million to someone for a negligent 
action by a doctor, perhaps half of it goes 
to the health insurance plan to look after 
the person. This is called subrogation.
“ Also, to give a person the amount of 
money needed to cover future health care 
and potential earnings, the court may 
double the award because it knows that 
the person is going to be taxed on the 
money. This is known as ‘grossing up’.
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“ Both subrogation and taxation con­
tribute to the high awards but not to the 
amount of money given as compensation 
to someone. If the idea is to recompense 
people for some misadventure, then the 
money should go to them.”
“ Subrogation and grossing up of pay­
ments have come about in the last 10 or 
15 years; they are not enshrined in an act 
or a bill, and provincial governments 
could make changes to them relatively 
easily.”
In contrast, says Railton, “ regulations 
on collateral payments [moneys received 
as compensation from sources other than 
defendants] have long-standing existence 
in common law and would be difficult to 
change, although I think that the Law
Malawi Orthopedic Project 
Seeks Volunteers
This month marks the official opening of 
a $1.4 million project in which orthopedic 
surgeons from Canada and elsewhere will 
train about 30 parasurgeons in Malawi to 
correct the crippling effects of poliomye­
litis.
The 4-year project, which is funded 
jointly by Canadian Rotary Clubs and the 
Canadian International Development 
Agency, is headed by Edward J. Blair and 
will get under way officially Mar. 10 after 
the head of Rotary International, also an 
orthopedic surgeon, arrives for a visit to 
the country.
Blair left his practice in St. Catharines 
to begin work late last year at the Queen 
Elizabeth Central Hospital in Blantyre, 
Malawi. The first 10 students, selected 
from a group of 150 applicants, have 
begun their course work, and $100 000 
worth of equipment purchased by rotar- 
ians for the project has been airlifted to 
the area.
Edward J. Blair, FRCSC heads Malawi ortho­
pedic project.
— orm Commission is looking at them.”
If the idea is to ensure that the person 
is appropriately compensated for past, 
present, and future losses and expenses 
caused by an injury, then other compen­
sation payments should figure in calcu­
lations of how much an injured person 
should receive.
Similarly, the onus on patients to show 
that someone is to blame for their mis­
fortune means that many people receive 
no compensation: that is, lawyers are the 
only participants in the action who have 
any guarantee of success in terms of dol­
lars and in most provinces of Canada only 
the rich who can afford the fees and the 
poor who can qualify for legal aid can 
undertake such an action. According to
In 1979, 7 in every 1000 healthy children in 
Malawi would have contracted poliomyelitis 
and many victims would need a type of 
surgical correction that Blair is teaching.
Blair came up with the idea for the 
project while putting his skills to work in 
an earlier effort between the rotarians and 
Malawi Against Polio, a local organiza­
tion that is involved in both prevention 
and cure of the disease. At present, there 
are 60 000 to 70 000 crippled peo­
ple in the small southeast African coun­
try, which covers about 80 000 km2 and 
has a population of about 7 million. Blair 
realized that his work and that of his col­
leagues would make little impact unless 
carried on and expanded by local people. 
So he decided to ask other orthopedic sur­
geons to volunteer for 3-month stints as 
teachers, during which they would receive 
a small stipend.
A.M. Adams, a retired food scientist 
in St. Catharines, is managing the project 
from this end and is overseeing the 
money-raising from the 68 rotary clubs 
in northeastern North America; the goal 
is to come up with about $60 000 to com­
plement a donation from Rotary Interna­
tional.
Although the project has enough 
volunteers for 1986, it is still looking for 
assistance during the next 3 years. Ortho­
pedic surgeons who are interested are 
asked to write to: Malawi Orthopedic 
Project, PO Box 512, St. Catharines, 
Ont. L2R 6V9.
A my C ho uina rd
Railton, the structure for legal aid 
encourages a patient to continue an action 
even though the indications are that he 
or she will be unable to show that the phy­
sician has been guilty of negligence, 
breach of confidence, breach of contract 
or battery.
These and other reasons have 
prompted some governments to introduce 
“ no fault” compensation. New Zealand 
and Sweden have fashioned legislation 
that will provide compensation for per­
sonal injuries or accidents of all sorts 
without tying up the courts. However, the 
systems are major departures from the 
existing setup in Canada, as they deny the 
injured person’s right to resort to the 
courts for compensation.
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W hen you want an effective antibiotic at all costs.But not at any price.
During the critical 24 to 48 
hour wait for susceptibility tests, 
you need an antibiotic with a clini­
cally proven spectrum of activity. 
An antibiotic with an excellent rec­
ord of safety. An antibiotic such 
as Cefobid*
When cost must also be 
considered, Cefobid* remains an 
antibiotic of choice. Its realistic
pricing structure and economical 
twice-a-day dosage make 
Cefobid* cost-effective therapy.12
Cefobid* is an advanced 
cephalosporin proven effective 
against a wide range of infections. 
It is very well tolerated. With a 
unique dual pathway of excretion, 
Cefobid* at usual dosage requires 
no modification of dosage in 
patients with renal impairment.
Cefobid* Effective antibiotic 
therapy you can well afford to use.
cefoperazone sodium/pfizer IV/ IM
First-line parenteral antibiotic therapy \ 1 FAABCCPP
First-line parenteral antibiotic therapy
Prescribing Information
Antibiotic For Intravenous or Intramuscular Injection
ACTION
In vitro studies indicate that the bactericidal action of CEFOBID (cefoperazone sodium) 
results from the inhibition of bacterial cell wall synthesis.
INDICATIONS AND CLINICAL USES
CEFOBID (cefoperazone sodium) may be indicated for the treatment of the following 
infections when caused by susceptible strains of the designated microorganisms: 
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, 
Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, Kleb­
siella species (including Klebsiella pneumoniae), Pseudomonas aeruginosa, Escheri­
chia coli, Proteus mirabilis, indole-positive Proteus species and Enterobacter species. 
URINARY TRACT INFECTIONS caused by Escherichia coli, Pseudomonas aeruginosa, 
Enterobacter species, Klebsiella species, Enterococcus, Proteus mirabilis, Staphylo­
coccus aureus, Staphylococcus epidermidis and indole-positive Proteus species. 
Due to the nature of the underlying conditions which usually predispose patients 
to Pseudomonas infections of the lower respiratory and urinary tracts, a good clini­
cal response accompanied by bacterial eradication may not be achieved despite 
evidence of in vitro sensitivity.
ACUTE BILIARY TRACT INFECTIONS ASSOCIATED WITH CHOLECYSTITIS OR CHO­
LANGITIS caused by Escherichia coli.
SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Strep­
tococcus agalactiae, Escherichia coli and Klebsiella species.
WOUND INFECTIONS (SURGICAL AND TRAUMATIC) caused by Staphylococcus 
aureus, Streptococcus pyogenes and Pseudomonas aeruginosa.
GYNECOLOGICAL INFECTIONS (SUCH AS PELVIC INFLAMMATORY DISEASE AND 
ENDOMETRITIS) caused by Streptococcus agalactiae, Neisseria gonorrhoeae, 
Escherichia coli, Bacteroides species (including Bacteroides fragilis), Peptococcus 
species and Peptostreptococcus species.
Specimens for bacteriologic culture should be obtained prior to therapy in order to iden­
tify the causative organism and to determine its susceptibility to CEFOBID (cefoperazone 
sodium). Therapy may be instituted before results of susceptibility testing are known; 
however, modification of the treatment may be required once these results become 
available.
CONTRAINDICATIONS: CEFOBID (cefoperazone sodium) is contraindicated in patients 
with known allergy to the cephalosporin class of antibiotics.
WARNINGS: Before therapy with CEFOBID (cefoperazone sodium) is instituted, careful 
inquiry should be made to determine whether the patient has had previous hypersensi­
tivity reactions to cephalosporins, penicillins or other drugs. CEFOBID (cefoperazone 
sodium) should be administered with caution to penicillin-sensitive patients or to any 
patient who has demonstrated some form of allergy, particularly to drugs. If an allergic 
reaction to CEFOBID (cefoperazone sodium) occurs, discontinue administration of 
the drug and treat the patient with the usual agents (e.g. epinephrine, antihistamines, 
pressor amines or corticosteroids).
Pseudomembranous colitis has been reported to be associated with the use of 
CEFOBID (cefoperazone sodium). Therefore, in those patients administered CEFOBID 
(cefoperazone sodium) who develop diarrhea, it is important to consider such a 
diagnosis.
Treatment with broad-spectrum antibiotics, including CEFOBID (cefoperazone 
sodium) alters the normal flora of the colon and may permit overgrowth of Clostridia. 
Studies indicate that a toxin produced by Clostridium difficile is one primary cause of 
antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe 
cases should be managed with fluid, electrolyte, and protein supplementation as indica­
ted. When the colitis is not relieved by the discontinuance of CEFOBID (cefoperazone 
sodium) or when it is severe, consideration should be given to the administration of oral 
vancomycin.
PRECAUTIONS
General: The concomitant administration of aminoglycosides and some cephalosporins 
has caused nephrotoxicity. Although transient elevations of BUN and serum creatinine 
have been observed, there is no evidence that CEFOBID (cefoperazone sodium) when 
administered alone causes significant nephrotoxicity. However, the effect of ad­
ministering CEFOBID (cefoperazone sodium) concomitantly with aminoglycosides is not 
known.
CEFOBID (cefoperazone sodium) is excreted in both the bile and urine. In normal 
volunteers, 19 to 41% of the dose is excreted in the urine, the remainder being excreted 
by the hepato-biliary system. The serum half-life of CEFOBID (cefoperazone sodium) is 
usually prolonged and urinary excretion of the drug increased in patients with hepatic 
disease and/or biliary obstruction. Serum concentrations of cefoperazone should be 
monitored in these patients treated with doses in excess of 2 grams daily and dosage 
should be adjusted as necessary.
Because renal excretion is not the main route of elimination of cefoperazone, adult 
patients with renal failure usually require no adjustment in dosage when daily doses of 
2 to 4 grams (1 to 2 grams every 12 hours) are administered. If higher doses of CEFOBID 
(cefoperazone sodium) are used, serum concentrations of cefoperazone should 
be monitored. If there is evidence of accumulation, dosage should be decreased 
accordingly.
In one study in patients with chronic renal failure, the half-life of CEFOBID (cefopera­
zone sodium) was reduced from 4.17 to 1.67 hours during hemodialysis. Thus, dosing 
should be scheduled to follow a dialysis period.
In patients with both hepatic dysfunction and renal impairment, the initial dosage of 
CEFOBID (cefoperazone sodium) should not exceed 1 to 2 grams daily and serum con­
centrations of cefoperazone should be monitored closely.
Vitamin K deficiency has occurred in a few patients treated with CEFOBID 
(cefoperazone sodium). The mechanism is most probably related to the suppression of 
gut flora which normally synthesizes this vitamin. Those at risk include patients with 
poor diet or malabsorption states (e.g. cystic fibrosis) and patients on prolonged intrave­
nous alimentation regimens. Prothrombin time should be monitored in these patients 
and exogenous vitamin K administered as indicated.
A reaction characterized by flushing, sweating, headache, and tachycardia has been 
reported when alcohol is ingested during and as late as the fifth day after CEFOBID 
(cefoperazone sodium) administration. Patients should be cautioned concerning inges­
tion of alcoholic beverages in conjunction with administration of CEFOBID (cefoperazone 
sodium). For patients requiring artificial feeding orally or parenterally, solutions con­
taining ethanol should be avoided.
CEFOBID (cefoperazone sodium) should be administered with caution to individuals 
with a history of gastrointestinal disease, particularly colitis.
Overgrowth of nonsusceptible organisms may occur during prolonged use of 
CEFOBID (cefoperazone sodium). Patients should be observed carefully during treat­
ment. If superinfection occurs, appropriate measures should be taken.
Drug Laboratory Test Interactions
A false-positive reaction for glucose in the urine may occur with Benedict’s or Folding's 
solution.
Pregnancy: The safety of CEFOBID (cefoperazone sodium) in pregnancy has not been 
established. The use of CEFOBID (cefoperazone sodium) in pregnant women requires 
that the likely benefit from the drug be weighed against the possible risk to the mother 
and fetus.
Reproduction studies have been performed in mice, rats and monkeys at doses up to 
10 times the human dose and have revealed no evidence of impaired fertility or teratoge­
nic effects due to cefoperazone sodium. Animal reproduction studies, however, are not 
always predictive of human response.
Nursing Mothers: Cefoperazone is excreted in low concentration (0.4 to 0.9 /ig/mL) in 
human milk. Caution should be exercised when CEFOBID (cefoperazone sodium) is 
administered to a nursing mother.
Children: The safety and efficacy of CEFOBID (cefoperazone sodium) in children have not 
been established.
ADVERSE REACTIONS
Hypersensitivity: Maculopapular rash, urticaria, pruritis, eosinophilia, drug fever. 
Hematology — Decreases in hemoglobin and/or hematocrit have occurred. Slight 
decreases in neutrophil count have been reported, and reversible neutropenia may occur 
with prolonged administration. Transient eosinophilia has occurred. Hypoprothrombi- 
nemia has been observed. Some individuals have developed positive direct Coombs' test 
during treatment.
Liver — Transient elevations in SGOT, SGFT and alkaline phosphatase levels have been 
noted. One patient with a history of liver disease developed significantly elevated liver 
function enzymes during therapy with CEFOBID (cefoperazone sodium). Clinical signs 
and symptoms of nonspecific hepatitis accompanied these increases. After CEFOBID 
(cefoperazone sodium) therapy was discontinued, the patient's enzymes returned to pre­
treatment levels and the symptomatology resolved.
Kidney — Transient elevations of blood urea nitrogen and serum creatinine have been 
noted.
Gastrointestinal — Altered bowel habits (loose stools or diarrhea) have been reported. 
Most of these events have been mild or moderate, but some have been severe. In all 
cases, these symptoms responded to symptomatic therapy or ceased when 
cefoperazone therapy was stopped. Nausea and vomiting have been reported rarely.
Pseudomembranous colitis has been reported rarely in patients administered 
CEFOBID (cefoperazone sodium). Symptoms of pseudomembranous colitis can appear 
during or for several weeks subsequent to antibiotic therapy.
Disulfiram-like Reaction
Disulfiram-like reactions have been reported when alcohol was ingested during and as 
late as the fifth day after CEFOBID (cefoperazone sodium) administration.
Central Nervous System — Headache and dizziness occur rarely.
Local Reactions — CEFOBID (cefoperazone sodium) is well tolerated following intra­
muscular administration. Occasionally, transient pain may follow administration by this 
route. When CEFOBID (cefoperazone sodium) is administered by the intravenous route, 
some patients develop phlebitis at the site of administration.
Other — Diaphoresis/chills
SYMPTOMS AND TREATMENT OF OVERDOSAGE 
Since no case of overdosage has been reported to date with CEFOBID (cefoperazone 
sodium), no specific information on symptoms or treatment of overdosage is available. 
Treatment should be symptomatic.
Hemodialysis is not effective in the removal of cefoperazone.
DOSAGE AND ADMINISTRATION
Dosage
CEFOBID (cefoperazone sodium) may be administered intravenously or intramuscularly.
Dosage and route of administration should be determined by severity of infection, 
susceptibility of the causative organism, and condition of the patient.
Adult
The recommended daily dose of CEFOBID (cefoperazone sodium) is 2 to 9 grams ad­
ministered in equally divided doses every 8 to 12 hours (See table below). The usual 
duration of treatment is 7 to 14 days.
Adult Dosage
Type of infection Daily Dose
Mild to moderately severe 2 to 4 grams
infections such as pneumonia, 
acute urinary tract infection, 
wound infection
Frequency and Route
1 to 2 grams 
every 12 hours 
I.M. or I.V.
Severe infections or infections 4 to 8 grams
caused by less sensitive
organisms
2 to 4 grams 
every 12 hours 
I.V.
Infections commonly requiring 9 grams 3 grams every
antibiotics in higher dosage 8 hours I.V.
(e.g. septicemia and life threatening 
infections)
The maximum adult daily dose should not exceed 9 grams.
For infections caused by Streptococcus pyogenes, therapy should be continued for 
at least 10 days.
Impaired Renal Function
Because renal excretion is not the main route of elimination of cefoperazone, adult 
patients with renal failure usually require no adjustment in dosage when daily doses of 
2 to4 grams (1 to2 grams every 12 hours) of CEFOBID (cefoperazone sodium) are admin­
istered. If higher doses of CEFOBID (cefoperazone sodium) are used, serum concentra- 
tionsof cefoperazone should be monitored. If there is evidence of accumulation, dosage 
should be decreased accordingly. For patients whose glomerular filtration rate is less 
than 18 mL/min orwhose serum creatinine level is greaterthan 3.5 mg/dL, the maximum 
CEFOBID (cefoperazone sodium) dosage should be 4 grams per day.
In patients undergoing hemodialysis, dosing should be scheduled to follow a dialysis 
period.
Hepatic Disease and Biliary Obstruction
The serum half-life of cefoperazone is increased 2 to 4 fold in patients with hepatic 
disease and/or biliary obstruction. Serum concentrations of cefoperazone should be 
monitored in patients treated with doses in excess of 2 grams daily and dosage should 
be adjusted as necessary.
Hepatic Dysfunction and Renal Impairment
In patients with both hepatic dysfunction and concomitant renal impairment, the initial 
dosage of CEFOBID (cefoperazone sodium) should not exceed 1 to 2 grams daily and 
serum concentrations of cefoperazone should be closely monitored.
Children
The safety and efficacy of CEFOBID (cefoperazone sodium) in children have not been 
established.
ADMINISTRATION
Intramuscular:
CEFOBID (cefoperazone sodium) should be administered by deep intramuscular 
injection into a large muscle mass such as the gluteus maximus or anteriorthigh. The 
maximum dose of CEFOBID (cefoperazone sodium) should be two (2) grams. 
Intravenous:
Direct Intravenous (bolus) injection: The reconstituted solution should be injected 
slowly over a period of no less than three (3) minutes. The maximum dose of 
CEFOBID (cefoperazone sodium) should be two (2) grams.
Intermittent Intravenous Infusion: The reconstituted solution may be infused over a 
period of 15 minutes to 1 hour through the tubing of an administration set while any 
of the intravenous solutions (See Solutions for I.V. Infusion) are being infused. During 
infusion of the solution containing CEFOBID (cefoperazone sodium), it is desirable to 
temporarily discontinue administration of the other solution.
Continuous Intravenous Infusion: CEFOBID (cefoperazone sodium) may also be 
administered over a longer period of time.
Note: If therapy with CEFOBID (cefoperazone sodium) is carried out in combination 
with an aminoglycoside antibiotic, each should be administered at different sites 
because of a physical incompatibility. An aminoglycoside should not be mixed with 
CEFOBID (cefoperazone sodium) in the same container.
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFOBIO
Proper Name: Cefoperazone sodium
Chemical Name:
Sodium (6R,7R)-7- ( (R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2- 
(p-hydroxyphenyl) acetamido] -3[ [ (1-methyl-1H-tetrazol-5-yl)thio ] methyl]-8-oxo- 
5-thia-1- azabicyclo[4.2.0] oct-2-ene-2-carboxylate
Description:
Cefoperazone sodium is a white powder, soluble in water, sparingly soluble in methanol, 
poorly soluble in ethanol, and insoluble in ethyl ether, acetone, chloroform, or n-hexane. 
Composition:
CEFOBID vials contain cefoperazone sodium (expressed in terms of free acid). The 
sodium content of each gram of CEFOBID is approximately 34 mg (1.5 mEq sodium ion). 
The pH of a 25% (w/v) solution is 4 5  to 65  and the solution is colorless to straw yellow 
depending on the concentration.
RECONSTITUTION
For Intramuscular Use:
Solution for Reconstitution
Sterile Water for Injection 
or, if required
Bacteriostatic Water for Injection 
05%  Lidocaine Hydrochloride Injection
Reconstitute as follows:
Volume to be Approximate Approximate
Vial Size Added to Vial Available Average Concentration
(g)____________ (mL)___________Volume (m l)____________(mg/mL)_______
1.0 3.5 4.0 250
2.0 __________ 7 9 ________________FLO__________________ 250_________
Shake well until dissolved. Solutions should be allowed to stand after reconstitution to 
allow any foaming to dissipate in order to permit visual inspection for complete solubili­
zation. Vigorous and prolonged agitation may be necessary to solubilize CEFOBID 
(cefoperazone sodium).
For Intravenous Use:
Solutions for Reconstitution and Dilution 
Sterile Water fo r Injection 
or, if required
Bacteriostatic Water for Injection 
Reconstitute as follows:
Volume to be Approximate Approximate
Vial Size Added to Vial Available Average Concentration
(g)____________ (m y___________ Volume (mL)____________(mg/mL)_______
1 9.5 10.0 100
2 ____________ 199_______________2 0 0_________________ 100__________
Shake well until dissolved. The prepared solution may be further diluted to the desired 
volume with any o f the solutions for I.V. infusion listed below.
For direct intravenous (bolus) injection: Reconstitute as directed above.
For intermittent intravenous infusion: Reconstitute as directed above.
For continuous intravenous infusion: Reconstitute with Sterile Water for Injection. The 
reconstituted solution may be added to an appropriate intravenous bottle/bag containing 
any of the solutions for I.V. infusion listed below:
Solution for I.V. Infusion 
5% Dextrose Injection (USP)
5% Dextrose and Lactated Ringer’s Injection 
5% Dextrose and 0.9% Sodium Chloride Injection (USP)
5% Dextrose and 0.2% Sodium Chloride Injection (USP)
10% Dextrose Injection (USP)
Lactated Ringer’s Injection (USP)
0.9% Sodium Chloride Injection (USP)
Normosol® M and 5% Dextrose Injection 
Normosol® R 
Stability of Solutions 
Storage:
Reconstituted solutions for intramuscular injection should be used within 24 hours if 
kept at room temperature, or 72 hours if stored under refrigeration (5° C).
Reconstituted solutions for I.V. injection or infusion should be used within 24 hours 
if kept at room temperature, or 72 hours if stored under refrigeration (5° C). 
Incompatibility
CEFOBID (cefoperazone sodium) should not be added to blood products, protein 
hydrolyzates, or amino acids. CEFOBID (cefoperazone sodium) should not be mixed 
together with an aminoglycoside.
DOSAGE FORMS
Availability:
CEFOBID (cefoperazone sodium) is available as a lyophilized powder:
1.0 g vial — cefoperazone 1.0 g as sodium salt
2.0 g vial — cefoperazone 2.0 g as sodium salt 
Storage
CEFOBID (cefoperazone sodium) should be stored protected from light and 
refrigerated (2 to 8° C).
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Transluminal Angioplasty: Indications and Overview
Reasons for the slow acceptance of per­
cutaneous transluminal angioplasty over 
the past 20 years are multiple and 
include the lack of understanding of the 
changes in the arterial wall caused by 
angioplasty. Factors responsible for the 
present popularity of the technique 
include a better understanding of the 
pathophysiology of catheter dilatation of 
an artery, more efficient catheters and 
monitors, increasing experience and 
competence of angiographers, better 
drugs to decrease spasm and thrombo­
sis, greater knowledge of the immediate 
and long-term results and social pressure 
to reduce both cost and time in treating 
patients. The indications for percutane­
ous transluminal angioplasty are being 
standardized, as were the indications for 
reconstructive arterial surgery, and now 
the role of angioplasty should be under­
stood by all physicians treating patients 
with arterial disease. The best results of 
this procedure are obtained with seg­
mental occlusive lesions of the iliac, 
superficial femoral, coronary and renal 
arteries.
II existe de multiples raisons pour la lente 
acceptation, au cours des 20 dernieres 
annees, de I'angioplastie transluminale 
percutanee, dont I'ignorance des change- 
ments causes par I'angioplastie dans la 
paroi arterielle. Les facteurs responsables 
de Tactuelle popularity de cette techni­
que comprennent une meilleur compre­
hension de la physiopathologie de ia dila­
tation par catheter des arteres, I'arrivee
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de catheters et de systeme de monito- 
rage plus efficaces, ('amelioration de 
I'experience et de la competence des 
specialistes de I'angiographie, la mise au 
point de meilleurs medicaments pour 
combattre les spasmes et thromboses, 
une meilleure connaissance des resultats 
immediats et a long terme et les pres- 
sions sociales qui s'exercent en vue de 
reduire les couts et la duree de traite- 
ment. Les indications de I'angioplastie 
transluminale percutanee sont en voie 
d'etre standardises, tout comme I'ont 
ete celles de la chirurgie arterielle recons­
tructive, et maintenant le role de I'angio- 
plastie devrait etre connu de tous les 
medecins traitant les maladies arterielles. 
Avec cette intervention, les meilleurs 
resultats sont obtenus dans les cas de 
lesions occlusives segmentaires des arte­
res iliaques, femorales superficielles, 
coronaires et renales.
The long and controversial history of per­
cutaneous transluminal angioplasty has 
demonstrated the difficulties most phy­
sicians have in accepting this unusual 
technique. As one who has watched the 
development of transluminal angioplasty, 
I have shared the general skepticism, espe­
cially strong among vascular surgeons. 
However, it appears that percutaneous 
transluminal angioplasty has finally 
reached the status of an “ idea whose time 
has come” . This paper presents the 
diverse factors responsible for the erratic 
progress of the technique in the 20 years 
since its inception and outlines accepta­
ble indications for the procedure.
Percutaneous entry techniques initially 
were described by Seldinger1 in 1953 and 
have kept pace with the development of 
vascular surgery during the past 30 years. 
The publication by Fogarty and 
colleagues2 in 1963 of a method for 
removing arterial emboli and thrombi 
using a balloon catheter is still hailed as 
one of the great advances in vascular 
surgery.
Dotter and Judkins3 reported in 1964 
on the first patients treated by their tech­
nique of percutaneous transluminal dila­
tation. It is interesting that Fogarty
interned at the University of Oregon and 
knew Dotter at that time; it is possible 
that their joint ideas were formed by that 
early association. Dotter’s first patient 
was an 82-year-old woman who presented 
with progressive gangrene of three toes. 
Angiography demonstrated an adductor 
canal thrombosis of the femoral artery 
and outflow disease in the lower leg. The 
patient refused reconstructive arterial sur­
gery or amputation, so Dotter dilated the 
area with a tapered radiopaque Teflon 
dilating catheter of approximately 25 mm 
outer diameter, greatly increasing blood 
flow, which relieved the woman of her 
rest pain and resulted eventually in spon­
taneous amputation of the three toes. The 
good result continued until the woman 
died 2 Vi years later. Instead of being 
acclaimed by his colleagues, Dotter heard 
armchair reasons why percutaneous 
transluminal angioplasty would not work 
and in fact received requests for angio­
grams only, specifically requesting him 
not to treat the lesion.
In 1964, a three-page photographic 
presentation in Life4 featured a picture 
of Dotter with the following caption: 
“ With a look of impending triumph Dr. 
Dotter forces his arterial ‘snake’ — a spe­
cially designed catheter — through the 
fatty plug blocking the main artery in a 
patient’s leg.” Instead of converting his 
colleagues, the article gave rise to further 
doubts and no referrals were forthcom­
ing. However, 500 people wrote to him 
after publication of the article and he 
eventually performed percutaneous trans­
luminal angioplasty on 75 of them.
Why did doctors not accept the role of 
transluminal dilatation? Roberts and 
Ring5 wrote, “ To those of us who oper­
ate upon blood vessels and know the great 
variety of lesions that may be encountered 
in an obstructed or stenotic artery the 
concept of treating such lesions by sim­
ple dilatation is not attractive. As one 
contemplates the possible problems that 
may arise from such an approach, it 
would seem reasonable to anticipate the 
result would be more often disastrous 
than beneficial. As a result, many sur­
geons have been unwilling to try the 
method despite many recent articles
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pointing out its usefulness for certain 
problems.”
Dotter originally believed that the 
plaque itself had been compressed and 
remoulded by the dilating catheter like a 
footprint in the snow. That this seldom 
occurs is now apparent and comes as no 
surprise to vascular surgeons who know 
that most plaques are firm and not 
usually compressible. This initial expla­
nation hindered the acceptance of his 
idea. With lack of North American sup­
port, the technique was exported to 
Europe where it was refined and used 
widely.
Following Dotter’s first publication in 
1964,3 interest was slow to develop but, 
after the first percutaneous transluminal 
coronary angioplasty was performed by 
Griintzig6 in Zurich in 1977, interest bur­
geoned and 188 publications were listed 
in “ Index Medicus” in 1982. Many 
reports were from Europe. The majority 
reported the results o f coronary 
angioplasty, while others reported its role 
in peripheral, renal and other arteries. 
Griintzig now performs over 100 proce­
dures per month in four laboratories at 
Emory University in Atlanta, and in the 
Soviet Union there are more than 170 spe­
cial centres for percutaneous translumi­
nal angioplasty.
Reasons for Renewed Interest 
in Percutaneous 
Transluminal Angioplasty
Factors responsible for this great 
upsurge of interest are multiple and 
include the following:
• A reasonable explanation, accept­
able to surgeons and other clinicians, has 
been provided for the pathophysiology of 
percutaneous transluminal angioplasty. 
The changes produced in the arteri­
osclerotic plaques have been attributed to 
intimal disruption and splitting,7 stretch­
ing of the media of the artery,8 remodel­
ling and redistribution of the inelastic core 
substance,9 fragmentation of the 
plaque10 and dissection of arterial wall 
layers.11 The actual morphologic change 
in the artery wall must determine the 
immediate and longer term response to 
dilatation. Zarins and colleagues12 
studied arteries dilated in vivo and sub­
sequently examined at autopsy or after 
amputation. Fourteen cadaver superficial 
femoral arteries were also dilated. All 
were assessed by serial angiography and 
microscopic sections. These were com­
pared to angiograms in 36 patients fol­
lowing angioplasty. In all pathological 
specimens, the plaque and media were 
ruptured with separation of the plaque 
and stretching of the adventitia. The usual 
postangioplasty angiographic changes are 
due to dissection channels and protrusion 
of intimal flaps. Restenosis may be due
to inadequate dilatation or extension of 
dissection channels. It was concluded that 
persistent overstretching of the artery wall 
was the reason for successful dilatation, 
not change in the plaque or remodelling 
of the wall. From a clinical series Zarins 
and colleagues12 reported that restenosis, 
as determined by measurement of ankle 
brachial pressure index, occurred in 
approximately 50% of patients within 6 
months, and the authors concluded that 
successful dilatation depends on medial 
and intimal rupture.
• High technology in catheter 
development has kept pace with similar 
developments in other fields. The initial 
catheter used by Dotter was a Teflon 
dilating catheter. Griintzig and Hopff13 
revolutionized the technique when they 
developed a soft, flexible, double-lumen 
balloon catheter. The original polyvinyl 
chloride catheter was hard to curve and 
the balloon would swell into an hour-glass 
configuration if too much pressure was 
applied. The polyethylene catheter can be 
curved and shaped with ease and can 
withstand great pressures while maintain­
ing a cylindrical shape and the diameter 
specified by the manufacturer, thus 
preventing inadvertent overdistension and 
rupture of the vessel. Monitors have 
improved, permitting accurate measure­
ment of pressure gradients across the 
lesion at the time of angioplasty, while 
digital imaging has expanded to improve 
the role of radiology.
• The use of drugs as adjunctive ther­
apy has improved the immediate and 
long-term results and decreased compli­
cations of the procedure. Heparin, 
usually 5000 units intra-arterially, is used 
by most angiographers when the catheter 
is passed. Local spasm that will prevent 
successful angioplasty has been treated by 
nifedipine, tolazoline and papaverine 
hydrochloride. Antiplatelet drugs are 
started 3 to 4 days before angioplasty and 
are usually continued indefinitely. Strep­
tokinase, given intra-arterially at the time 
of angioplasty, has been used to control 
distal acute thrombosis and to expand the 
role of this procedure.
• The social pressure to treat patients 
faster, better and cheaper is increasing 
owing to extensive media dissemination 
of information on medical topics, thus 
creating more demand on doctors. 
Naisbitt14 has followed in the footsteps 
of other futurists such as Toffler and 
McLuhan by describing 10 new trends 
that are transforming our lives.14 His 
conclusions are obtained by “ content 
analysis” , a method based on intelligence­
gathering techniques used in World War 
II and arrived at by statistically analys­
ing all media information. One such trend 
is a loss of faith in medicine’s traditional 
treatment of disease by drugs or surgery 
and the expectation that much can be 
achieved by less-invasive and less-painful
methods, including percutaneous trans­
luminal angioplasty. A trend to describe 
this technique as an easy alternative to 
surgery has been apparent in many 
newspaper and magazine articles and 
many patients request it.
There is also considerable government 
and public pressure to contain the cost of 
health care, and percutaneous translumi­
nal angioplasty is much less expensive 
than arterial surgery, even if it must be 
repeated earlier because the long-term 
results are not as good. The comparison 
of costs for percutaneous transluminal 
angioplasty of a stenosed femoral artery 
requiring 2 days’ admission to hospital 
and femoropopliteal bypass grafting with 
10 days in hospital show that the latter 
is five times more expensive. A compara­
ble ratio exists for coronary artery lesions 
treated by percutaneous transluminal 
coronary angioplasty and coronary artery 
bypass surgery.
An unresolved question is who should 
perform angioplasties. The Committee on 
Vascular Surgery of the Inter-Society 
Commission for Heart Disease Re­
sources, formed by the United States 
Department of Health, Education, and 
Welfare,15 listed many requirements for 
the performance of high-quality vascular 
surgery. The committee members con­
cluded: “ We believe that the factors most 
responsible for the quality of vascular sur­
gery are the judgement and technical skill 
of the surgeon, both developed through 
properly supervised train ing  and 
experience.” There is no doubt that this 
applies equally to a person performing 
angioplasty, who must possess a thorough 
knowledge of all aspects of arterial dis­
ease and technical competence to perform 
the procedure well. Whether that person 
should be a radiologist, cardiologist or 
vascular surgeon is still unresolved.
One strong surgical viewpoint was 
presented in 1983 by Pfeiffer16 who 
stated, “ Vascular surgeons should per­
form PTA’s and offer it as a standard 
alternative to the patient’s treatment regi­
men. The surgeons’ clinical and surgical 
background makes him the person best 
suited to use this form of treatment. Vas­
cular radiologists, although experts at 
angiography, have little training or clini­
cal experience in the diagnosis, treatment 
and follow-up care of patients with vas­
cular disease. For them to select therapeu­
tic options and perform therapeutic oper­
ations is an inappropriate use of their 
talents.”
A solution to the problem is an efficient 
working relationship between surgeon, 
radiologist and the referring doctor, so 
that all may be involved in the decision­
making process and that the indications 
for percutaneous transluminal angio­
plasty are based on widely accepted 
criteria.
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Indications for Percutaneous 
Transluminal Angioplasty
The indications for percutaneous trans­
luminal angioplasty are being stan­
dardized, just as were the indications for 
reconstructive arterial surgery, by careful 
reporting of the early and longer term 
results of the procedure. However, 
decision-making is difficult because there 
are no randomized prospective studies 
comparing transluminal dilatation and 
vascular reconstructive surgery. The indi­
cations for percutaneous transluminal 
angioplasty of peripheral, renal and coro­
nary arteries are becoming more uniform 
and more acceptable to clinicians. Other 
arteries have been treated by this method 
although in smaller numbers. They 
include the vertebral, subclavian, pulmo­
nary, mesenteric and infrapopliteal arter­
ies, coarctation of the aorta and graft 
stenoses. The number is insufficient to 
arrive at any valuable conclusions.
The suggested indications for per­
cutaneous transluminal angioplasty com­
prise three groups as follows:
• Indications for surgery are valid but 
the patient (a) refuses an operation, (b) 
is a poor surgical risk or (c) has 
unfavourable run-off making reconstruc­
tion difficult.
• Mild symptoms interfere with life­
style but are not severe enough to war­
rant arterial surgery. It should be stressed 
that the lesion must be shown by clinical 
examination, noninvasive studies and 
pressure gradients to be hemodynamically 
important and not just a chance anatom­
ical angiographic finding.
• The patient has combined lesions. 
One lesion is treated by percutaneous 
transluminal angioplasty and the other by 
reconstructive surgery.
Peripheral Arterial Disease
The indications for transluminal 
angioplasty in peripheral arteries are as 
follows: stenosis of the iliac artery; ste­
nosis or thrombosis of the superficial 
femoral artery less than 5 cm long — 
longer segments can be dilated but the 
results are not as good; stenosis of graft 
anastomoses; stenoses of popliteal arter­
ies, at times aided by intra-arterial strep­
tokinase to lyse distal thrombus.
The contraindications to this technique 
in peripheral arteries are multiple sequen­
tial lesions in the common and external 
iliac arteries, lesions in the common 
femoral artery and lesions adjacent to the 
origins of the deep femoral, internal iliac 
and possibly the origins of the common 
iliac arteries.
Renal Artery Disease
Percutaneous transluminal angioplasty
is indicated for renal artery disease in 
patients with proven renovascular hyper­
tension and possibly those with failing 
renal function due to renal artery steno­
sis, who have fibromuscular hyperplasia, 
non-ostial arteriosclerotic lesions, reste­
nosis after previous percutaneous trans­
luminal angioplasty, or in whom recon­
structive surgery has failed. However, the 
method is contraindicated in patients with 
ostial or bifurcation lesions and renal 
arteries containing fresh mural thrombus.
Coronary Artery Disease
The classic indications for percutane­
ous transluminal coronary angioplasty 
have been disabling angina in patients 
who may require operation for stenosis 
in a single coronary artery — usually in 
the left anterior descending but also in 
other arteries and coronary artery bypass 
grafts. With increasing experience and 
better results the technique is now indi­
cated in less severe angina, if the stenosis 
is in a single vessel and in patients with 
two stenoses in one artery or a single ste­
nosis in each of two arteries.
Conclusions
Percutaneous transluminal angioplasty 
has evolved from an uncertain beginning 
to an accepted method of treating selected 
arterial lesions. Indications for the proce­
dure are becoming standardized and the 
results more predictable. More experience 
and improved techniques will probably 
result in greater use of this relatively sim­
ple method of treatment. All physicians
involved in the care of patients with 
arterial lesions should become ex­
perienced in this technique to provide 
optimal patient selection and results.
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SESAP IV Question
121. A man with severe pelvic trauma has blood dripping from the ure­
thral meatus. The prostate is elevated on rectal examination. The next step 
to assess the extent of urologic injury should be
(A) insertion of a Foley catheter
(B) cystogram
(C) retrograde urethrogram
(D) intravenous pyelogram (IVP)
(E) arteriogram
For the incomplete statement above select the best completion of the five 
given. For the critique of Item 121 see page 106.
(Reproduced by permission from SESAP IV  Syllabus; Surgical Education 
and Self-Assessment Program No. 4. For enrolment in the Surgical Educa­
tion and Self-Assessment Program No. 4, please apply to the American 
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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Cardiac Mortality and Morbidity 
After Vascular Surgery
To determ ine the clinical, hemodynamic 
and pathological features that contribute 
to  major cardiac complications after vas­
cular surgery, six patients w ith  early 
postoperative cardiogenic shock (group 
1) were analysed retrospectively and 
compared to nine patients w ithou t com ­
p lications (group 2) w ho were carefully 
analysed prospectively. Four group 1 
patients had elective repair o f an 
abdom inal aortic aneurysm, one had 
repair o f a false iliac artery aneurysm 
and one had a femoropopliteal g ra ft 
inserted. Four group 2 patients had elec­
tive  repair o f an abdominal aortic 
aneurysm and five had aortobifemoral 
reconstruction. The Goldman m ultifac­
toria l index was similar in both groups 
and indicated an expected death rate of 
2%  and a m orbid ity rate of 5%. in group 
1, the earliest sign o f cardiovascular 
comprom ise was an elevated pulmonary 
wedge pressure during operation. 
Postoperatively, electrocardiographic evi­
dence o f myocardial ischemia was 
present in all six patients and preceded 
cardiogenic shock. A utopsy of the four 
patients w ho died demonstrated trip le ­
vessel disease in all but recent occlusion 
in only one patient. There was evidence 
o f extensive subendocardial in farction in 
all four. Angiography of the tw o  sur­
v ivors in group 1 also demonstrated 
triple-vessel disease.
The authors conclude tha t by using 
ordinary clinical methods it  is d ifficu lt to
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iden tify  patients likely to  have major 
com plications postoperatively. Elevated 
pulm onary wedge pressures or elec­
trocard iographic evidence o f myocardial 
ischemia may be early w arning signs o f 
im pending cardiac catastrophe and 
should be treated aggressively. The 
underlying pathophysiology appears to  
be perioperative stress in a setting of 
severe triple-vessel coronary artery 
disease.
Dans le but de determ iner quels sont les 
facteurs cliniques, hemodynamiques et 
pathologiques qui contribuent aux com ­
p lications cardiaques de la chirurgie vas- 
culaire, on a analyse retrospectivem ent 
six patients qui ont subi un choc cardio- 
gene dans la periode postoperatoire pre- 
coce (le groupe 1) et on les a compares 
a neuf patients (le groupe 2) qui n 'on t 
pas eu de com plications et qui ont ete 
analyses soigneusement, de facon pros­
pective. Quatre patients du groupe 1 
avaient subi une reparation non urgente 
d 'un  anevrisme de I'aorte abdominale, un 
ava it eu une reparation d 'un faux ane­
vrism e de I'artdre iliaque et un avait eu 
une gre ffe  fem oro-poplitee. Quatre 
patients du groupe 2 avaient eu une 
reparation non urgente d 'un  anevrisme 
de I'aorte  abdominale et les cinq autres 
avaient subi une reconstruction aorto- 
bifemorale. L 'index m ultifactorie l de 
Goldman e ta it similaire pour les deux 
groupes et indiquait un taux apprehende 
de deces de 2%  e t un taux de morbidite 
de 5% . Dans le groupe 1, le signe le 
plus precoce d 'a tte in te  cardiovasculaire a 
ete une augmentation de la pression 
capillaire pulmonaire durant I'operation.
En postoperatoire, des signes electrocar- 
d iographiques d'ischem ie myocardique 
eta ient presents chez les six patients et 
ceci a precede I'apparition du choc car- 
diogene. Pour les quatre patients qui 
sont decedes, I'autopsie a re v ile  une 
stdnose de tro is vaisseaux mais I'occlu- 
sion e ta it recente dans un seul cas. On a 
constate dans les quatre cas un in fa rctus 
sous-endocardique etendu. L'angiogra- 
phie des deux survivants du groupe 1 a
aussi dem ontr6 une trip le  occlusion coro- 
narienne.
Les auteurs concluent qu a I’aide des 
m ethodes cliniques conventionne lles, il 
est d iffic ile  d ’ identifier les patients qui 
sont susceptibles de presenter des com ­
p lica tions postoperatoires. Une elevation 
de la pression capillaire pulm onaire ou 
des m anifestations e lectrocard iographi- 
ques d 'ischem ie m yocardique peuvent 
etre des signes avant-coureurs precoces 
d 'une  catastrophe cardiaque im m inente 
et do ivent etre traites agressivem ent. La 
physiopathologie sous-jacente semble 
etre un stress peroperatoire dans un 
tableau d 'occlusion coronarienne trip le .
Patients requiring vascular surgery are a 
high-risk group for several reasons — 
their advanced age, the presence of gener­
alized atherosclerosis, especially o f the 
coronary arteries, and the nature o f sur­
gery with infrarenal aortic cross­
clamping. The operative death rate for all 
types of vascular surgery averages 5%. 
The 3% to 5% risk in elective infrarenal 
aortic aneurysm surgery is the same as in 
any major abdominal operation1 and has 
been reported at less than 2%.2 The 
majority of these deaths are due to com­
plications of atherosclerosis in coronary 
or cerebral vessels.
Over 1 year, we saw six patients (group 
1) who suffered cardiogenic shock early 
after vascular surgery. Four died and two 
survived. Coronary anatomy was defined 
in all six patients and their postoperative 
courses were reviewed retrospectively 
to determine common factors that might 
be responsible. Subsequently we studied 
nine patients (group 2) who underwent 
abdominal aortic surgery on the same sur­
gical service, and recorded pertinent 
historic, electrocardiographic and 
hemodynamic data. These patients had 
no complications and served as a control 
for group 1.
Patients and Method
From Feb. 1, 1984 to Jan. 31, 1985, six 
men, ranging in age from 60 to 73 years
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(mean 68 years), underwent reconstruc­
tive vascular surgery. Four had elective 
repair of an abdominal aortic aneurysm, 
one had repair of false iliac artery 
aneurysm and one had a femoropopliteal 
bypass graft inserted. Five of the six 
patients had historical evidence of coro­
nary artery disease (previous myocardial 
infarction or angina), and the sixth had 
dyspnea on exertion. All were heavy 
smokers, averaging 50 pack-years. 
Preoperatively, chronic obstructive lung 
disease was evident in two, one patient 
was diabetic (taking oral hypoglycemic 
agents) and two had mild renal dysfunc­
tion. Electrocardiograms were abnormal 
in four: conduction disturbance (right 
bundle branch block or left anterior 
hemiblock) in three, ST-T anomalies in 
two and left ventricular hypertrophy with 
strain pattern in one. Two patients had 
normal electrocardiograms. The Gold­
man multifactorial index3 for these 
patients ranged from 3 to 11 (average 
5.6). This placed all the patients into class 
II cardiac risk with an expected death rate 
of 2°7o and morbidity rate of 5%. All 
underwent hemodynamic monitoring 
with a thermodilution no. 7 French 
Swan-Ganz catheter, four during opera­
tion and two immediately postopera- 
tively. The perioperative hemodynamic 
studies, postoperative electrocardiograms 
and clinical courses were reviewed.
Subsequently, nine patients (eight men, 
one woman) were studied prospectively 
for comparison. They ranged in age from 
57 to 86 years (mean 71 years) and also 
underwent major vascular surgery. Four 
had elective repair of an abdominal aor­
tic aneurysm and five had aortobifemoral 
reconstruction. Four patients had no 
symptoms of coronary artery disease; the 
other five had a history of angina or 
myocardial infarction. AH were heavy 
smokers, four were being treated for 
hypertension, five demonstrated chronic 
obstructive lung disease, three had previ­
ously suffered transient ischemic attacks 
or mild strokes and one was diabetic. 
Preoperatively the electrocardiograms in 
this group were normal in four and 
abnormal in five (evidence of previous 
myocardial infarction in four, left ventric­
ular strain pattern in two, atrial fibrilla­
tion in one, right bundle branch block in 
one and nonspecific ST-T anomalies in 
one). The Goldman multifactorial index 
ranged from 3 to 15 (average 6.8), plac­
ing this group also into class II cardiac 
risk. All patients underwent intraopera­
tive and postoperative hemodynamic 
monitoring with a Swan-Ganz catheter. 
Hemodynamic values of cardiac index 
and pulmonary capillary wedge pressure 
(PCWP) were obtained at three specific 
stages during surgery (before, during and 
after aortic cross-clamping), and again 
three times postoperatively (days 0, 1 and
Fig. la Fig. lb
FIG. 1—Intraoperative and postoperative hemodynamics in group 1 patients with cardio­
genic shock. White rectangles represent mean values for PCWP (a) and cardiac output (b) 
intraoperatively before aortic cross-clamping (PC), during cross-clamping (CC), after cross­
clamping (POC) and postoperatively on days 0, 1 and 2. Blacked out areas encompass mean 
± 1 standard deviation for control population (group 2).
Fig. 2a
Fig. 2b
FIG. 2—(a) Preoperative and (b) postoperative electrocardiograms of group 1 patient who 
died. Preoperatively only nonspecific T-wave changes can be seen, but postoperatively there 
is 3 mm of ST-segment depression in leads V5 and V6. R-wave voltage is also markedly decreased 
in anterior precordial leads.
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2). Electrocardiograms were obtained on 
days 0, 1, 2 and 7.
Results
At varying times postoperatively, cardi­
ogenic shock developed in all six group 
1 patients. It was defined by hypotension 
(blood pressure less than 80 mm Hg), 
oliguria and pulmonary edema. In four 
of them a low cardiac output syndrome 
developed within 48 hours of operation. 
In the other two shock developed on days 
6 and 16, respectively. The four deaths 
occurred within 1 to 48 hours after the 
episode of shock. The two survivors 
required multiple inotropic agents for 
several days.
The nine patients in group 2 had no 
complications and were ready for dis­
charge by day 12 after operation. The 
hemodynamic values from this group 
served as a control for comparison with 
those of group 1 patients (Fig. 1). In 
group 2, the PCWP decreased slightly 
during cross-clamping and increased sub­
stantially in the immediate postoperative 
period (day 0). All group 1 patients had 
values exceeding one standard deviation 
(SD) above the mean at some point 
intraoperatively or postoperatively. In 
many it exceeded two SDs (Fig. la) and 
generally remained elevated postopera­
tively.
The cardiac index in group 2 patients 
also decreased with cross-clamping but 
then recovered and increased sharply after 
operation. The intraoperative values of 
cardiac index in group 1 patients did not 
differ greatly from those of group 2, but 
postoperatively they failed to increase 
normally and were lower than those of 
group 2 patients (Fig. lb).
Electrocardiograms done postopera­
tively, hours before the episode of cardi­
ogenic shock, invariably showed severe 
myocardial ischemia (Fig. 2) (1 to 4 mm 
of ST depression in precordial leads). The 
length of time between the abnormal elec­
trocardiograms and the episodes of shock 
varied from 2 to 24 hours, the majority 
being closer to 24 hours. The electrocardi­
ographic findings are summarized in 
Table I.
Autopsies were performed on the four 
who died, and coronary angiography and 
left ventriculography were carried out on 
the two survivors (Table I). Three of the 
four who died had severe triple-vessel 
atherosclerosis without recent occlusion. 
Examination of the left ventricles showed 
extensive subendocardial infarction with 
occasional focal areas of transmural 
infarction. Angiography of the two sur­
vivors showed a normal ventricle in one 
and a globally hypokinetic ventricle in the 
other. Both patients showed the same 
severe atherosclerosis involving major
arteries or branches of all three coronary 
artery systems (Fig. 3).
The following two reports are typical, 
first of the four patients who died and 
second of the two survivors in group 1.
FIG. 3—Coronary angiogram in surviving 
patient from group 1. Right coronary artery 
(top panel) is occluded. Left anterior descend­
ing artery has proximal stenosis of 70% (white 
arrow), and distal left circumflex artery (black 
arrow) is occluded.
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Case Reports
Case 1
A 69-year-old man, who was a 55 pack-year 
smoker, was admitted with gangrene of his left 
foot. Past history included diabetes mellitus 
and a transient attack of ischemia 13 months 
earlier. He denied suffering from angina and 
his preoperative electrocardiogram appeared 
normal. Left femoropopliteal grafting was 
uncomplicated apart from an episode of ven­
tricular trigeminy and transient mild bron- 
chospasm just after induction of anesthesia. 
Immediately after the operation he became 
acutely dyspneic, hypoxic (partial pressure of 
oxygen 70 mm Hg while receiving 70% oxy­
gen), hypercarbic (partial pressure of carbon 
dioxide 60 mm Hg) and required reintubation. 
He then became hypotensive, and tachycardia 
and pulmonary edema developed. A pulmo­
nary artery catheter was inserted. After dopa­
mine was administered, the PCWP was 16 mm 
Hg. A few hours later an electrocardiogram 
showed 4 mm ST depression in lateral precor­
dial leads and a reduction of 75% of the R- 
wave amplitude (maximal decreases in leads I 
and AVL). After this acute episode, his con­
dition improved temporarily and dopamine 
was discontinued on day 2. On postoperative 
day 3 he extubated himself and within hours 
severe pulmonary edema developed with sinus 
tachycardia (heart rate 130 beats/min), a high 
PCWP (22 mm Hg) and a cardiac index of 3.5 
L/min • rr r2. Over the next 48 hours his con­
dition deteriorated and he required increasing 
amounts of inotropic agents (epinephrine, 
dopamine, dobutamine and amrinone) because 
of falling cardiac output. An electrocardiogram 
obtained the day before his death showed 
widespread ST-segment depression with a fur­
ther reduction in R-wave amplitude. He finally 
succumbed on postoperative day 6 with a triad 
of hypotension, pulmonary edema and anuria. 
Autopsy revealed extensive subendocardial 
infarction in posterior, lateral, septal and 
anterior walls with focal extension in the sep­
tal wall. Serial sections of his coronary arter­
ies showed 90% stenosis of the right coronary 
artery, 50% stenosis of the circumflex artery, 
60% stenosis of the left anterior descending 
coronary artery and 90% stenosis of the first 
diagonal branch.
Case 2
A 67-year-old man who was a 100 pack-year 
smoker was admitted for surgery on an aortic 
aneurysm because serial computed tomograms 
had demonstrated a recent increase in 
anterior-posterior diameter to 6.8 cm. His 
medical history included dyspnea on walking 
one block (no angina) and palpitations, which 
were treated with Inderal. The preoperative 
electrocardiogram showed left anterior hemib- 
lock and nonspecific ST-segment anomalies 
with T-wave inversion in leads V3 to V6. The 
operation was technically uncomplicated, but 
hemodynamically myocardial function was 
depressed intraoperatively: the cardiac index 
ranged from 1.55 to 1.65 L/min • m"2, the 
PCWP was 19 mm Hg and systemic vascular 
resistance ranged from 1760 to 2400 dyn s 
c m '5. Within 1 hour of operation, the 
patient had profound pulmonary edema with 
hypoxia and severe bronchospasm. Hypoten­
sion (systolic blood pressure 60 mm Hg)
responded initially to inotropic agents (calcium 
gluconate and dopamine) but recurred in 
association with elevated filling pressures 
(PCWP 31 mm Hg, central venous pressure 34 
mm Hg). Low cardiac output (cardiac index 
1.03 L/min *m"2) persisted for 6 hours, but 
with the administration of multiple drugs 
(dopamine, calcium gluconate, epinephrine, 
nitroglycerin, Inderal, aminophylline, sodium 
bicarbonate, morphine, digoxin and Pavulon) 
his condition improved. Electrocardiograms 
obtained during this period showed ischemic 
changes in the anterolateral precordial leads 
and a generalized 60% to 70% reduction of R- 
wave amplitude. He required inotropic agents 
for 4 days and was extubated on day 5. Sub­
sequently, he made a smooth recovery. Cardiac 
catheterization carried out just before he was 
discharged on day 25 demonstrated a normal 
left ventricle with a left ventricular end-diastolic 
pressure of 8 mm Hg and also triple-vessel dis­
ease: 70% stenosis of the right coronary artery, 
80% stenosis of first marginal artery and 70% 
stenosis of the left anterior descending coro­
nary artery.
Discussion
We believe that the cardiogenic shock 
suffered by our six patients was caused 
by severe triple coronary artery atheros­
clerosis in a setting of major cardiovas­
cular stress (aortic cross-clamping, fluid 
loading and hypotension). Myocardial 
ischemia from triple-vessel disease either 
intraoperatively or postoperatively leads 
to extensive subendocardial myocardial 
infarction with progressive cardiac dila­
tation and the clinical features of 
hypotension, pulmonary edema and 
oliguria that proved lethal in four cases 
and almost so in two. Transmural infarc­
tion with the development of new Q 
waves occurred in two of the patients, one 
of them being the only patient to show 
evidence of a recent coronary occlusion 
at autopsy.
Preoperative assessment of these 
patients (history, physical examination, 
electrocardiography and Goldman clas­
sification) failed to identify high-risk 
persons. The Goldman classification was 
comparable (class II) in the group of 
patients with cardiogenic shock and 
in the control group and, in both, in­
dicated a possible death rate of 2%, 
which is relatively low. Our previous 
efforts to identify patients at risk 
for cardiovascular complications, using 
routine clinical assessment, showed 
four factors that predicted cardiac com­
plications.4 The New York Heart Associ­
ation classification in group 1 patients 
identified one patient as being in class III 
and none in class IV, the highest risk 
categories. The second factor (ST- 
segment depression greater than 1 mm on 
the preoperative electrocardiogram) was 
present in two patients of each group. The 
third factor (electrocardiographic evi­
dence of previous myocardial infarction) 
was not present in any of the group 1
patients. The fourth factor was age. The 
mean age of 68 years in group 1 represents 
a 17% risk of cardiac complication in our 
experience. The mean age of patients in 
the control group was 71 years which 
represents a slightly greater risk (21%).
Hence, clinical identification of 
patients who must undergo major vascu­
lar surgery and may have catastrophic 
cardiac complications is quite difficult 
and underscores the need for a combina­
tion of noninvasive and invasive cardiac 
assessment preoperatively.
Early signs of myocardial dysfunction 
are an inordinately high (more than 18 
mm Hg) PCWP intraoperatively (Fig. la) 
and severe myocardial ischemia as 
observed on postoperative electrocardio­
grams. Both preceded the development of 
cardiogenic shock by at least 24 hours. 
The PCWP measured in four group 1 
patients exceeded 18 mm Hg at some 
point intraoperatively. Several studies5-8 
have attempted to determine an optimal 
filling pressure intraoperatively and sug­
gested keeping the PCWP above 10 mm 
Hg, to avoid the decrease in PCWP and 
cardiac output that is observed during 
cross-clamping in patients who do not 
have cardiac disease. Patients with 
cardiac disease often show an increase in 
PCWP during cross-clamping. So long as 
this increase is small and the pressure is 
less than 18 mm Hg, cross-clamping 
would appear to be well tolerated.
The electrocardiographic findings of 
myocardial ischemia observed in this 
study need to be emphasized.
We have shown that ST-segment 
depression on the preoperative elec­
trocardiogram predicts cardiac complica­
tions, also that postoperative ST-segment 
depression precedes catastrophic cardiac 
complications, so this change must be 
noted early in the postoperative period 
and treated aggressively.
In contrast, cardiac output intraoper­
atively did not predict complications. 
However, our study indicates that an 
increase in cardiac output should be anti­
cipated postoperatively. This finding is 
not new; Bush and colleagues9 reported 
perioperative hemodynamic values, up to 
48 hours postoperatively, in 22 high-risk 
patients who underwent abdominal aor­
tic aneurysm surgery. Although 21 
patients showed evidence of pre-existing 
cardiovascular disease (e.g., myocardial 
infarction and arrhythmia) there were no 
deaths and no major cardiovascular com­
plications. The cardiac index (pre-, intra- 
and postoperatively) parallels our 
experience in the control patients (Fig. 
lb). The mechanism explaining this rise 
in cardiac index after operation is 
unknown, but several factors are proba­
bly responsible; for example fluid load­
ing during cross-clamping to prevent 
generalized stress-induced release of 
catecholamines.10 Failure to observe an
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increase in cardiac output postoperatively 
should be a cause for concern.
We recommend continued close moni­
toring of the PCWP and cardiac index 
both intraoperatively (before, during and 
after cross-clamping) and postoperatively, 
until the patient is stable. Optimal filling 
pressures intraoperatively, from this 
study, would be a PCWP of less than 18 
mm Hg. Daily cardiac output determina­
tions and electrocardiography for 72 
hours after operation constitute ideal 
monitoring and may identify patients in 
imminent cardiovascular danger. For 
patients whose cardiac index is subop- 
timal, aggressive drug therapy with 
inotropic agents and reduction of after­
load may offset episodes of myocardial 
ischemia that may cause clinically down­
ward spirals and subsequent death.
Conclusions
Conclusions can be made in four areas: 
clinical, electrocardiographic, hemo­
dynamic and pathologic. From this study, 
it is evident that clinical markers for 
cardiovascular disease are variable and 
often fail to predict postoperative prob­
lems. The Goldman multifactorial index 
of cardiac risk was not of value in our 
study. Electrocardiographic evidence of
myocardial ischemia may be a sign of 
impending acute cardiac failure and we 
recommend that it be treated aggressively 
with intravenous administration of 
nitrates. High-risk patients may be iden­
tified (a) in the operating room during 
cross-clamping by a PCWP greater than 
18 mm Hg, and (b) in the early postoper­
ative period by lack of the normal exag­
gerated response in cardiac output dur­
ing the first 48 hours. Severe triple-vessel 
disease, not necessarily associated with 
acute coronary artery occlusion, appears 
to be responsible for the episodes of clin­
ical shock and attempts should be made 
preoperatively to identify patients with 
coronary artery disease. Damage to the 
myocardium is subendocardial rather 
than transmural, as in typical myocardial 
infarctions. Perioperative death in these 
high-risk patients can be reduced by pay­
ing close attention to intra- and postoper­
ative hemodynamic measurements, opti­
mizing filling pressures and cardiac 
function, and identifying and treating 
myocardial ischemia early.
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PIPRACIL
Parental Antibiotic for Intravenous and Intramuscular Use
INDICATIONS AND CLINICAL USES: Treatment of serious infections caused by susceptible strains of the 
designated organisms in the conditions listed below. Intra abdominal Infections including hepatobiliary and 
surgical infections caused by Escherichia coli, Pseudomonas aeruginosa, enterococci. Clostridium sp., anaerobic 
cocci, and Bacteroides sp., including B. fragilis. Urinary Tract Infections (complicated and uncomplicated) 
caused by Escherichia coli, Klebsiella sp., Pseudomonas aeruginosa, Proteus mirabilis and enterococci. Also 
uncomplicated urethritis caused by Neisseria gonorrhoeae. Gynecological Infections including endometritis and 
pelvic inflammatory disease caused by Bacteroides sp., including B. fragilis, anaerobic cocci, Neisseria 
gonorrhoeae, and enterococci (Streptococcus faecalis). Septicemia caused by Escherichia coli, Klebsiella sp., 
Serratia sp., Proteus mirabilis, S. pneumoniae, enterococci, Pseudomonas aeruginosa, Bacteroides sp., and 
anaerobic cocci. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella sp., Enterobacter sp., 
Pseudomonas aeruginosa, Serratia sp., Haemophilus influenzae, Bacteroides species and anaerobic cocci 
Although improvement has been noted in patients w ith  cystic fibrosis, lasting bacterial eradication may not be 
achieved. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella sp., Serratia sp., 
Acmetobacter sp., Enterobacter sp., Pseudomonas aeruginosa, indole-positive Proteus sp., Proteus mirabilis, 
Bacteroides sp., including B. fragilis, anaerobic cocci and enterococci Bone and Joint Infections caused by 
Pseudomonas aeruginosa, enterococci, Bacteroides sp., and anaerobic cocci. PIPRACIL* is useful for the 
treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms; 
infections produced by organisms resistant to other penicillins, some aminoglycosides and cephalosporins; and 
infections at various sites caused by streptococcus species including Group A beta-hemolytic Streptococcus and 
Streptococcus pneumoniae.
PIPRACIL* may be administered as single drug therapy in some situations where normally tw o antibiotics might 
be employed. In vitro synergism has been shown between Piperacillin and some aminoglycosides in some 
bacterial strains. PIPRACIL* has been used clinically w ith  aminoglycosides, especially in patients w ith  impaired 
host defences. Both drugs were used in full therapeutic doses. PIPRACIL'can be used safely in combination w ith 
a penicillinase-resistant penicillin, e.g. oxacillin, in mixed infections when beta-lactamase-positive Staphyloccus 
aureus is isolated along w ith  piperacillin-susceptible organisms. It may be administered concomitantly w ith  a 
cephalosporin, provided that an additive or synergistic antibacterial action of the two antibiotics is ascertained 
through in vitro tests. Based on in vitro data, cefoxitin should not be given w ith  piperacillin when Pseudomonas 
infections are suspected or confirmed.
Because PIPRACIL* is excreted not only renally, but also by the biliary route, it can be used in patients with 
hepatobiliary infections, or severely restricted kidney function, and in patients who have had nephrotoxic 
reactions to other drugs, w ith  appropriate adjustment of dosage (See DOSAGE).
Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if 
appropriate, once the results are known.
CONTRAINDICATIONS: A history of allergic reactions to any of the penicillins and/or cephalosporins. 
WARNINGS: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in 
patients receiving therapy w ith  penicillins. These reactions are more apt to occur in persons w ith  a history of 
sensitivity to multiple allergens.
Cross-sensitivity of patients to penicillins and cephalosporins has been reported. Before initiating therapy 
w ith  PIPRACIL* careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, 
cephalosporins and other allergens.
If an allergic reaction occurs, the antibiotic should be discontinued. SERIOUS ANAPHYLACTOID REACTIONS 
REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS 
AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS NECESSARY. 
PRECAUTIONS: Bleeding manifestations have occurred in some patients receiving beta-lactam antibiotics 
including piperacillin. These reactions have sometimes been associated w ith  abnormalities of coagulation tests 
such as clotting time, platelet aggregation and prothrombin time and are more likely to occur in patients w ith 
renal failure.
If bleeding manifestations or significant leukopenia occur, PIPRACIL* should be discontinued and appropriate 
therapy instituted.
The possibility of the emergence of resistant organisms and the development of superinfections should be kept in 
mind, particularly during prolonged treatment. As w ith  other penicillins, patients may experience neuromuscular 
excitability or convulsions if higher than recommended doses are given intravenously.
Dosage adjustment should be made in renal insufficiency.
PIPRACIL* is a monosodium compound containing 1.98 milliequivalents (45.5 mg) of Na +  per gram based on 
vial content which includes the U.S.P. allowed average. The calculated value, based on molecular weight is 1.85 
mEq/g (42.55 mg). Periodic electrolyte determinations should be made in patients w ith  low potassium reserves 
and the possibility of hypokalemia should be kept in mind w ith  patients who have potentially low  potassium 
reserves, receiving cytotoxic therapy or diuretics. Electrolyte and cardiac status should also be monitored during 
prolonged-treatment in patients w ith impaired cardiac function.
Prior to treatment, patients w ith  gonorrhea should also be evaluated for syphilis. Specimens for darkfield 
examination should be obtained from patients w ith  any suspected primary lesions, and serologic tests should be 
performed. In all cases where concomitant syphilis is suspected, monthly serological tests should be made for a 
minimum of 4 months.
The use of penicillins (ampicillin, amoxicillin) has been associated w ith  morbilli form rashes in some cases of 
infectious mononucleosis. PIPRACIL* should be used w ith  caution in the treatment of patients w ith  infectious 
mononucleosis.
Drug Interactions: The mixing of PIPRACIL* w ith  an aminoglycoside in vitro can result in substantial inactivation 
of the aminoglycosides.
Usage During Pregnancy or Lactation: Safety of PIPRACIL* use in pregnant women has not been determined 
Because animal reproduction studies are not always predictive of human response, this drug should be used 
during pregnancy only if clearly needed. It has been found to cross the placenta in rats. Caution should be 
exercised when PIPRACIL* is administered to nursing mothers. It is excreted in low concentrations in milk. 
Pediatric Use: Dosages for children under the age of 12 have not been established.
ADVERSE REACTIONS: PIPRACIL* is generally well tolerated. The most common adverse reactions have been 
local in nature, following intravenous or intramuscular injection. The follow ing adverse reactions may occur:
Local Reactions-ln clinical trials thrombophlebitis was noted in 3.8% of patients. Pain, erythema, and/or 
induration at the injection site in 1.9% of patients. Less frequent reactions: ecchymosis, deep vein thrombosis 
and hematomas. Hypersensitivity Reactions-Rash was noted in 1.9% of patients. Drug fever 2.1%. Less 
frequent findings: Pruritus, vesicular eruptions, positive Coombs tests Gastrointestinal-Diarrhea and loose 
stools were noted in 2.8% of patients. Less frequent reactions: vomiting, nausea, bloody diarrhea. 
Hepatic-Increases in liver enzymes (LDH, SGOT, SGPT), hyperbilirubinemia. Rarely, cholestatic hepatitis. 
Renal-Elevations of creatinine or BUN. Central Nervous System-Headache, dizziness, fatigue. Hemic and 
Lymphatic-Reversible leukopenia, thrombocytopenia and/or eosinophilia, bleeding and decreases in prothrombin 
time have been reported. Reversible leukopenia (neutropenia) is more apt to occur in patients receiving prolonged 
therapy at high dosages or in association w ith  drugs known to cause this reaction. Serum Electrolytes-lndividuali 
w ith  liver disease or individuals receiving cytotoxic therapy or diuretics, were reported rarely to demonstrate a 
decrease in serum potassium concentrations w ith  high doses of PIPRACIL*. Musculo-Skeletal-Rarely, prolonged 
muscle relaxation. Other-Superinfection, including candidiasis.
ADMINISTRATION
Intramuscular: When indicated by clinical and bacteriological findings, intramuscular adminstration of 6 to 8 g 
daily of PIPRACIL* in divided doses, may be utilized for initiation of therapy and this route may be considered for 
maintenance therapy after clinical and bacteriologic improvement has been obtained w ith intravenous piperacillin 
sodium treatment. Administration should not exceed 2 g per injection at any one site. This route has been used 
primarily in the treatment of patients w ith  uncomplicated gonorrhea and urinary tract infections.
Adults and Children More Than 12 Years of Age: The reconstituted solution is given by deep intramuscular 
injection. The preferred site of injection is the upper outer quadrant of the buttock (i.e. gluteus maximus). Also 
may be given in the mid-lateral muscles of the thigh. The deltoid area should be used only if well developed, and 
then only w ith  caution to avoid radial nerve injury. Intramuscular injection should not be made into the lower or 
mid-third of the upper arm.
Intravenous: The intravenous route should be used in the treatment of serious infections.
Direct Intravenous (Bolus) Injection: The vials should be reconstituted w ith  5 mL of suitable diluent listed below 
and the resulting solution should be injected slowly over a period of 3 to 5 minutes to help avoid vein irritation. 
Intravenous Infusion: A dilution of at least 15 mL per gram is recommended to reduce potential for vein 
irritation. The reconstituted and diluted solution may be administered by interm ittent or continuous drip.
Intermittent infusion should be administered over a period of about 30 minutes. During intermittent infusion it is 
desirable to discontinue the primary intravenous solution. Any unused portion must be discarded. For continuous 
infusion the solution may be administered over a longer period of time 
RECONSTITUTION
For Intramuscular Use: Solutions for Reconstitution: Sterile Water for injection, or if required Bacteriostatic 
Water for Injection, Lidocame HC1 0.5 or 1% (without epinephrinel-For Intramuscular Use Only.
For Intravenous Use: Solutions for Reconstitution: Sterile Water for Injection, or if required, Bacteriostatic Water 
for Injection. Either parabens or benzyl alcohol. Lidocaine HC1 is contraindicated in patients w ith a known history 
of hypersensitivity to local anesthetics of the amide type.
RECONSTITUTION TABLE
Product Size
Volume of Diluent 
to be added
Approximate Available 
Volume
Approximate Average 
Concentration
Vials 2 g 4.0 mL 5.0 mL 1 g/2.5 mL
3 g 6.0 mL 7.5 mL 1 g/2.5 mL
4g 7.8 mL 10.0 mL 1 g/2.5 mL
Infusion Bottles 
3 g 15 mL 17 mL
4g 20 mL 23 mL
The prepared solution may be further diluted to the desired volume w ith any of the solutions for intravenous 
infusion listed below.
The contents of the 3 and 4 g infusion bottles should be diluted to at least 15 mL per gram.
The appropriate quantity of reconstituted solution may be added to an intravenous bottle or bag containing any 
of the solutions for intravenous infusion listed below.
Solutions for Intravenous Infusion: 
Intravenous Solutions:
5% Dextrose in Water IDsWI.
0.9% Sodium Chloride (Normal Saline) (NS). 
Dextrose 5% and 0.9% Sodium Chloride IDsNS) 
Lactated Ringer's Injection, U.S.P.
Dextran 6% in 0.9% Sodium Chloride
Intravenous Admixtures:
Normal Saline I +  KCL 40 mEq.)
5% Dextrose/Water ID'.WI I +  KCL 40 mEql.
5% Dextrose/Normal Saline (D‘-NS) ( +  KCL 40 mEql. 
Ringer's Injection, U.S.P. I +  KCL 40 mEq).
Lactated Ringer's Injection, U.S.P. I +  KCL 40 mEq).
STABILITY OF SOLUTIONS: PIPRACIL* is stable in both glass and plastic containers when reconstituted with 
recommended diluents and further diluted w ith  the indicated intravenous solution and intravenous admixtures. 
Stability studies have demonstrated chemical stability (pH, potency and clarity! through 24 hours at room tern 
perature and up to 72 hours refrigerated. Appropriate consideration of aseptic technique, however, recommends 
discarding unused portions after storage for 24 hours at room temperature or 48 hours refrigerated If used as a 
multi-dose container, the vials must be reconstituted only w ith  the bacteriostatic diluents noted above 
INCOMPATIBILITY: Because of chemical instability, PIPRACIL* should not be used for intravenous 
administration w ith  solutions containing sodium bicarbonate.
PIPRACIL* should not be added to blood products, protein hydrolysates or amino acids.
When PIPRACIL* is given concurrently w ith  aminoglycosides, it is recommended that both drugs be used in full 
therapeutic doses, but administered separately. PIPRACIL* should not be mixed w ith an aminoglycoside in a 
syringe or infusion bottle, since this can result in inactivation to the aminoglycoside.
DOSAGE FORMS: PIPRACIL’  (sterile, lyophilized piperacillin sodium) is available in vials containing amounts of 
piperacillin sodium equivalent to 2, 3 and 4 grams of piperacillin. Available in boxes of 12 vials.
Product Numbers: 2 g/vial-3879-48 3 g/vial-3882 49 4 g/vial-3880-50.
Available in 100 mL size infusion ("piggyback") bottles, containing sterile, freeze-dried piperacillin sodium powder 
equivalent to 3 and 4 grams of piperacillin. Boxes of 12 infusion bottles.
Product Numbers: 3 g/bottles-3882-41 4 g/bottles-3880-42.
Pipercillin Sensitivity Discs impregnated w ith  100 / ig  of piperacillin are also available.
Storage: PIPRACIL'vials and infusion bottles should be stored at controlled room temperatures of 15 30°C 
(59-86°F).
Pipercillin Sensitivity Discs should be refrigerated upon receipt. Product Monograph available on request. 
DOSAGE AND ADMINISTRATION: PIPRACIL* may be administered by the intramuscular route or intravenously 
by injection or infusion. Dosage and route of administration should be determined by the severity of the infection 
and condition of the patient. The usual dosage for serious infections is 3 to 4 grams given every 4 to 6 hours as a 
20 to 30 minute infusion administered intravenously. The maximum daily dose usually administered to adults is 
24 g/day, although higher doses have been used.
DOSAGE
Type of Infection Usual Total Daily Dosage Frequency of Administration
Serious infections such as septicemia, nosocomial 12-18 g I V. Every 4 to 6 hours
pneumonia, intra-abdominal infections, aerobic (200-300 mg/kq)
and anaerobic gynecologic infections, and skin
soft-tissue infections.
Complicated urinary tract infections. 8-16 g I.V. (125-200 mq/kq) Every 6 to 8 hours
Uncomplicated urinary tract infections and most 6-8 Q 1 M. or I.V. Every 6 to 12 hours
community-acquired pneumonia. (100-125 mg/kg)
Uncomplicated gonococcal urethritis. 2 g I.M .* Single dose
*0ne gram of probenecid given orally 1/2 hour prior to injection.
Dosage in Renal Impairment
Creatinine Clearance 
mL/min.
Urinary Tract Infection Urinary Tract Infection 
(uncomplicated) (complicated)
Serious Systemic 
Infection
> 4 0 No dosage adjustment necessary
20-40 No dosage adjustment necessary 9 g/day 3 g every 8 hrs. 12 g/day 4 g every 8 hrs.
< 2 0 6 g/day 3 g every 12 hrs. 6 g/day 3 g every 12 hrs. 8 g/day 4 g every 12 hrs.
Patients on 
Hemodialysis*
‘ Hemodialysis removes 30-50% of piperacillin in 4 hours; 
1 g additional dose should be administered following 
each dialysis period.
6 g/day 2 g every 8 hrs.
For patients w ith  renal failure and hepatic insufficiency, measurement of serum levels of PIPRACIL* w ill provide 
additional guidance for adjusting dosage.
Infants and Children-Dosages in infants and children under 12 years of age have not been established.
The average duration of PIPRACIL* treatment is from 7 to 10 days, except for gynecologic infections, in which 
it is from 3 to 10 days; the duration should be guided by the patient's clinical and bacteriological progress. For 
most acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes 
asymptomatic. Therapy for Group A beta-hemolytic streptococcal infections should be maintained for at least 10 
days to reduce the risk of rheumatic fever of glomerulonephritis.
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Sensitivity of the Hemoccult II Slide Test 
in Detecting Colonic Neoplasms
It is common clinical practice to test 
stools for occult blood and to rely heav­
ily upon the result in deciding whether to 
investigate further. Because the accuracy 
of such testing has been questioned, a 
study was conducted to estimate the 
sensitivity of the Hemoccult II slide test 
in detecting colonic carcinoma and 
polyps. Patients with lesions demon­
strated on barium enema roentgenogra­
phy had their stools examined for occult 
blood. One to 2 weeks before 
colonoscopy, stool specimens were col­
lected for 3 consecutive days according 
to the manufacturer's instructions. The 
sensitivity of occult blood testing was 
38% for patients with benign polyps and 
64% for patients with polypoid carci­
nomas. Thus, the authors conclude that 
the Hemoccult II test is not reliable as a 
diagnostic tool and that a negative test 
result does not exclude the presence of 
a colonic neoplasm in any patient.
II est courant sur le plan clinique de 
depister le sang occulte dans les selles 
et de se fier beaucoup au resultat pour 
determiner s'il y a lieu de poursuivre plus 
amples recherches. Etant donne que la 
precision de ce genre de depistage a ete 
I'objet de questions, une etude a ete 
menee pour evaluer la sensibilite du test 
sur lame, I'Hemocculte II, dans la detec­
tion du carcinome et des polypes du 
colon. Les patients dont les lesions ont 
ete demontrees grace au lavement baryte 
se sont fait examiner les selles pour 
determiner si elles contenaient du sang 
occulte. Durant une periode d'une a 2 
semaines avant la colonoscopie, des
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echantillons de selles ont ete preieves 
pendant 3 jours consecutifs selon les 
directives specifiees par le fabricant. La 
sensibilite de ce depistage du sang 
occulte dans les selles etait de 38%  
chez les patients souffrant de polypes 
benins et de 64% chez des patients 
souffrant de carcinomes polypoides. La 
reaction de I'Hemocculte II de la 
presente etude ne s'est pas reveiee etre 
un test fiable de diagnostic. Par conse­
quent, un resultat negatif n'eiimine pas 
la possibiiite d'un neoplasme colique.
Colorectal carcinoma is the second com­
monest internal malignant lesion in North 
American people.1 Survival of patients 
with this disease is better when it is 
detected and treated early. Over the past 
30 years the death rate from colorectal 
carcinoma has not improved appreciably 
despite the introduction of new surgical 
techniques and various chemotherapeu­
tic protocols.2 Among methods available 
to screen for malignant lesions of the 
large intestine, barium enema roentgenog­
raphy and colonoscopy are not practical. 
The use of blood tests such as the one to 
measure the carcinoembryonic antigen 
level has not yet proven of value. Fecal 
occult blood testing and rigid sig­
moidoscopy have been actively promoted 
in screening for large-bowel neoplasms. 
In the past it was suggested3 that routine 
rectal examination and expert rigid rec­
tal sigmoidoscopy would be able to detect 
two thirds of all colorectal neoplasms. 
However, it has been shown4 recently 
that the distribution of carcinoma of the 
large bowel has changed from the rectum 
and left colon to the right colon. This 
diminishes the value of rigid sig­
moidoscopy as the only screening method 
for detecting colorectal carcinoma.
Testing stool samples for occult blood 
in the manner proposed by Greegor5 is 
currently advocated as a means of screen­
ing populations for colorectal carcinoma. 
Initial reports of randomized prospective 
trials using the Hemoccult slide test have
indicated a high specificity with a false­
positive rate of only 0.5% to 2.1% for 
neoplasms of the colon and rectum.6 
However, it will take 5 to 10 years before 
the sensitivity of stool occult blood test­
ing can be obtained, as the false-negative 
results only surface after several years of 
follow-up.7 For a screening test to be 
useful both the sensitivity and specificity 
must be high. A screening test with a low 
sensitivity will give many false-negative 
results with many affected persons being 
missed. There is a growing consensus that 
the majority of colorectal carcinomas 
begin as adenomas.8 This would suggest 
that the secondary prevention of colorec­
tal carcinoma might be possible by early 
detection and removal of the precursor 
lesions. To estimate the sensitivity of the 
Hemoccult II slide test (SmithKline Diag­
nostics, Sunnyvale, Calif.) in detecting 
colonic carcinomas and polyps, patients 
with known lesions of the colon were 
tested before colonoscopy.
Methods
All patients with colonic lesions 
demonstrated by barium enema examina­
tion were entered into the trial. Those 
with lesions within 15 cm of the anal verge 
were excluded. Since Hemoccult testing 
is meant to screen asymptomatic persons, 
individuals with anemia were excluded. 
Patients with a coagulopathy, those on 
anticoagulants and those taking salicy­
lates were also excluded. Those with a 
previous history of rectal bleeding were 
included provided the above criteria were 
met and there was no evidence of blood 
on proctosigmoidoscopy carried out 
before the occult blood testing. One to 2 
weeks before colonoscopy the patients 
were given the Hemoccult II slides and 
were told to follow the dietary instruc­
tions outlined by the manufacturer. The 
stool specimens were collected for 3 con­
secutive days. Two samples were obtained 
from different portions of the same stool, 
each being smeared on a separate window
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of the slide. The subjects were asked to 
return the cards as soon as possible after 
obtaining the samples. The slides were not 
rehydrated before testing. All results were 
read by one of the two technicians who 
process all occult blood tests for the 
hospital and its outpatient clinics. They 
were not aware of the nature of the study.
In all, 72 patients completed the slides. 
They ranged in age from 40 to 79 years 
(mean 60.3 ± 11.6 years). Of the 72, 61 
had benign polyps and 11 carcinomas.
Results
In 38 patients with one or more benign 
polyps, the Hemoccult II test gave a nega­
tive result, for a sensitivity of 38%; in 
other words, this test failed to detect 
blood in 62% of cases. Sensitivity with 
respect to size is shown in Table I. Of the 
11 patients with polypoid carcinomas, 4 
had test results that were negative for 
occult blood, a sensitivity of 64% (i.e., 
blood was not detected in 36%). Table II 
illustrates the sensitivity for benign and 
malignant lesions.
Discussion
The use of occult blood testing of stool 
to detect and prevent colorectal carci­
noma has been advocated by the Ameri­
can Cancer Society9 and the Canadian 
Task Force on the Periodic Health 
Examination.10 The question remains 
whether current tests available for detect­
ing occult blood in the stool are the ideal 
screening methods for detecting colorec­
tal neoplasms
Several issues regarding the use of 
occult blood testing have not been 
resolved. These include age of onset of 
screening, patient compliance, diet while 
stools are being collected, time limit of 
slide storage, necessity for rehydration, 
sensitivity, effect on the natural history 
(i.e., morbidity, mortality) of colonic 
cancer and cost-effectiveness.
Current, ongoing, prospective studies 
of Hemoccult testing have reported a rate 
of slide positivity of 1% to 3.7% and a 
false-positive rate of 0.5% to 2.1%.6'n
These results suggest a relatively high 
specificity, defined as the percentage of 
patients without disease who have a nega­
tive test. The validity of the screening test 
also depends on a low false-negative rate 
or a high sensitivity. Sensitivity can be 
defined as the percentage of patients with 
disease who have a positive test.
The relatively low sensitivity of Hemoc­
cult II for carcinomas (64%) and polyps 
(38%) in our series is similar to that 
reported by others (Table III6-12' 18). In 
assessing the sensitivity of Hemoccult II 
for patients with colorectal carcinoma, 
Van Maercke and colleagues12 found 
30.2% of patients to be Hemoccult nega­
tive. In a preliminary report of a large, 
ongoing, mass screening study, the false­
negative rate of the Hemoccult II test was 
76% for adenomas in the rectosigmoid.6 
In another study using Hemoccult alone, 
58% of adenomas were not detected.13 
Hagihara and colleagues14 suggested that 
the results of the stool Hemoccult test to 
detect neoplastic polyps were size-related. 
Of 20 polyps ranging in size from 0.5 to 
1.0 cm, negative results were obtained for 
19. Even for the 32 polyps measuring 1 
cm or greater, 19 (60%) tested negative.
in studies by Macrae and col­
leagues,15-19 the sensitivity could be
Table III—Studies of Hemoccult Sensitivity 
False-negative, %
Series________________ Polyps Carcinoma
Schewe and
associates, 197913 58 36
Winawer, 19806 76 —
Gnauck, 198016 40 13
Griffith and
associates, 198117 — 18
Van Maercke and
associates, 198212 — 30
Hagihara and 95* -
associates, 198214 601 —
Macrae and
associates, 198215 — 31
Crowley and
associates, 198318 77 48
Present series 62 36
* <  1 cm. 
t >  1 cm.
improved by rehydrating the slides before 
testing. Their previous work had sug­
gested that rehydration resulted in an 
unacceptable rise in the false-positive rate. 
They suggested that this problem could 
be prevented if the patients followed a 
strict red-meat-free diet and avoided 
vegetables with a high peroxidase activity. 
The issue of rehydration was not 
addressed in our study and is still con­
troversial.
These slide tests are meant for asymp­
tomatic individuals on a regular basis. 
When using the Hemoccult test the 
patient must complete all six slides. Anal­
ysis of daily individual smears indicated 
that only 41% of neoplastic lesions would 
have been detected if only one smear per 
day was examined instead of the two 
smears required.6 A recent report20 on 
the use of HemoQuant, a new technique 
for detecting occult blood in stool, shows 
considerable promise and may prove to 
be a more sensitive method, but clinical 
confirmation is still necessary. Hemo­
Quant is not yet available commercially.
The current evidence of a low sensitiv­
ity or high false-negative rate of Hemoc­
cult II slide testing suggests that this 
approach alone is not reliable in screen­
ing patients for colorectal carcinoma. Evi­
dence from our personal experience and 
from the literature suggests that some cli­
nicians have been erroneously using 
Hemoccult testing to replace rectosig- 
moidoscopy.21 Anyone using this test 
must recognize that it is only as good as 
our results show. Individuals at increased 
risk of colonic carcinoma, such as those 
with a strong family history of cancer of 
the large bowel or a previous personal his­
tory of colonic cancer or adenomatous 
polyps, should be investigated more 
aggressively by rectosigmoidoscopy, bar­
ium enema roentgenography or 
colonoscopy, or all three.
We thank Judy Pollack for typing the 
manuscript.
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NOTICES
P o s tg ra d u a te  C o urse  
in G e n e ra l S urgery
The Paul A. Ebert Postgraduate Course 
in General Surgery will be held Apr. 
17-19, 1986, at the Hyatt on Union 
Square, San Francisco, Calif. This pro­
gram is presented by the Department of 
Surgery and the Howard C. Naffziger 
Surgical Society of the University of Cali­
fornia School o f Medicine in San Fran­
cisco and is sponsored by Extended 
Programs in Medical Education.
Clinically oriented, the program offers 
general surgeons an intensive overview of 
problems encountered in daily practice. 
The emphasis is on venous thromboem­
bolism, burns, acute pancreatitis, biliary 
tumours, portal hypertension, esophageal 
disease and colorectal cancer.
Advance registration is recommended. 
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N e u ro v a s c u la r  S u rg e ry
The 3rd annual meeting of the Neurovas­
cular Society of North America and the 
Society for Neurovascular Surgery will be 
held in Chicago, 111., Apr. 17-19, 1986.
General sessions will strive to identify 
problems affecting the heart, blood ves­
sels and brain, pathologic mechanisms, 
and methods of diagnosis and manage­
ment. Special sessions will address in 
detail such topics as vertebral artery sur­
gery, ultrasonography, headaches, nerve 
repair and anticoagulation. The meeting 
will be open to all diagnostic, medical and 
surgical specialties.
For further information write the 
Executive Director, Neurovascular Soci­
ety o f North America/Society for Neu­
rovascular Surgery, PO Box 679, Oak 
Park, IL 60302; or call (312) 482-3950.
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Chondromalacia of the Fabella: a Case Report
A 46-year-old man suffered from chon­
dromalacia of the fabella after minor 
trauma to the back of the knee. The con 
dition was misdiagnosed initially as fasci­
itis, tendinitis, a Baker's cyst and a her­
niated lumbar intervertebral disc. 
Pathognomonic signs were pain behind 
the lateral femoral condyle on palpation 
and compression of the fabella and also 
on passive extension of the knee. Con­
servative management was unsuccess­
ful. Excision of the fabella gave quick 
and lasting relief.
Un diagnostic de chondromalacie fabel- 
laire a ete pose chez un homme de 46 
ans ayant recu un trauma mineur a I'ar- 
riere de son genou. Cette pathologie fut 
initialement confondue avec une fasciite, 
une tendinite, un kyste de Baker et une 
hernie discale lombaire. Les signes 
pathognomoniques etaient une douleur a 
I'arriere du condyle femoral externe a la 
palpation et compression de la fabella, 
de meme qu'a I'extension passive du 
genou. Le traitement conservateur fut 
sans succes; par contre I'exerese de la 
fabella soulagea rapidement et de facon 
permanente les symptomes de notre 
patient.
HG. 1—Lateral and anteroposterior roentgenograms show normal-looking fabella (arrows) 
lying behind and articulating with lateral femoral condyle.
Chondromalacia of the fabella is uncom­
mon. Fewer than 30 cases have been 
described in the French and English liter­
ature.1-9 Because o f its rarity, the condi­
tion is easily misdiagnosed, and it can be 
quite disabling. This paper describes the 
management of such a case.
Case Report
The patient, a 46-year-old man, banged the 
back of his right knee on a desk edge when
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FIG. 2—Section of fabellar articular cartilage shows structural disorganization and fibril­
lar degeneration. Cartilage-bone junction is seen at upper right (hematoxylin and eosin, origi­
nal magnification x 5).
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jumping down from it to the floor. For the next 
12 months he had pain over the back of the 
lateral femoral condyle, radiating up and down 
the back of the limb. During that time he was 
investigated and treated for a number of con­
ditions — plantar fasciitis with a bone spur, 
tendinitis, lumbar degenerative disc disease and 
a Baker’s cyst seen on an arthrogram — all to 
no avail. When a myelogram for herniated disc 
and an arteriogram for arterial insufficiency 
were suggested, the patient demurred and was 
referred to the Hotel-Dieu Hospital.
On examination, both compression of a pal­
pable fabella against the femoral condyle and 
passive extension of the knee reproduced the 
patient’s symptoms. Otherwise the findings on 
examination of the knee and of the neurologic 
and vascular examinations were normal. 
Roentgenograms showed a fabella of normal 
appearance behind the lateral femoral condyle 
(Fig. 1).
The fabella was removed through a posterior 
longitudinal incision, identifying and retract­
ing the common peroneal nerve, which lay 
directly over it, and splitting the fibres of the 
gastrocnemius tendon which was later resu­
tured. The articular surface of the fabella was 
yellowish and roughened, but the femoral con­
dylar cartilage appeared normal. Microscopic 
examination of the fabella showed fibrillar 
degenerative changes of the articular cartilage 
with fibrosis and mucilaginous cystic degener­
ation of adjacent synovia (Fig. 2).
The patient returned to work 2 weeks after 
the operation and was pain free when seen 1 
year later.
Discussion
The fabella is a fibrocartilaginous or 
ossified sesamoid bone most commonly 
situated in the lateral head of the gastroc­
nemius muscle, and rarely in the medial 
head. The anterior surface is usually 
covered with hyaline cartilage and artic­
ulates with the posterior aspect of the 
femoral condyle.6 In the coronal plane 
the fabella is oval with average dimen­
sions of 4 mm x 8 mm, but in the sagit­
tal plane it is semicircular with the flat, 
articular surface anteriorly.10 Ossifica­
tion, when it occurs, is endochondral and 
starts between 12 and 15 years of age. An 
ossified fabella, visible on roentgeno­
grams, is present in 9% to 29% of peo­
ple and occurs in both knees in more than 
two thirds of these.5,6
A painful fabella has been reported in 
both adolescents and adults. Many cases 
were initially misdiagnosed as a knee 
sprain, Baker’s cyst, torn lateral meniscus 
or sciatica.1-3,11 The diagnosis was likely 
missed because the condition is rare and 
the examining physician did not palpate 
the fabella. A number of patients had 
already been treated for months or years 
by physiotherapy, casts, braces and local 
intra-articular cortisone injections. One 
patient had a lateral meniscectomy. Con­
servative treatment seldom gave lasting 
relief of pain.1-3,5-8,11
The typical clinical presentation is one 
of intermittent posterolateral knee pain
accentuated by knee extension and also 
by compression directly over the palpa­
ble fabella.7 The syndrome may occur 
with an ossified fabella, a cartilaginous 
model or a thickened area of tendinous 
fibres in the gastrocnemius.7 The differ­
ential diagnosis of the painful fabellar 
syndrome includes fabellar fracture, 
osteoarthritis and chondromalacia. The 
common peroneal nerve may be com­
pressed or irritated by the fabella, which 
lies immediately underneath or adjacent 
to the nerve.2,6 In this instance, the sym­
ptoms may include hyper- or hypoesthe- 
sia and muscle weakness in the distribu­
tion of the nerve.
The pathologic changes of the fabellar 
articular cartilage are often similar to 
those of chondrom alacia of the 
patella,1-3,5-8 and Goldenberg and Wild3 
coined the term “ chondromalacia fabel- 
lae” . Goldenberg2,3 found localized or 
generalized degenerative changes with 
fibrillation and pitting in the fabella of 
four patients.2,3
Some authors2,3,5 have noted degener­
ative changes in the contiguous lateral 
femoral condyle with chondromalacia 
fabellae. Goldenberg2 recommended 
excision of this cartilage in conjunction 
with fabellectomy. We doubt the wisdom 
of removing cartilage from the back of 
the femoral condyle, especially as this 
area of the bone is non-weight bearing. 
Patients reported in the literature had per­
manent relief of symptoms after fabellec­
tomy alone,1,5-8,11 as did our patient. The 
fabella should be excised as soon as the 
diagnosis is made, thus avoiding 
prolonged and relatively ineffective 
treatment.
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Posterior Sternoclavicular Dislocations
Twelve cases of posterior sternoclavicu­
lar dislocation were seen over 15 years 
at the Victoria General Hospital and the 
Izaak Walton Killam Hospital for Children 
in Halifax, IMS. Tw o patients 
required open reduction of the disloca­
tion but the rest were treated by closed 
reduction. One of the former group 
required threaded K wires for stability, 
but all other dislocations were deemed 
stable after reduction and application of 
a figure-of-eight bandage and an arm 
sling. There were no failures of reduction 
and no recurrent dislocations; the 
authors have been successful even in 
late closed reduction (up to 5 days) and 
therefore recommend it highly as the 
primary treatment. Open reduction is 
much more difficult and hazardous.
En 15 ans, 12 cas de dislocations ster- 
noclaviculaires ont ete vus au Victoria 
General Hospital et au Izaak Walton Kil­
lam Hospital for Children de Halifax, 
Nouvelle Ecosse. Deux patients ont 
necessity une reduction ouverte alors 
que les autres etaient traites par reduc­
tion fermee. Dans le premier groupe, un 
patient a eu besoin de fil K pour assurer 
la stability, alors que toutes les autres 
dislocations ont paru stables apres 
reduction, bande en huit et immobilisa­
tion du bras dans une echarpe. II n'y eut 
ni echec ni recidive. Les auteurs ont 
reussi meme dans les cas de reduction 
tardive (jusqu'd 5 jours) et recomman- 
dent fortement cette approche comme 
traitement primaire. Une reduction 
ouverte est beaucoup plus difficile et 
risquee.
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Fig. lb
FIG. 1— (a) Anteroposterior view of chest showing normal mediastinum, (b) Coned view 
of sternoclavicular joint shows posterior dislocation of left sternoclavicular joint.
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Dislocation of the sternoclavicular joint 
is uncommon, accounting for less than 
3% of shoulder girdle injuries and less 
than 1% of all dislocations.1 Posterior 
dislocations of the joint are even rarer. 
Gazak and Davidson2 found fewer than 
100 cases in the literature since Sir Ast- 
ley Cooper first described a case in 1824.
The literature documents the difficulty 
radiologically in demonstrating the 
posterior dislocation of the sternoclavic­
ular joint.3 Selesnick and colleagues4 
suggested computed tomography as a 
definitive diagnostic test.
In this paper we review our experience 
with 12 posterior dislocations of the ster­
noclavicular joint between 1969 and 1984.
Patients and Methods
Twelve patients with posterior ster­
noclavicular dislocations were treated at 
the Victoria General Hospital or the Izaak 
Walton Killam Hospital in Halifax dur­
ing the study period. In all patients the 
diagnosis was made clinically on presen-
' 4*:,#
FIG. 2—Anteroposterior view of chest 
showing asymmetric widening of mediastinum.
tation and confirmed by oblique roent­
genograms, with or without tomography. 
The dislocations were reduced in the oper­
ating room. There was one failure of 
closed reduction secondary to buttonhol­
ing through the posterior capsule. This 
required open reduction and soft-tissue 
repair but no internal fixation. One other 
dislocation was judged to be unstable and 
was treated with threaded K wires.2 All 
the other dislocations were reduced by 
closed manipulation and held with a 
figure-of-eight bandage and a sling. One 
of these cases is presented in detail, to 
illustrate some of the interesting points.
Case Report
A 16-year-old boy was seen at the Izaak Wal­
ton Killam Hospital for Children with an injury 
to the posterolateral aspect of the left shoul­
der, sustained when he was checked into the 
boards while playing hockey. He had shoul­
der pain and his neck was flexed laterally to 
the left. The left arm was flexed and he sup­
ported it with the opposite arm. He felt a lump 
in his throat and had slight dysphagia but no 
dyspnea or stridor.
There was an obvious depression at the left 
sternoclavicular joint. The outer edge of ster­
num was palpable with definite swelling cen­
trally around the sternal notch. There was no 
evidence of vascular damage.
Chest films and sternoclavicular oblique 
views demonstrated normal lung parenchyma 
and a normal mediastinum (Fig. la) with 
posterior dislocation of the left sternoclavicu­
lar joint (Fig. lb).
Under general anesthesia a sand bag was first 
placed between his scapulae. The area of the 
clavicle was prepared and draped in the usual 
fashion. Traction was applied to the left arm 
and a towel clip used to grasp the medial end 
of the clavicle as anteriorly as possible to avoid 
vascular injury. The end of the clavicle was 
then pulled forward. Traction was released and 
the reduction checked for stability.
A large hematoma now became apparent
over the sternoclavicular joint, with extension 
laterally. A roentgenogram showed a widened 
mediastinum (Fig. 2). However, all pulses 
remained strong and there was no evidence of 
active bleeding. The patient was placed in the 
intensive care unit, supervised by cardiovascu­
lar and orthopedic surgical staff, with monitor­
ing by radial arterial line, electrocardiogram 
and serial chest films. Twelve hours later the 
chest film appeared normal (Fig. 3).
A figure-of-eight strap plus a sling were 
applied, and the patient was discharged home 
24 hours later. He wore the restraints for 4 
weeks.
Results
All patients were treated similarly after 
reduction of the dislocation. The two 
patients who had open reductions were 
immobilized for 8 weeks versus 4 to 6 
weeks for those treated by the closed 
method. The threaded K wires were 
removed at 8 weeks. One migrated out 
and one migrated in, making its removal 
difficult. There were no failures of reduc­
tion and no recurrent dislocations.
Discussion
To our knowledge, this series of 
posterior sternoclavicular dislocation is 
the largest in the literature to date. Some 
authors differentiate between a true dis­
location and a Salter-Harris type I epi­
physeal injury.1 In our opinion this is 
unnecessary as in the acute stage, both are 
treated in the same fashion. The period 
of immobilization for a true dislocation 
in an older patient is increased (6 weeks 
versus 4 weeks).
The most common injury reported is 
a blow to the posterolateral aspect of the 
shoulder.5 Another is a direct forceful 
blow to the chest.2 The clinical 
manifestations may range from shoulder 
pain to hoarseness, dyspnea, dysphagia 
with or without numbness, or weakness 
of the upper extremity. The injury may 
also cause a pneumothorax, pneu­
momediastinum or a tear in a major 
vessel.6
Although none of our patients had a 
widened mediastinum on initial examina­
tion, we agree with W orman and 
Leagus7 that arteriography should be 
done in these cases to rule out serious 
underlying vascular injury. Most authors 
agree that open reduction is indicated 
only when closed reduction is unsuccess­
ful or instability persists.6,8
We recommend early closed reduction 
under general anesthesia. This prevents 
such long-term problems as thoracic out­
let syndrome.9 We have perform ed 
closed reduction successfully as late as 5 
days after dislocation with no increase in 
complications. During manipulation we 
have not heard an audible click upon 
reduction, as suggested by some.3,10 The 
stability of the reduction must be
FIG. 3—Anteroposterior view of chest with normal mediastinum after only 12 hours in 
intensive care unit.
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checked, before the patient leaves the 
operating room, by pushing posteriorly 
with the towel clip in the clavicle. We do 
not advocate internal fixation as the com­
plications can be serious.11 This series 
and others support the conclusion that 
once reduction is obtained it is 
stable.10-11
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SESAP IV Critique
ITEM 121
Blood dripping from the urethral meatus of a patient who has had severe 
pelvic trauma is a classic sign of disruption of the prostatic urethra. 
In this type of injury the prostatic urethra is torn off the pelvic 
diaphragm. Insertion of a Foley cathether contaminates the urethra and 
serves no purpose. A cystogram is done if a retrograde urethrogram 
shows that the urethra is intact and no extravasation is noted. 
Intravenous pyelograms should be done after the urethrogram and 
cystogram, because the dye from the intravenous pyelogram would 
obscure extravasation. An arteriogram would not be useful to evaluate 
this injury.
C
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Nontraumatic Spontaneous Rupture 
of the Urinary Bladder
Rupture of the urinary bladder without a 
history of recent trauma or instrumenta­
tion is rare; it is usually associated with 
bladder disease or outlet obstruction. 
The patient is usually seen as an emer­
gency case and has an atypical clinical 
picture. The four patients in this report 
were initially seen and treated by a 
general surgeon; in only two was the 
diagnosis established preoperatively and 
confirmed by retrograde cystography. 
Awareness on the part of the consulting 
surgeon that bladder rupture is possible 
in a predisposed patient may lead to a 
correct preoperative diagnosis. In this 
series, early operation — removing urine 
from the peritoneal cavity or retropubic 
space, closing the rupture and securing 
good vesical drainage — resulted in 
resumption of vesical function in all four 
patients and there were no deaths.
En I'absence d'antecedents de trauma- 
tisme recent ou d'exploration a I'aide 
d'instruments, une rupture de la vessie 
est rare; ceci survient habituellement en 
presence d'une maladie de la vessie ou 
d'une obstruction de I'orifice de sortie.
Le patient est habituellement vu en 
urgence alors qu'il presente un tableau 
Clinique atypique. Dans cet article, les 
quatre patients ont ete vus et traites par 
un chirurgien general; dans seulement 
deux cas, le diagnostic avait ete etabli 
en preoperatoire et confirme par cysto- 
graphie retrograde. Si le chirurgien soup- 
conne la possibilite d’une rupture de la 
vessie chez un patient predispose, on 
peut anticiper un diagnostic preoperatoire 
exact. Dans la presente serie, une opera­
tion pr£coce, comprenant evacuation de
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I'urine de la cavite peritoneale et de 
I’espace retropubien, fermeture de la 
lesion et poste d'un bon drain vesical, a 
reinstaure la fonction vesicate chez les 
quatre patients. II n’y eut aucun deces.
Spontaneous rupture of the urinary blad­
der is the extravasation o f urine into the 
intra- or extraperitoneal spaces without 
evidence of recent trauma. Usually, a 
predisposing bladder lesion or urinary 
retention can be found,1 but it has been 
claimed that rupture of a normal bladder 
can also occur.2
Because of the low frequency and atyp­
ical presentation of this event, diagnosis 
and treatment are usually delayed, lead­
ing to an increased death rate and 
prolonged hospitalization. Because of the 
urgent nature of the condition such 
patients are commonly seen and treated 
initially by a general surgeon. The usual 
presentation is that of an acute abdomen. 
At operation the patient’s abdomen is 
often explored extensively, the surgeon 
seeking a perforated viscus, mainly a duo­
denal ulcer, as a first possibility. 
Although uncommon, the condition is 
not rare, so we thought we should alert 
the general surgeon who is the one most 
likely to encounter it.
We present four patients treated in our 
department for nontraumatic perforation 
of the urinary bladder. All were initially 
seen by the general surgeon. The diagno­
sis was made preoperatively in only two 
cases, one o f  which involved an 
extraperitoneal rupture. In all patients the 
rupture was closed, and eventually blad­
der function was restored. There were no 
deaths and no complications involving the 
urinary system.
Case Reports
Case I
A 76-year-old white woman, known to have 
a well-differentiated lymphocytic lymphoma 
for which she was taking cyclosphosphamide, 
was admitted to the emergency department, 
complaining of chest pain, dyspnea and cough. 
Her blood pressure was 140/80 mm Hg and
pulse rate 100 beats/min. Her lungs were clear 
and heart sounds normal. The abdomen was 
soft and not tender. Chest films and elec­
trocardiogram were normal. Measurement of 
blood gases revealed hypoxemia and respira­
tory alkalosis. Lung scanning confirmed the 
presumed diagnosis of multiple pulmonary 
emboli to the left lung. Treatment with hepa­
rin led to relief of symptoms and evidence of 
improvement on lung scanning. Ten days after 
admission, she experienced sudden suprapubic 
pain and was unable to pass urine. In an other­
wise soft abdomen there was bulging of the 
suprapubic area with marked tenderness. A 
Foley catheter inserted into the urinary blad­
der drained 25 mL of clear urine, changing to 
macroscopic hematuria. A retrograde cysto- 
gram showed an anterior perforation of the 
bladder with extravasation of contrast material 
into the retropubic space. Cystoscopy under 
anesthesia confirmed the perforation and 
showed normal bladder mucosa.
At laparotomy, the area of perforation was 
trimmed and closed around a suprapubic 
catheter. A urethral catheter was inserted. Her 
postoperative course was uncomplicated. The 
suprapubic catheter was removed after 2 weeks, 
the urethral catheter a few days later. Bladder 
function returned to normal. Histologic exami­
nation of the specimen from the edge of the 
perforation revealed changes in the mucosa and 
submucosa typical of those seen after long-term 
use of cyclophosphamide.
Case 2
A 75-year-old white man was admitted to 
the neurology department after an acute 
cerebrovascular accident. During the first week 
he was treated with heparin, leading to some 
improvement in his neurologic deficit. On day 
10 he complained of diffuse abdominal pain 
and nausea. His abdomen was distended with 
guarding, generalized and rebound tenderness 
and no audible bowel sounds. A condom 
catheter attached to his penis was twisted, but 
there was urine in the bedside bag. His leuko­
cyte count was 12.0 x 109/L, and the urea 
nitrogen level was 12 mmol/L urea. Abdomi­
nal roentgenography showed moderately 
dilated loops of small bowel, but there was no 
evidence of free air under the diaphragm. The 
diagnosis was perforated duodenal ulcer.
At laparotomy, the peritoneal cavity was 
found to contain 2 L of yellowish fluid. The 
gastrointestinal tract was intact. There was an 
anterior intraperitoneal perforation of the uri­
nary bladder. The perforation was trimmed 
and the bladder closed around a suprapubic
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catheter that was brought out extraperitoneally. 
A urethral catheter was inserted. The patient 
had no complications postoperatively related 
to the urinary system.
Case 3
A 72-year-old white woman had been treated 
for squamous cell carcinoma of the esophagus 
3 years before admission. She received radio­
therapy only. Subsequently she suffered from 
irradiation myelitis and a neurogenic bladder 
for which she had required an indwelling Foley 
catheter for the last 2 years. Her presenting 
complaint was diffuse abdominal pain and 
vomiting that had begun 24 hours earlier. She 
was in a state of shock, with a blood pressure 
of 60/40 mm Hg and a pulse rate of 134 
beats/min. Her abdomen was tender and 
edematous. The Foley catheter was occluded. 
Insertion of a new catheter drained a small 
amount o f cloudy urine. After resuscitation 
with fluid replacement, antibiotics and dopa­
mine, the abdomen was found to be more 
tender with diffuse guarding and rebound 
tenderness. Both inguinal regions were red and 
swollen. A retrograde cystogram confirmed the 
presumptive diagnosis of rupture of the urinary 
bladder.
At operation, the abdominal cavity was 
found to contain a large amount of urine. A 
hole in the dome of the bladder was identified 
and closed after a suprapubic catheter had been 
inserted through a separate incision. A urethral 
catheter was also inserted. Pulmonary compli­
cations and sepsis developed following the 
operation, but the patient eventually recovered. 
The suprapubic catheter was removed 4 weeks
postoperatively. She was discharged home 60 
days after admission with an indwelling ure­
thral catheter in place.
Case 4
A 30-year-old schizophrenic man was 
brought to the emergency room for evaluation 
of abdominal pain and fever. He was known 
to have suffered from renal stones and had 
passed several small stones spontaneously. 
Three weeks before admission he complained 
of difficulty in urinating and an associated 
burning sensation. For 3 days he had had a 
fever (body temperature to 39°C), and subse­
quently he stopped voiding. On the day of 
admission he complained of diffuse abdomi­
nal pain without nausea or vomiting. On 
examination the patient was somnolent, his 
blood pressure was 130/80 mm Hg, pulse rate 
140 beats/min and rectal temperature 39°C. 
The abdomen was slightly distended, with no 
audible bowel sounds. There was guarding with 
diffuse and rebound tenderness. A Foley 
catheter was inserted with some difficulty as 
there seemed to be partial obstruction at the 
level of the posterior urethra. The catheter 
drained 300 mL of dark yellow urine. The 
nasogastric aspirate contained a small amount 
of “ coffee ground” material. No free air was 
seen under the diaphragm in the chest film. The 
diagnosis was an acute abdomen, probably due 
to a perforated duodenal ulcer.
The peritoneal cavity contained 3 L of dark 
yellowish fluid. The gastrointestinal tract was 
intact. There was a 2-cm longitudinal tear in 
the inflamed and friable anterior wall of the 
urinary bladder. At this stage the existence of
an obstructing stone was suspected, and indeed 
a  small stone measuring 1 cm in diameter was 
extracted from the posterior urethra. The rup­
ture was closed and the bladder drained with 
a urethral whistle-tip catheter for 2 weeks. 
There were no complications, and the patient 
was released 3 weeks later with normal blad­
der function.
Discussion
Spontaneous rupture of the urinary 
bladder is rare. The prevalence was 
reported to be around 1:126 000 admis­
sions to a London hospital1 and was 
found to be 1:100 000 admissions to our 
hospital. Most of the patients reported 
had a predisposing factor that could inter­
fere with the normal bladder function and 
cause perforation.1'3
An outlet obstruction causing an over­
distended bladder may lead to rupture. 
Various neurologic disorders and organic 
urethral obstructions have been reported, 
such as tabes dorsalis, urethral stricture 
and an enlarged prostate. Recent alcohol 
intake, which increases output and 
decreases mental awareness, may lead to 
rupture following minor trauma to an 
overdistended bladder.4 Obstruction of 
an indwelling catheter as in our case 3, 
or by a urethral stone as in case 4, can 
also be responsible.
Lesions of the bladder such as tuber­
culosis, prolonged cystitis and carcinoma
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may account for the nontraumatic rup­
ture. In our first case, prolonged 
cyclosphosphamide treatment concomi­
tant with typical histologic changes in the 
bladder could have led to the rupture. To 
the best of our knowledge this is the first 
description of such an event. No associ­
ation could be made between the continu­
ous treatment with heparin received by 
two of our patients and the vesical rup­
ture. There were no vascular abnormali­
ties or hematomas in the areas of perfo­
ration. Rupture in an otherwise normal 
bladder has been reported and designated 
idiopathic.2 It is our impression that the 
term “ spontaneous rupture of the blad­
der” should be used to describe all non­
traumatic ruptures, bearing in mind the 
possibility of underlying disease and its 
contribution to the mechanism leading to 
rupture. Such a predisposing factor can 
be detected in a few of the cases reported 
as idiopathic rupture.2
The rupture is usually intraperitoneal, 
since the pelvic attachments of the blad­
der allow its expansion into the peritoneal 
cavity where it eventually tears at its thin­
nest part.2 The patient usually has gener­
alized peritonitis, with an elevated blood 
urea nitrogen level due to the absorption 
of urine from the peritoneal cavity.5 An 
extraperitoneal rupture can occur if the 
disease is in the extraperitoneal part of the 
bladder wall, as in our case 1. In such a
case the patient may complain of sharp 
suprapubic pain and be unable to pass 
urine. The suprapubic area is tender and 
may be swollen and edematous. This sit­
uation will develop within the first 24 
hours following rupture and draw atten­
tion to specific diagnostic procedures and 
a correct preoperative diagnosis.
Insertion of a catheter and the finding 
of urine in the bladder does not exclude 
the possibility of rupture. From the 
presenting signs and symptoms the 
general surgeon will usually suspect an 
acute abdomen. Awareness of the possi­
bility of rupture in all patients suffering 
from urinary tract disease is essential if 
the correct diagnosis is to be made and 
extensive and time-consuming explorative 
surgery avoided. When the condition is 
suspected, retrograde cystography should 
be done to confirm the diagnosis. 
Although not infallible, it is the only relia­
ble method of making the diagnosis 
preoperatively. Cystoscopy done before 
operation can exclude other bladder con­
ditions that may interfere with the surgi­
cal procedure. We recommend it be done 
in the operating room immediately before 
exploration, as the entrance of irrigating 
fluid may exacerbate the intraperitoneal 
infection.
Operative treatment includes removing 
urine from the peritoneal cavity or retro­
pubic space, closing the rupture, secur­
ing good vesical drainage and draining the 
retropubic space. We recommend the use 
of both suprapubic and urethral catheters 
to minimize the possibility of urine 
leakage.
The death rate in nontreated patients 
has been reported to be 80%.6 After the 
introduction of surgical repair there was 
a gradual improvement in survival, reach­
ing 50% in the early 1960s1'3 and even 
higher in the last decade.2 It should be 
noted that all our patients survived oper­
ation and eventually regained their previ­
ous vesical function. This can be 
explained by the relatively early diagno­
sis, prompt surgical repair and intensive 
postoperative care.
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Aneurysmal
Twenty-six cases of aneurysmal bone 
cyst are reviewed to determine the fre­
quency, preferred treatment and progno­
sis. Some observations are made as to 
the existence of aneurysmal bone cyst 
as a primary entity or a secondary 
manifestation of a more serious underly­
ing condition. The difficulty of differen­
tiating an aneurysmal bone cyst from a 
giant cell tumour of bone is 
acknowledged and certain similarities to 
unicameral bone cyst are noted, with 
reference to some intriguing hypotheses 
put forward in the literature.
Vingt-six cas de kystes osteoides ane- 
vrismaux ont ete passes en revue afin 
d'en determiner la frequence, le traite- 
ment de premier choix et le pronostic. 
Certaines observations font 6tat de 
kystes osteoides an£vrismaux en tant 
qu'entit6 primitive, ou en font mention 
comme manifestation secondaire d'une 
maladie sous-jacente plus s£rieuse. On 
reconnait la difficult^ de diffgrencier le 
kyste osteoide anevrismal de la tumeur 
osseuse 6 cellules g6antes; on note ega- 
lement certaines similarit6s avec le kyste 
osteoide uniloculaire, a I'origine de cer­
taines hypotheses fascinantes avanc6es 
dans la presse m6dicale
Aneurysmal bone cyst is a benign, local­
ized lesion of bone formed of fibrous tis­
sue honeycombed by vascular spaces. It 
has a predilection for the shafts of long 
bones and vertebrae, it bulges and erodes 
the cortex but is limited peripherally by 
a thin shell of reactive new bone.
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Bone Cyst: a Review of 26 Cases
Although the lesion was encountered 
earlier (when it was known variously as 
aneurysmal giant cell tumour, benign 
bone aneurysm or ossifying subperiosteal 
hematoma), it was not until 1942 that it 
was recognized as an entity by Jaffe and 
Lichtenstein1 and as recently as 1950 
became incorporated into the orthopedic 
terminology with the publication of 
separate papers by Jaffe2 and by 
Lichtenstein.3
From the beginning its pathogenesis 
has been an enigma. Thompson4 noted 
that trauma was associated in 61% of 
cases in the literature, but most5 believe 
that injury simply calls attention to the 
lesion. Most of the controversy centres 
around whether it is a primary entity, 
produced by a local alteration of vascu­
lar hemodynamics,3,6 or whether it is a 
secondary manifestation in a pre-existing 
lesion, altered by hemorrhage or cystic 
degeneration.2 Lichtenstein6 in 1953 
denied that aneurysmal bone cyst was 
secondary to hemorrhagic alteration of a 
pre-existing lesion: in a 1957 report, he7 
steadfastly maintained it was the product 
of “ some persistent local alteration of 
hemodynamics leading to increased 
venous pressure and the subsequent 
development (in ramifying bayou-like 
fashion) of a dilated and engorged vas­
cular bed within the transformed bone 
area” . Jaffe,2 on the other hand, first 
mentioned in 1950 that aneurysmal bone 
cyst might be a “ hemorrhagic blow-out 
of a pre-existing benign lesion” . This 
hypothesis has continued through the 
literature and Enneking8 in his recent 
textbook accepts both hypotheses, 
describing primary aneurysmal bone cyst 
(an entity in itself) and secondary 
aneurysmal bone cyst (a secondary vas­
cular manifestation of some primary con­
dition such as non-ossifying fibroma,9 
giant cell tumour10 or even osteogenic 
sarcoma10).
Whatever its pathogenesis, aneurysmal 
bone cyst remains an entity. Dahlin11 
referred to the Mayo Clinic experience of 
134 cases; Schajowicz12 illustrated its 
gross and microscopic appearance and 
Enneking8 has described his experience 
of 80 cases in a chapter of his book deal­
ing with lesions of uncertain origin aris­
ing in bone.
To reach some definitive conclusions 
on the frequency, treatment and progno­
sis of aneurysmal bone cyst, we in the 
Department of Orthopedics at the Univer­
sity of British Columbia have reviewed 
the experience of these lesions entered in 
the university’s bone tumour registry.
Materials and Methods
From 1956 to 1984 inclusive, 26 cases 
of aneurysmal bone cyst were registered 
in the University of British Columbia 
Bone Tumour Registry. We have 
reviewed the case records, radiologic 
appearance, operative observations and 
microscopic appearance of these cysts. 
We also made some observations on its 
pathogenesis, particularly the “ hemor­
rhagic blow-out” hypothesis of Jaffe, in 
relation to giant cell tumour and certain 
malignant lesions, and on similarities to 
unicameral bone cyst. During the same 
29-year period, 62 cases of unicameral 
bone cyst and 44 cases of giant cell 
tumour of bone were documented in the 
bone tumour registry.
Observations
Frequency
Age (Table I) ranged from 2 to 50 years 
with 12 cases occurring in the first decade 
and 22 of the 26 cases in the first three 
decades of life. Dahlin’s much larger ser­
ies of patients11 showed a similar age dis­
tribution with 78% of patients being 
younger than 20 years.
In our series 14 of the 26 patients were 
male, which is unusual. D ahlin11
Table 1-Age Distribution of 26 Patients 
With Aneurysmal Bone Cyst
Age, yr
No. of 
patients
0-10 12
11-20 6
21-30 4
31-40 2
41-50 2
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reported the more usual female prepon­
derance of almost 1.5 to 1.
Sites involved in this series are shown 
in Table II. Notable is the wide distribu­
tion with five cases involving the vertebral 
column and seven the knee. The same 
observations were made in the larger 
Mayo Clinic series.11
Treatment
All patients were treated surgically. 
Thirty-nine procedures were carried out 
in the 26 patients — 1 procedure in 17 
patients, 2 in 7, 3 in 1 and 5 in 1 other 
patient. Biopsy was done as a separate 
procedure in only eight patients.
The commonest operation was curet­
tage and bone grafting (21 procedures). 
Autogenous bone was used in 14, 
homologous bank bone in 5 and Boplant* 
in 2. Nine lesions were curetted but not 
grafted. In four instances the procedure 
could be described as total excision, in 
three as subtotal resection. Radiotherapy 
was added to surgical treatment in three 
cases (in one patient with a sacral lesion, 
in the patient operated upon five times 
and in one who eventually underwent 
amputation because of complications of 
local treatment). Carbolic cautery accom­
panied curettage in two early cases and 
arterial embolization preceded surgery in 
one recent case.
Outcome
One 50-year-old woman died. She had 
a sacral aneurysmal bone cyst treated first 
by decompression laminectomy followed 
by radiotherapy and, within 2 months, an 
attempt at local excision. Death occurred 
6 months later in the presence of con­
tinued cauda equina deficiency, local 
infection and septicemia. A second
T a b le  I I — B o n e  In v o lv e d  in  2 6  C a s e s  o f  
A n e u r y s m a l B o n e  C y s t
B o n e  in v o lv e d
N o . o f  
p a t ie n ts
V e r te b r a e 5
D is ta l fe m u r 4
D is ta l t ib ia 3
P ro x im a l t ib ia 3
T a rs u s 3
P ro x im a l f ib u la 2
D is ta l f ib u la 1
P ro x im a l h u m e ru s 1
P ro x im a l u ln a 1
P ro x im a l fe m u r 1
C la v ic le 1
P e lv is 1
‘Commercially prepared heterogenous corti­
cal bone obtained from calves, subjected to 
extraction by a detergent, a fat solvent and 
prolonged washing, sterilization by beta- 
propiolactone, freeze-drying and sterile pack­
aging under vacuum for storage at room tem­
perature.
patient required hindquarter amputation 
to control her disease in the proximal 
femur and complications of its treatment 
(local recurrence, dislocation of a custom 
total hip replacement and draining infec­
tion). She was alive and well 9.5 years 
later.
Of the 24 remaining patients, 15 were 
followed up for 2 years or more after 
treatment, 5 for 6 months to 2 years and 
4 for less than 6 months.
Of the 15 patients followed up for more 
than 2 years, 3 were treated by intrale- 
sional curettage alone for cysts involving 
the 12th dorsal vertebra, the 4th lumbar 
vertebra and the femoral condyle. Treat­
ment was successful in all, with no local 
recurrence at 10 years, 7 years and 4 years 
respectively. In three patients total exci­
sion was possible (two proximal fibulas 
and one small lesion in the medial femoral 
condyle). All were free of their disease 
2.75 years, 5.5 years and 2.08 years later, 
respectively. One patient treated by sub­
total resection of the distal fibula was 
fully functional, with a small residual 
cyst, at 6.5 years.
The remaining 8 patients in this group 
of 15 were treated initially by curettage 
and bone grafting. All results were con­
sidered satisfactory even though one 
patient required five surgical procedures 
over 14 months, underwent radiotherapy 
and was left with quiescent chronic 
osteomyelitis. One patient required resec­
tion arthrodesis of the knee as a second 
and successful procedure, and another 
required a second operation described as 
subtotal resection of his olecranon lesion. 
Two patients, although fully functional, 
had radiologic evidence of cysts 2.5 years
FIG. 1—Case 1. Radiologic appearance of 
left hip in May 1982, after two surgical proce­
dures. Local recurrence of tumour is evident 
in enlarged osteolytic greater trochanter.
after operation. It is interesting that of 
these eight patients who had bone graft­
ing, the initial procedure used autogenous 
bone in six, and three grafts failed, neces­
sitating a second procedure. One initial 
bone-bank graft failed and in another the 
source of the bone graft could not be 
determined.
Discussion
The recent literature on aneurysmal 
bone cyst has emphasized its possible 
pathogenesis and its appearance secon­
dary to other disease entities. The two 
most discussed theories of origin overlap 
in that they both involve vascular abnor­
m ality or a lte ra tion  of vascular 
hemodynamics, and both have a bearing 
on discussions of whether aneurysmal 
bone cyst is a primary lesion or a secon­
dary manifestation of previously existing 
disease.
Aneurysmal Bone Cyst 
as a Primary Entity
Lichtenstein3 suggested that aneurys­
mal bone cyst resulted from a local alter­
ation of vascular hemodynamics, and his 
theory suggested to some13 that aneurys­
mal bone cyst was simply a secondary 
manifestation of a pre-existing lesion, 
altered by hemorrhage or cystic de­
generation. Donaldson14 nevertheless 
remained convinced that aneurysmal 
bone cyst has “ distinct clinical patholog­
ical and roentgenographic characteris­
tics”  and is not produced by secondary 
pathologic changes in a primary lesion. 
The opposing view is put forth by 
Biesecker and colleagues9 who believe 
that a primary lesion of bone initiates an 
osseous arteriovenous malformation and 
the altered hemodynamic forces produce 
a secondary reactive lesion recognized as 
aneurysmal bone cyst. They documented 
this sequence of events in 21 of 66 cases; 
all were benign and 2 followed curettage 
of other lesions (unicameral bone cyst and 
giant cell reparative granuloma).
Levy and colleagues10 favoured the 
“ secondary”  hypothesis even more 
strongly, reporting 57 such lesions in 54 
patients, including 12 osteogenic sarco­
mas. Even so, both groups9’10 acknowl­
edged that aneurysmal bone cyst may also 
be present as a de novo lesion.
Clough and Price15 probably come 
closer to reality by accepting aneurysmal 
bone cyst as a definite recognizable des­
tructive vascular lesion of bone, proba­
bly not truly neoplastic but rather the 
result of overgrowth of juxtaepiphyseal 
tissue with vascular change. It is proba­
bly better thought of as an aberration of 
enchondral bone growth and remodelling 
(as may be the case in unicameral bone 
cyst16), but Clough and Price accepted 
that this histologic appearance secondary
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to another lesion is theoretically possible. 
This less-rigid view is accepted in 
Enneking’s8 recent text.
Experience convinced us that there is 
a hard core of bone lesions that fit 
Lichtenstein’s3 original description and 
cannot be called anything else but 
aneurysmal bone cyst. We believe that 
lesions that at first glance may appear to 
be aneurysmal bone cysts but later prove 
not to be so are really examples of misdi­
agnosis, as illustrated in the following 
case report.
Case 1.—A 27-year-old man complained of 
pain, stiffness and weakness of his left hip in 
1977. His symptoms increased, and on the basis 
of a radiologic diagnosis of aneurysmal bone 
cyst the highly vascular lesion was curetted and 
bone grafted in May 1980. One year later a 
minor injury resulted in increasing pain of the 
left hip. A second operation — curettage, 
autogenous iliac bone grafting and fixation
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FIG. 2—Case 1. (a) Appearance of lesion under low power. Bands of tissue containing 
spindle cells and giant cells surrounding vascular spaces could be interpreted as aneurysmal bone 
cyst (hematoxylin and eosin, original magnification x 30). (b) High-power appearance reveals 
large round clear cells with pleomorphic nuclei and occasional mitotic figure properly inter­
preted as clear cell chondrosarcoma (hematoxylin and eosin, original magnification x 500).
with a nail-plate — was carried out in October 
1981. Again, aneurysmal bone cyst was the 
diagnosis. However, his pain persisted, he 
required crutches for walking and there 
appeared to be radiologic progression of the 
tumour. When 1 first saw him in May 1982, 
the radiologic appearance was as shown in Fig. 
1. It was consistent with, but not diagnostic 
of, aneurysmal bone cyst. Review of the patho­
logical material from his first two surgical 
procedures (Fig. 2) revealed that radiologic and 
surgical enthusiasm for this diagnosis proba­
bly led the pathologist to misinterpret large 
areas of hemorrhage as representing aneurys­
mal bone cyst and not to recognize that the 
intervening lesional tissue was not formed by 
benign spindle cells with a few giant cells but 
rather by malignant cells, a variety of chon- 
droblasts that Unni and colleagues17 have 
named clear cell chondrosarcoma. The patient 
underwent a limb salvaging wide local excision
Fig. 3a
Fig. 3b
FIG. 3—Case 2. (a) Oblique and (b) lateral 
radiographs of distal femoral tumour showing 
large lytic lesion with permeative pattern, cor­
tical destruction and (in lateral projection) large 
anterior soft-tissue mass.
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with reconstruction by custom total hip 
replacement and was alive and free of tumour 
3 years later.
Aneurysmal Bone Cyst and 
Giant Cell Tumour o f  Bone
Our experience with aneurysmal bone 
cyst and with giant cell tumour of bone18 
has led us to appreciate the difficulty in 
distinguishing the two lesions in certain 
instances and that any series of each may
FIG. 4—Case 2. Postoperative lateral film 
with lesional tisue excised and resulting defect 
replaced with autogenous bone graft.
FIG. 5—Case 2. Five months after opera­
tion. Oblique roentgenogram shows aggressive 
advance of tumour with destruction of bone 
graft.
include examples of the other. Two of our 
cases illustrate this point.
Case 2.—A 20-year-old woman complained 
of pain and swelling at her right knee for 4 
months. Pain gradually increased in severity 
so that she required crutches for walking. 
Roentgenograms (Fig. 3) show the epiphyseal 
and metaphyseal location of a lytic lesion, cor­
tical destruction and a large soft-tissue mass 
not characteristically outlined by a thin shell 
of reactive bone. Following an open-biopsy
diagnosis of aneurysmal bone cyst she was 
treated by subtotal resection and curettage with 
autogenous iliac and tibial bone grafting (Fig. 
4). Five months later (Fig. 5) there was clini­
cal and radiologic evidence of continued 
activity of the lesion with destruction of the 
bone graft, requiring further treatment by 
resection arthrodesis of the knee. Enneking8 
commented on this aggressive behaviour as fol­
lows: “ When poorly contained aggressive 
expanding aneurysmal bone cysts are curetted 
and packed with bone graft, recurrence may
Fig. 6b
FIG. 6—Case 2. (a) Low-power appearance with folded membrane-like areas enclosing 
loculated vascular spaces was initially interpreted as aneurysmal bone cyst (hematoxylin and 
eosin, original magnification x 30). (b) Review of available tissue following second resection 
aknowledged similarities to giant cell tumour by adding qualification “ with giant cell reaction” 
(hematoxylin and eosin, original magnification X 125).
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be quite explosive.” This patient remained well 
and free from local recurrence 3.5 years after 
the second surgical procedure.
The biopsy and residual tissue from the first 
surgical procedure were described as aneurys­
mal bone cyst on the basis of vascularity, locu- 
lated spaces and folded membrane-like areas 
(Fig. 6) but a later review, together with tissue 
from the second resection, acknowledged 
similarities to giant cell tumour by adding the 
qualification “ with giant cell reaction” .
Case 3 .—In 1969, a 42-year-old woman 
suffered a severe injury to her right ilium and 
acetabulum, treated by open reduction. By 
1978 she had a painful right hip with post- 
traumatic arthritis, and late in 1980 roentgeno­
grams revealed a large, lytic, expansile lesion 
of the right ischium (Fig. 7). After investiga­
tion by computed tomography and radio­
nuclide scanning, the lesion was biopsied. From 
the radiologic appearance, the great vascular­
ity described at operation and the histologic 
features (Fig. 8), the lesion was diagnosed as 
an aneurysmal bone cyst. Successful emboli­
zation was carried out in preparation for defini­
tive surgical treatment. In March 1981 the 
lesion was treated by subtotal excision, curet­
tage and left iliac bone grafting. Rapid ossifi­
cation occurred obliterating the lesion which 
remained healed 4 years later (Fig. 9). 
However, examination of the excised specimen 
in this patient led to a change in diagnosis to 
giant cell tumour of bone because there were 
large cellular masses with numerous giant cells, 
and the aneurysmal vascular spaces were con­
sidered secondary (Fig. 10).
It is acknowledged that in these two 
cases it may not be possible to diagnose 
the aneurysmal bone cyst definitively as 
a primary or secondary manifestation. In 
the informed opinion of the pathologist, 
the first was a primary aneurysmal bone 
cyst and the second a giant cell tumour 
with secondary aneurysmal appearances. 
Even so, the initial radiologic appearance 
and the subsequent behaviour of the 
tumour led to labelling the first case as 
giant cell tumour, and the prompt 
response to treatment in the second case 
(case 3) seemed to favour a diagnosis of 
primary aneurysmal bone cyst rather than 
giant cell tumour.
Aneurysmal Bone Cyst and Unicameral 
Bone Cyst
Without wishing to confuse the issue, 
we have been impressed, as have 
o thers,19,20 by the striking similarity 
between unicameral bone cyst and persist­
ing aneurysmal bone cysts, particularly 
those persisting after treatment by curet­
tage and bone grafting. No longer is the 
lesion a “ bloody sponge” but rather there 
is a dearth of soft tissue, with the ex­
pected incomplete bone septa resulting 
from the ineffective bone graft and the 
presence only of a heavily stained serous 
fluid rather than gross blood. One 
wonders whether these two lesions might 
have similar pathogeneses, the one being
a hematogenous manifestation, the other 
lymphogenous. Radiologic follow-up of 
residual cysts of both types also suggests 
such a relationship.
In regard to this similarity, Edling20 
proposed an intriguing hypothesis, 
describing aneurysmal bone cyst, 
unicameral bone cyst and giant cell 
tumour as dysfibroplastic processes, the 
result of developmental errors at the 
epiphyseal plate, the type of lesion 
produced by this dysfibroplasia depend­
ing on the site in bone and the blood sup­
ply. Hence, the disturbance occurring
centrally in the diaphysis produces 
unicameral bone cyst, eccentrically or 
subperiosteally produces aneurysmal 
bone cyst, and in the epiphysis itself 
produces a giant cell tumour.
Conclusions
Based on the observations made in the 
analysis of 26 examples of aneurysmal 
bone cyst, a number of relevant com­
ments can be made.
No specific statement can be made as 
to the role of radiotherapy (three cases)
FIG. 7—Case 3. Initial appearance of right hip region showing severe post-traumatic arthritis 
of right hip and expanded lytic lesion of right ischium.
FIG. 8—Case 3. Histologic features of spindle cell stroma enclosing vascular areas, together 
with radiologic and gross appearances at operation, led to diagnosis of aneurysmal bone cyst 
(hematoxylin and eosin, original magnification x 30).
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mended a repeat procedure for failures.)
Wide local excision, when applicable, 
is certain to cure the patient of aneurys­
mal bone cyst, as it did in three of our 
patients in which it was a primary proce­
dure and two patients in which it was a 
secondary procedure.
Aneurysmal bone cyst is an entity in 
itself and not simply a hemorrhagic or 
degenerative product of some underlying 
lesion. Superficial exam ination of 
histopathologic material may lead to mis­
diagnosis of the tissue as certain malig­
nant tumours and other benign lesions. 
An awareness of the ability of a number 
of pathologic entities to mimic the 
appearance of aneurysmal bone cyst is 
essential so that diligent examination of 
general tissue samplings will ensure that 
an accurate histopathological diagnosis is 
made.
The gross appearance of aneurysmal 
bone cyst at second operations and in 
radiologic follow-up of residual disease 
suggests similarities to unicameral bone 
cyst and the possibility of a common 
pathogenetic mechanism. Others have 
made this observation16 and Edling20 has 
proposed an intriguing explanation of this 
possible relationship.
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and arterial embolization (one case) in the 
definitive or adjunctive treatment of 
aneurysmal bone cyst.
The cyst presents a serious problem as 
evidenced by the one death and the one 
hindquarter amputation.
Biopsy as a preliminary diagnostic 
procedure was thought necessary in 8 of 
26 cases. Rush or frozen section at the 
time of surgery was not used consistently. 
The surgeon usually relied for operative 
management on the radiologic appear­
ance strongly suggesting a diagnosis of 
aneurysmal bone cyst and the gross
appearance at operation being consistent 
with that diagnosis.
Intralesional excision (curettage), with 
or without bone grafting, can cure the 
patient with one operation. (This was true 
for 6 of 11 patients or 8 of 11 in our ser­
ies if the 2 fully functional patients with 
residual disease are included. A second 
curettage with bone grafting cured 2 more 
patients — that is, 10 of 11 — when fol­
lowed up for more than 2 years. These 
results are comparable to those of 
Enneking8 who quoted a 70% success 
rate with a first operation and recom-
F1G. 9—Case 3. Roentgenogram of right hip 4 years after subtotal excision, curettage and 
bone grafting. Lesion is inactive and remains completely ossified.
FIG. 10—Case 3. Examination of surgically excised tissue led to change in diagnosis to 
giant cell tumour because of large cellular masses with numerous giant ceils (hematoxylin and 
eosin, original magnification x 125).
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Tetracycline Instillation for 
Recurrent Cystic Thyroid Nodules
Ten patients, 5 with recurrent pure cys­
tic and 5 with recurrent mixed cystic- 
solid thyroid nodules, were studied.
When repeated needle aspirations failed 
to decrease reaccumulation of fluid, 
tetracycline was injected directly into the 
cysts. As a result, all the pure cysts 
resolved completely, and four of the five 
mixed cystic-solid nodules diminished in 
size and fluid did not reaccumulate. 
Follow-up ranged from 12 to 20 months 
(mean 15 months). The procedure was 
generally well tolerated. It is concluded 
that instillation of tetracycline into both 
recurrent pure cystic and mixed cystic- 
solid thyroid lesions is a simple, safe and 
effective treatment.
Cette etude porte sur 10 patients; 5 por- 
teurs de nodules kystiques thyroidiens 
recidivants purs, 5 de nodules mixtes 
recidivants, a la fois solides et kystiques.
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Quand la ponction a I'aiguille n'a pu 
reduire ('accumulation de liquide, de la 
tetracycline a ete injectee directement 
dans le kyste. On a alors constate une 
resorption complete des kystes purs, et 
quatre des cinq nodules mixtes ont dimi- 
nu6 de volume, ne montrant plus d'accu- 
mulation de liquide. Les examens de sur­
veillance se sont repartis sur de 12 h 20 
mois (15 mois en moyenne). Generale- 
ment, ('intervention a ete bien toleree.
On conclut que I'instillation de tetracy­
cline dans les cas de nodules thyroidiens 
kystiques recidivants purs ou mixtes, est 
une technique de traitement simple, sure 
et efficace.
Single, hypofunctioning thyroid nodules 
are common and approximately 15% are 
cystic.1 Although most are effectively 
treated by a single aspiration,2 about 
30% will recur.3 Even when careful aspi­
ration cytology has eliminated the likeli­
hood of thyroid cancer, the patient is 
often concerned because of local discom­
fort, dysphagia or cosmetic implications. 
Levo-thyroxine therapy does not gener­
ally prevent cystic fluid recurrence and 
surgical removal has its risks.
Prompted by successful treatment of 
recurrent pleural effusions with 
intrapleural instillation of tetracycline,4 
Georgitis and associates5 6 reported the
first successful treatment of recurrent 
pure thyroid cysts with tetracycline instil­
lation. Since then, there has been one 
other report of one patient by Ryan and 
associates.7
We describe our experience with 10 
patients, 5 with pure cystic and 5 with 
mixed cystic-solid thyroid nodules, who 
were treated with tetracycline instillation 
when repeated aspirations failed to 
resolve the recurrent cysts.
Patients
The 10 patients had single cold thyroid 
nodules on iodine 131 scanning; one also 
had a small goitre. All were clinically and 
chemically euthyroid. All had undergone 
fine-needle aspiration of their nodules for 
cytologic examination, and to determine 
whether the nodule was a pure cyst or a 
cystic-solid lesion. Complete regression 
of the nodule after needle aspiration, as 
judged by palpation, was considered to 
indicate a pure cyst and persistence of a 
palpable nodule a mixed cystic-solid 
lesion. On this basis, two separate 
categories were established: pure cyst (five 
cases) and mixed cystic-solid (five cases).
One patient with a pure cyst received 
sodium L-thyroxine until the tetracycline 
instilled. All patients with mixed lesions 
received sodium L-thyroxine therapy 
throughout the study. Each patient had 
complete evacuation of the cystic fluid
Tab le  1 - C h a ra c te r is t ic s  o f P a tie n ts  W ith  Thyro id  N odules Before  and A fte r  T e tra c y c lin e  In stilla tio n
Type  
o f c y s t
Patien t
no.
Age,
yr Sex
Original 
s ize , cm
B efo re  instilla tion A fte r  instilla tion
No. of 
asp ira tions
Volum e of 
asp ira te , mL
Time from 1st to 
last aspiration, mo
L-thyroxine 
dose , mg
Follow-up,
mo
C yst 
s ize , cm
Pure i 65 F 3 .0 6 4 ,6 ,1 0 ,1 0 ,6 ,6 3 2 0 .1 5 16 —
2 31 F 2 .0 4 7 ,6 ,6 .5 ,6 36 — 18 -
3 58 F 1 .5 2 2 ,2 9 — 12 -
4 75 M 2 .0 2 4 ,2 14 — 14 —
5 62 M 8 .0 3 4 0 ,6 0 ,4 0 18 — 12 —
M ixed 6 55 F 4 .0 6 1 ,1 0 ,1 0 ,1 0 ,1 5 ,2 5 13 0 .1 5 20 0 .5
7 76 F 3 .0 2 1 0 ,1 5 6 0 .1 0 20 0 .5
8 71 F 3 .0 4 4 ,1 1 ,1 2 ,1 6 64 0 .2 0 12 2 .0
9 28 F 2 .0 5 3 ,1 ,2 ,1 ,1 30 0 .1 5 12 1 .5 *
10 18 F 2 .0 3 3 ,1 ,1 ,2 15 0 .1 5 18 1 .0
“ R epeat a sp ira tio n  fo r 1 .5  m L, a t 6  m o, and 1 m L a t 12  mo a fte r  te tra cy c lin e  in stilla tion .
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from two to six times before instillation 
of tetracycline. None of the aspirates were 
grossly hemorrhagic.
Method
With the patient supine on an examin­
ing table, the neck was extended to a 30° 
angle and the thyroid nodule located by 
palpation. No local anesthetic was used 
and aspiration was performed using a 
10-mL syringe in a Cameco holder (Pre­
cision Dynamics Corp., Burbank, Calif.) 
with a 21- or 23-gauge needle. The fluid 
was removed completely, and then 1 to 
2 mL of the aspirate was reinjected to 
maintain cyst distension. With the needle 
in place, the syringe was removed and 
replaced by one containing 100 mg of 
tetracycline hydrochloride in 1 mL of 
0.9% saline. This solution was instilled 
into the cyst cavity and left for 2 to 3 
minutes. All fluid was then aspirated, the 
needle removed and pressure applied for 
several minutes with a sterile gauze pad. 
The aspirate was inspected and sent for 
cytologic examination. After the proce­
dure, patients were re-examined for 
residual thyroid nodules. They were asked 
to report immediately any adverse effects 
from the procedure and were given a 
follow-up appointment.
Results
A summary of patient data is set out 
in Table I. Most patients tolerated the 
procedure well. One woman had intense 
local pain which resulted from extrava­
sation of the tetracycline, but it subsided 
within a few minutes. For several hours 
she had a dull ache, which was eased by 
warm compresses.
All patients with pure cysts had com­
plete resolution of their cysts following 
tetracycline instillation. In the second 
category, four of the five patients had 
reduction in size of their mixed cystic- 
solid nodules. Repeat aspiration in these 
patients after 12 to 20 months showed no 
recurrent fluid accumulation, except for 
the one failure.
Discussion
In the past decade, fine-needle aspira­
tion of thyroid nodules has become an 
important diagnostic tool.8 It is the most 
cost-effective way of determining whether 
a nodule is solid or cystic, benign or 
malignant. Suppressive therapy with l- 
thyroxine did not prevent recurrences in 
any of our patients, and repeated needle 
aspirations did not lead to a lessening of 
fluid accumulation. Having done a num­
ber of needle aspirations, all of which 
failed to show malignant cells, we under­
took to instil tetracycline as a sclerosing 
agent. Both Treece and colleagues6 and 
Ryan’s group7 reported that this tech­
nique is effective in patients with recur­
rent pure cystic thyroid nodules.
In Treece’s series of purely cystic 
thyroid nodules, tetracycline instillation 
led to complete resolution in seven and 
a partial response in two of their nine 
cases. In Ryan’s report of a single patient, 
it is unclear whether the lesion was a pure 
cyst or mixed cystic-solid nodule. 
However, there was a decrease in nodule 
size from 2 cm to less than 0.5 cm with 
treatment.
Crile and Hawk8 first described the 
use of sodium tetradecyl sulfate as a 
sclerosing agent to treat thyroid cysts. 
Sykes9 used this agent in 75 patients, but
the results were given for only 7 of them. 
Of these seven, the cysts apparently 
resolved in six, although the exact follow­
up was not reported. In the seventh 
patient, the cyst recurred within 4 weeks, 
so the patient underwent operation. We 
preferred tetracycline because of its avail­
ability and lesser toxicity.10
During a 12- to 18-month follow-up 
period, none of the pure cysts in our 
patients have recurred since tetracycline 
instillation, even though there were 
numerous recurrences before this treat­
ment (Table I, Fig. 1).
Four of our five patients with mixed 
cystic-solid thyroid nodules had good 
shrinkage of the nodule after tetracycline 
was given. Of even greater importance is 
that repeated aspirations up to 20 months 
later failed to show any reaccumulation 
of fluid. Our one failure was probably 
due to extravasation of the tetracycline 
resulting in inadequate dosage.
Conclusions
Tetracycline instillation appears to be 
a simple, safe and effective treatment for 
recurrent cystic thyroid nodules, of both 
the pure and mixed type. Careful cyto­
logic examination of the fluid aspirate 
and solid component, if present, should 
always be done first to rule out the 
presence of a malignant lesion. If tests 
indicate a benign lesion after at least two 
fine-needle aspirations, tetracycline instil­
lation is a useful approach.
We thank Dr. Arthur Rizzo for doing the 
tetracycline instillation in case 5 and Lyne 
Maurice for valuable technical assistance.
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TETRACYCLINE
THERAPY
FIG. 1—Recurrence of cystic fluid before and after tetracycline instillation. Each patient 
is shown as solid horizontal line. Each recurrence is shown as closed circle (pure cysts) or open 
circle (mixed cystic-solid lesions).
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White Clot Syndrome: 
a Rare Complication of Heparin Therapy
A case of white clot syndrome in a 
61-year-old man is reported. The patient 
suffered simultaneous aortic and vena 
caval thromboses while receiving heparin 
therapy for pulmonary embolism. Throm­
bocytopenia was noted. Thrombectomies 
successfully relieved the thromboses. 
Apart from heparin, no factors predispos­
ing to aortic thrombosis were evident, 
and the patient remained well in the suc­
ceeding 7 years since. A brief review of the 
literature on the white clot syndrome 
suggests that the entity remains poorly 
defined, regarding both the mechanism 
of heparin-induced thrombocytopenia and 
its relation to thrombosis.
On signale un cas de syndrome thrombo- 
tique leucocytaire chez un homme de 
61 ans. Ce patient a souffert de throm­
boses simultanees de I’aorte et de la 
veine cave alors qu'il recevait de I'hepa- 
rine pour une embolie pulmonaire. Une 
thrombocytopenie a ete observee. Les 
thromboses ont ete gueries par throm- 
bectomie. A part I'heparine, aucun fac- 
teur predisposant a une thrombose aorti- 
que n'a ete notee, et le patient demeure 
en bonne sante 7 ans apres cet incident. 
Une breve revue de la litterature sur ce 
sujet indique que cette entite reste mal 
definie, aussi bien en ce qui concerne le 
mecanisme par lequel I'heparine provo- 
que une thrombocytopenie qu'en son 
rapport avec la thrombose.
The term white clot syndrome describes 
spontaneous major arterial thrombosis in 
a patient receiving heparin therapy.1 It 
may involve an immune reaction to hepa­
rin, resulting in excessive platelet aggre­
gation and thrombosis.2 Regardless of 
the etiology and pathogenesis, it is very 
rare, having been recognized only once
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during the past 20 years on the vascular 
surgical service at the Health Sciences 
Centre, Winnipeg. A major international 
symposium on heparin in 1974 made no 
mention o f heparin-induced throm­
bocytopenia and throm bosis.3 We 
describe a case and discuss the related 
literature.
Case Report
A 61-year-old white man sustained a frac­
ture of the lateral condyle of the right tibia, 
with ligamentous injury. He was admitted to 
a rural hospital where open reduction was per­
formed and a cylinder cast applied. He was dis­
charged home 39 days after admission, but was 
readmitted a month later because of shortness 
of breath and right-sided chest pain. Because 
perfusion to the right upper lobe appeared 
decreased on the lung scan, continuous, 
intravenously administered heparin was given 
for 10 days. Shortly after heparin was discon­
tinued the right leg began to swell. Venogra­
phy showed absence of contrast in the deep 
venous system of that limb. He was transferred 
to the Health Sciences Centre for further treat­
ment. There were no allergies, bleeding dis­
orders or thromboembolic diseases in his own 
history, family history or a review of systems.
The patient was in no apparent distress but 
had a grossly swollen right lower limb from 
groin to foot. The dorsum of the foot was 
warm, erythematous and mildly tender. There 
was moderate tenderness on the medial aspect 
of the right thigh, but none in the calf. Hepa­
rin therapy was resumed with an intravenous 
bolus of 10 000 units, followed by continuous 
intravenous infusion at 1000 units/h.
For the next 5 days, heparin therapy was con­
tinued at a rate ranging from 500 to 1500 
units/h, depending upon Lee-White clotting 
times that were kept between 30 and 60 
minutes. There was then evidence of lower limb 
arterial ischemia, with pain, pallor and cold­
ness in the right foot, weakened femoral pulses, 
absent distal pulses and a loud abdominal 
bruit. Transaxillary aortography demonstrated 
a localized filling defect at the bifurcation of 
the abdominal aorta (Fig. 1). At this time, the 
platelet count was 50.0 x 109/L , the 
hemoglobin was 113 g/L and the clotting time 
30 minutes.
Operative exploration carried out the next 
day confirmed the presence of fresh thrombus 
in an otherwise normal distal abdominal aorta 
(Fig. 2). Mobile thrombus was identified in the 
inferior vena cava also. The latter was ligated 
distal to the renal veins, and thrombectomies
FIG. 1—Pear-shaped radiolucency is seen at 
bifurcation of abdominal aorta. Apart from 
tortuosity, lower abdominal aorta and iliac 
arteries appear normal.
FIG. 2—Upper limit of pale thrombotic 
material (white clot) can be seen through ver­
tical aortotomy just above bifurcation. 
Grossly, aortic wall is normal.
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of both vena cava and aorta were done through 
vertical incisions (Fig. 3).
Postoperatively, arterial perfusion to both 
lower limbs was excellent, despite minor skin 
necrosis on the right toes, presumably the result 
of peripheral embolization. Heparin therapy 
was resumed on postoperative day 1. Two days 
later the platelet count was 94.0 x 109/L. 
Anticoagulant therapy was continued orally 
starting on day 11. The patient was returned 
to the rural hospital in good condition 8 days 
later. This man has had no further peripheral 
vascular disease and was in good health 7 years 
after operation.
Fig. 3a
Discussion
In 1962, Gollub and Ulin4 reported an 
immediate drop in platelet count of up to 
33% in healthy persons associated with 
the administration of heparin. This could 
be an aggregation phenomenon, but it is 
not necessarily associated with throm­
boembolic disease. The white clot syn­
drome, on the other hand, is said to occur 
after either several days of heparin ther­
apy or repeated therapy, suggesting an 
immune reaction, perhaps mediated by an
Fig. 3b
Fig. 3c Fig. 3d
FIG. 3—(a) Pale thrombus (white clot) removed from aorta, (b) Pale thrombus with 
propagated red clot removed from inferior vena cava, (c) Photomicrograph of aortic thrombus, 
suggesting platelet aggregation (hematoxylin and eosin, original magnification x 100). 
(d) Photomicrograph of fibrin clot in inferior vena cava (hematoxylin and eosin, original mag­
nification x 64).
immunoglobulin G fraction forming a 
complex between heparin, IgG and plate­
lets.511 On the basis of in-vitro tests of 
heparin-induced platelet aggregation, 
clinical reports of the white clot 
syndrome1,2 have included patients with 
venous thromboembolic disease. Whether 
these patients should be included is 
debatable, since platelet aggregation does 
not necessarily imply thrombosis. 
Moreover, since venous thromboembolic 
disease is quite common, the findings may 
be disease-related rather than heparin- 
related in this circumstance. If patients 
with only venous thrombosis are exclu­
ded the white clot syndrome becomes a 
rarer phenomenon with perhaps more 
clinical validity.
A discussion of the white clot syndrome 
raises two important clinical questions: 
First, should heparin be stopped in the 
thrombocytopenic patient? On the basis 
of their experience, Kapsch and Silver2 
believe it is dangerous to continue hepa­
rin therapy in the presence of throm­
bocytopenia. In contrast, King and 
Kelton11 have observed a return to nor­
mal platelet count with continued hepa­
rin administration. Second, do heparin 
requirements increase in the white clot 
syndrome (as monitored by partial throm­
boplastin time)? Theoretically, heparin 
would be bound in the platelet thrombus, 
and thus be rendered inactive. The oppo­
site has, in fact, been observed.1 There 
may be several reasons for variations in 
heparin anticoagulant activity, given the 
complexity both of the heparin molecule 
and of its interactions with the coagula­
tion mechanisms in the blood stream. 
Further monitoring of patients receiving 
heparin will be necessary to answer these 
questions.
The most striking feature of our case 
was the pale aortic thrombus, observed 
while the patient was fully heparinized 
and thrombocytopenic and in the absence 
of any obvious arteriosclerotic disease. 
Kapsch and Silver2 reported 7 patients 
who underwent distal aortic thromboem- 
bolectomies, among 31 with throm­
bocytopenia receiving heparin therapy. 
However, they did not indicate whether 
these phenomena were recurrent, embolic 
or associated with arteriosclerosis. If the 
arterial occlusion is recurrent or embolic, 
or if it occurs in the presence of arterios­
clerosis, then the circumstantial evidence 
incriminating heparin is less acceptable.
Weismann and Tobin12 reported on 10 
patients who suffered arterial throm­
boembolism while taking heparin; in 4 of 
them the original disease was venous, 
which perhaps implies a relative absence 
of underlying arteriosclerosis. Unfor­
tunately, they did not perform platelet 
counts, so that any inference of a platelet- 
heparin interaction in their patients is 
impossible. Towne and colleagues1 
described acute arterial occlusions in four
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patients out of seven who received hepa­
rin for a variety of reasons and subse­
quently suffered thromboembolic disease. 
In only one patient did arterial occlusion 
probably arise in the absence o f underly­
ing arterial disease. Thus, our case seems 
to be one of the few bona fide examples 
of this syndrome, if in fact it exists. Con­
tinued clinical diligence when using hepa­
rin is necessary to distinguish the true 
nature o f  the white clot syndrome.
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13 PersantineV “Asasantine1
Brief Prescribing Information
Therapeutic or Pharmacological Classification:
Persantine: 1. Coronary vasodilator
2. Inhibitor of platelet adhesion & aggregation 
Asasantine: 1. Inhibitor of platelet adhesion & aggregation 
Indications and Clinical Uses 
Oral Dose Forms:
•  Coronary A rtery  Disease —  Combined therapy with di­
pyridamole and ASA (Asasantine) is indicated in patients who 
are recovering from a myocardial infarction. The rate of re­
infarction is significantly reduced by such therapy.
•  Coronary A rtery  Bypass Surgery —  Combined treatment with 
dipyridamole and ASA (Asasantine) is indicated for the 
prevention of occlusion of saphenous vein coronary artery 
bypass grafts.
•  Chronic Angina Pectoris —  Persantine (dipyridamole) has 
been used successfully in the long-term treatment of a variety 
of clinical conditions caused by decreased coronary flow. In 
chronic angina pectoris, dipyridamole may often eliminate or 
reduce the frequency of anginal attacks and improve exercise 
tolerance, as well as lessen nitroglycerin requirements. 
Dipyridamole is not intended to abort the acute anginal attack.
Patients recuperating after the acute phase of myocardial 
infarction may benefit from the coronary dilating effect of 
dipyridamole and its potential ability to improve collateral 
circulation in the myocardium.
In therapeutic doses, dipyridamole does not produce a fall in 
blood pressure or an increase in heart rate. However, in the 
acute phase of myocardial infarction the blood pressure may be 
quite labile and the possible hazards of dipyridamole under 
these conditions have not been fully evaluated. Dipyridamole is 
not recommended, therefore, in the treatment of acute 
myocardial infarction.
•  Thromboembolic Disease —  Persantine is indicated for the 
prevention of post-operative thromboembolic complications 
assicated with prosthetic heart valves.
CO NTR A IN D IC A TIO N S — Salicylate sensitivity, active peptic 
ulcer, hypersensitivity to dipyridamole.
W AR NINGS —  Patients should be cautioned about the 
possibility of additional toxic effects of ASA if they are taking 
‘'over-the-counter” ASA containing remedies, including cough 
and cold medications.
PRECAUTIONS — Since excessive doses of dipyridamole can 
produce peripheral vasodilation, it should be used with caution 
in patients with hypotension.
ASA should be administered cautiously to patients with 
asthma and other allergic conditions, a history of gastro­
intestinal ulcerations, bleeding tendencies, significant anemia 
or hypo-prothrombinemia.
Patients taking 2 to 3 g of ASA daily are at an increased risk 
of developing severe gastrointestinal bleeding following the 
ingestion of alcohol.
Since salicylates interfere with maternal and infant blood 
clotting and lengthen the duration of pregnancy and parturition 
time, they should not be administered during the last trimester 
of pregnancy unless the need outweighs the potential risks.
Caution is necessary when salicylates and anticoagulants 
are prescribed concurrently, as salicylates can depress the 
concentration of prothrombin in the plasma.
Patients receiving concurrent salicylates and hypoglycemic 
therapy should be monitored closely, since reduction of the 
hypoglycemic drug dosage may be necessary.
Although salicylates in large doses are uricosuric agents, 
smaller amounts may depress uric acid clearance and thus 
decrease the uricosuric effects of probenecid, sulfinpyrazone, 
oxyphenbutazone and phenylbutazone.
Caution should be exercised when corticosteroids and 
salicylates are used concurrently. Acute hepatitis has been 
reported rarely in patients with systemic lupus erythematosus 
and juvenile rheumatoid arthritis with plasma salicylate con­
centrations above 25 mg/100 mL. Patients have recovered 
upon cessation of therapy.
Salicylate ingestion should be restricted in patients receiv­
ing indomethacin (and perhaps other non-narcotic analgesics) 
for conditions such as rheumatoid arthritis. Salicylates can 
produce changes in thyroid function tests.
Sodium excretion produced by spironolactone may be 
decresed by salicylate administration. Concomitant ingestion of 
salicylates and aminosalicylic acid (PAS) or aminobenzoic acid 
(PABA) in normal doses may lead to increased toxicity and 
salicylism.
Salicylates reportedly displace sultonylureas, penicillins 
and methotrexate from their binding sites on plasma proteins. 
Salicylates also retard the renal elimination of methotrexate. 
ADVERSE REACTION S — In a trial of 2026 patients in whicli 
dipyridamole was used in combination with ASA for the 
prevention of recurrent myocardial infarction, the most 
common patient complaints, except for headaches, were those 
associated with ASA administration. In order of frequency of 
occurrence, these were stomach pain, headaches, heartburn, 
dizziness, constipation, hematemesis, bloody stools and/or 
black, tarry stools, nausea and vomiting. An increased 
frequency of elevations of serum urea nitrogen, uric acid and 
creatinine were noted in the active treatment groups but 
increases for individual patients were small and not associated 
with clinical problems. There was also a slightly greater 
frequency of elevated systolic blood pressure readings in the 
active treatment groups.
When dipyridamole has been used aione, headache, dizzi­
ness, nausea, flushing, syncope or weakness and skin rash
have occurred during initiation of therapy. In most cases, these 
tend to be minimal and transient. Gastric irritation, emesis anA< 
abdominal cramping may occur at high dosage levels. Rare 
cases of what appears to be an aggravation of angina pectoris 
have been reported, usually at the initiation of therapy. On ' 
those uncommon occasions when adverse reactions have been 
persistent or intolerable to the patient, withdrawal of medk 
cation has been followed promptly by cessation of the 
undesirable symptoms
For ASA alone the following side effects have been reported ’  
gastrointestinal — nausea, vomiting, diarrhea, gastrointes­
tinal bleeding and/or ulceration; ear — tinnitus, vertigo, hearing, 
loss; hematologic —  leukopenia, thrombocytopenia, purpura"; 
dermatologic and hypersensitivity —  urticaria, angioedema, 
pruritis, skin eruptions, asthma, anaphylaxis; miscellaneous — *  
acute, reversible hepatotoxicity, mental confusion, drowsiness, I  
sweating, thirst. 1
At the higher doses of Persantine recommended for use ill J 
patients with artificial heart valves, there may be an increase in 
the incidence of adverse reactions.
SYM PTOM S AND T R EA TM EN T OF 0VE R 00SA G E —  Hypotension, 
as a result of high serum levels of dipyridamole, is likely to be of 
short duration if it occurs but vasopressor substances may be 
used if necessary.
Salicylate overdosage SYMPTOMS may include rapid and 
deep breathing, nausea, vomiting, vertigo, tinnitus, flushing, 
sweating, thirst and tachycardia. In more severe cases, acid- 
base disturbances including respiratory alkalosis and meta- 
bolic acidosis can occur. Severe cases may show fever, 
hemorrhage, excitement, confusion, convulsions or coma and 
respiratory failure. TREATMENT of salicylate overdosage con­
sists of prevention and management of acid-base and fluid and 
electrolyte disturbances. Renal clearance is increased by* 
increasing uring flow and by alkaline diuresis but care must be 
taken in this approach to not further aggravate metabolic 
acidosis and hypokalemia. Acidemia should be prevented by "* 
administration of adequate sodium containing fluids and 
sodium bicarbonate. «
Hypoglycemia is an occasional accompaniment of salicylate 
overdosage and can be managed by glucose solutions. If a 
hemorrhagic diathesis is evident, give Vitamin K. HemoA * 
dialysis may be useful in complex acid-base disturbances 
particularly in the presence of abnormal renal function. ^  
DOSAGE AND A D M IN IS T R A T IO N
Coronary Artery Disease —  The recommended oral dose is 75 mg 
of Persantine together with 325 mg ASA or one Asasantine 4 
capsule three times a day, in patients who have suffered a 
previous acute myocardial infarction.
Coronary Artery Bypass Surgery '
For 2 days pre-operatively: Persantine 100 mg (oral)
Q.I.D. j a
Day of surgery: morning of
operation: Persantine 100 mg (oral)
1 hour post-op: Persantine 100 mg 
(via nasogastric tube)
7 hours
post-op: 1 Asasantine capsule
Daily maintenance dosage: 1 Asasantine capsule T.I.D.
(for the next 12 months)
Chronic Angina Pectoris —  The recommended oral dose is 50 mg 
t.i.d., taken at least one hour before meals. In some cases 
higher doses may be necessary. Clinical response is gradual,^ 
reaching a maximum effect within three months of unin­
terrupted therapy. ( -
Thromboembolic Disease —  The recommended oral dose is 100 
mg q.i.d, one hour before meals. A lower dose of 100 mg of 
Persantine daily together with 1 g ASA daily, prolongs platelet< 
survival to the same extent.
Availability t
1. 25 mg tablet: An orange, round sugar-coated tablet, 
imprinted with the Ingelheim tower.
2. 50 mg tablet: A coral, round sugar-coated tablet, imprinter? - 
with the Ingelheim tower.
3. 75 mg tablet: A red, round sugar-coated tablet, imprinter^ 4 
with the Ingelheim tower.
4. 100 mg tablet: A white, round sugar-coated tablet,
imprinted with the Ingelheim tower. *
5. Asasantine: an opaque orange and yellow hard gelatin 
capsule. Each capsule contains 75 mg Persantine and 330 
mg ASA.
PERSA NTINE 25 mg, 50 mg and 75 mg are supplied in bottles 
of 100 and 500 tablets. ,
PERSA NTINE 100 mg is supplied in bottles of 100 tablets. 
ASASA N TIN E CAPSULES are supplied in boxes of 100.
PRODUCT MONOGRAPH AVAILABLE ON REQUEST. v
(X ) Boehringer 
“T7, Ingelheim PAABCCPP
Boehringer Ingelheim (Canada) Ltd./Ltee.
977 Century Drive, Burlington, Ontario L7L 5J8
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Chronic Ileal Obstruction in Adults Due 
to Peri-ileal Vitelline Vascular Remnants
Two young adults had distal ileal 
obstruction at sites where a fold of 
mesentery extended from its posterior 
leaf to the antimesenteric border of the 
bowel. No Meckel's diverticulum or 
mesoumbilical band was present in either 
case. Clinical, gross and microscopic 
findings suggested that the mesenteric 
fold represented a remnant of vitelline 
vessel that persisted in the peri-ileal por­
tion of its course. Chronic ileal obstruc­
tion was apparently due to disordered 
peristalsis caused by the fold tethering 
the adjoining posterior bowel wall. In one 
patient, a chronic ulcer at the site of 
obstruction was interpreted as being an 
additional complication of the congenital 
lesion.
Deux jeunes adultes ont presente une 
obstruction de la partie distale de I'ileon 
en un point 0C1 un pli du mesentfere 
s'etendait a partir de son feuillet poste- 
rieur jusqu'au bord externe de I'intestin. 
On n'a constate dans les deux cas ni 
diverticule de Meckel, ni bandelette 
meso-ombilicale. Le tableau clinique, de 
meme que les r6sultats des examens 
macro et microscopiques indiquent que 
ce pli mdsenterique reprdsentait un ves­
tige de vaisseau viteliin dont la partie 
p£ri-il6ale avait persiste. L'obstruction 
ileale chronique etait apparemment due a 
un probl&me du pdristaltisme cause par 
I'attachement de ce pli h la paroi intesti- 
nale posterieure adjacente. Chez un de 
ces patients, un ulc&re chronique au 
point d'obstruction a 6t§ interprets 
comme etant une complication suppIS- 
mentaire de la ISsion congenitale.
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Obstruction of the distal ileum is a com­
mon complication of a Meckel’s divertic­
ulum, a persistent omphalomesenteric 
duct or a persistent vitelline vessel that 
joins the ileum to the umbilicus.1'4 We 
describe two adults in whom a vitelline 
vascular remnant, persisting only in its 
peri-ileal segment, appeared to be the 
cause of recurrent obstruction that 
required surgical treatment. To our 
knowledge only one similar case, in an 
8-month-old infant, has been described 
previously.5
Case Reports
Case 1
A 20-year-old man complained of acute, 
crampy, central abdominal pain, similar to that 
of previous episodes occurring over several 
years. He had had an umbilical hernia repaired 
in Germany when he was 8 years old, but no 
record was available. His mother had had 
bowel malrotation repaired in her infancy.
Abdominal films showed dilated loops of 
small bowel in terpreted  as ileus. At 
laparotomy, the site of obstruction was found 
60 cm proximal to the ileocecal valve. There, 
a tongue of mesentery containing a central 
blood vessel extended from the posterior leaf 
of the mesentery to the antimesenteric border 
of the ileum (Fig. la). Proximally, the ileum
measured 4 cm in diameter and distally, 2 cm. 
A 10-cm segment of ileum was resected and an 
end-to-end anastomosis done. Recovery was 
uncomplicated.
Case 2
A 30-year-old woman presented with acute, 
crampy, central abdominal pain, similar to 
attacks that had occurred for several years. 
Abdominal films showed distended loops of 
small bowel, consistent with a localized ileus 
or partial obstruction. A barium enema 
relieved the pain temporarily, so a resolved vol­
vulus of the ileum was suspected. At operation, 
a dilated ileum narrowed abruptly 35 cm prox­
imal to the ileocecal valve, where a fold of 
mesenteric fat encroached on the posterior ileal 
serosa to reach its antimesenteric border. A 
26-cm segment of ileum was resected with end- 
to-end anastomosis. The bowel circumference 
proximally was 10 cm and distally, 5 cm.
The woman had a pectus excavatum and 
broad, short thumbs but did not have a recog­
nizable syndrome of congenital malformation.
Pathological Findings
Grossly, the two resected segments of 
ileum were similar. A fold of fat covered 
a segment of the serosal surface, extend­
ing from the posterior leaf of the mesen­
tery to the antimesenteric border of the 
bowel (Fig. la). Opened lengthwise, the
FIG. 1—Case 1. (a) Gross view of resected ileum. Fold of mesenteric fat crossing posterior 
serosal surface demarcates distended proximal bowel on left from ileum of normal diameter 
on right, (b) Microscopic view shows hypertrophied muscularis propria in proximal bowel (arrow­
heads), above level of tethering mesenteric fold attached to serosa (arrow), compared with nor­
mal muscle thickness below this level (hematoxylin and eosin, original magnification x 7).
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bowel from case 2 showed a mucosal ulcer 
(2 cm in diameter) on the anterior wall of 
the ileum opposite the mesenteric fold 
posteriorly (Fig. 2a). Microscopically, the 
mesenteric extensions consisted of mature 
fat, with a centrally placed vein in case 
1 (Fig. lb).
In each case, the proximal bowel had 
hypertrophied muscularis propria (Fig. 
lb) but no deficiency in myenteric or sub­
mucosal plexus ganglion cells. The ulcer 
in case 2 (Fig. 2b) had a floor of granu­
lation tissue covering scar tissue in the 
submucosa that did not extend into the 
underlying muscle coats. A small focus 
of pyloric glandular metaplasia was 
present at the edge of the ulcer, but no 
heterotopic epithelium was evident in 
either case. Hypertrophied nerves were 
prominent in Meissner’s plexus deep to 
the ulcer in case 2 (Fig. 2b).
Discussion
While the yolk sac supplies nutrition to 
the developing embryo, a network of 
blood vessels connect its broad base in the 
body stalk to the primitive paired dorsal 
aortas and cardinal veins.1-3'5 As the 
umbilical cord develops, vitelline vessels 
are simplified into a pair of arteries and 
a pair of veins that accompany the vitel­
line (omphalomesenteric) duct. The lat­
ter regresses by the 5th week and the ves­
sels involute later.6-7 The right artery and 
left vein persist longer than the con­
tralateral vessels. The right (anterior) 
vitelline artery contributes to the proximal 
superior mesenteric artery and the left 
(posterior) vitelline vein forms part of the 
portal venous system.1-6 Vitelline vessels 
distal to the ileum normally regress before 
the 8th week of gestation but may persist 
as vascular bands connecting to the 
umbilicus.4-6-7 Bands containing vascular 
remnants may pass either anterior or 
posterior to the ileum to become continu­
ous w ith the superior mesenteric
artery.4-7 Kleinhaus and colleagues7 
observed that a persistent vitelline vascu­
lar remnant may be distinguished from a 
persistent vitelline duct because the lat­
ter ends at its attachment to  the 
antimesenteric border of the ileum but the 
former continues across the serosa of the 
ileum on one or other side to enter the 
mesentery.
Mesodiverticular vessels are obvious in 
newborn infants because the mesentery 
and mesodiverticulum have not become 
adipose at this age (Fig. 3). Some 
Meckel’s diverticula are so short at birth 
(Fig. 3) that they could disappear during 
postnatal growth or by incorporation into 
a distended segment of ileum. We liken 
the mesenteric folds in our two patients 
to a mesodiverticulum of an incorporated 
or “ flat” diverticulum.
Seagram and colleagues5 described an 
infant with ileum dilated proximal to a 
“ bound-down” mesodiverticular band 
that ran from the mesentery to the apex 
of the cystically dilated bowel, in which 
heterotopic epithelia were identified 
microscopically.4 Their Fig. 2 depicted 
an obstructive lesion of the ileum that 
resembled the one we describe (Figs, la 
and 2a) except the band crossed the
FIG. 3—Short, wide Meckel’s diverticulum 
(asterisk) is seen on antimesenteric border of 
ileum of newborn infant. Vascular supply of 
diverticulum is from vessel running in free edge 
of mesodiverticulum (arrowheads). Islands of 
adipose tissue are visible in attached mesentery 
but have not yet appeared in mesodiverticulum.
anterior ileum rather than the posterior 
aspect as in our two cases.
No-one appears to have reported ileal 
obstruction in adults occurring at the 
“ apex o f the bowel” (midpoint of the 
primitive midgut) in the absence of a 
Meckel’s diverticulum or a mesoumbili- 
cal band. This site is well known for intus­
susception in infancy, presumably due to 
reverse or disordered peristalsis. We could 
find no evidence of segmental aganglio- 
nosis at the site of ileal narrowing in our 
cases and believe that the hypertrophied 
submucosal nerves in case 2 resulted from 
the chronic ulcer, akin to the neural 
hypertrophy seen in Crohn’s disease. 
Both patients presented with cramping 
abdominal pain that had recurred over a 
number of years, and the degree of hyper­
trophy of ileal muscle wall proximal to 
the mesenteric fold (Fig. lb) in each case 
correlates well with this history. Disor­
dered peristalsis, owing to part of the 
bowel wall being tethered to the mesen­
tery by the vascular remnant, may explain 
long-standing functional obstruction in 
the two cases. Because of the hyper­
trophy, we do not believe that simple exci­
sion of the mesenteric fold would have 
treated the obstruction adequately in 
either patient.
We also believe that the ulcer present 
in case 2 (Fig. 2) was the result and not 
the cause of obstruction because the mus­
cularis propria deep to it showed no scar­
ring and no heterotopic gastric mucosa 
was evident. Therefore, we suggest that 
a peri-ileal vitelline vascular remnant 
could be a cause of so-called solitary ulcer 
in the ileum. We recommend that sur­
geons and pathologists examining such an 
ulcer look for evidence of a congenital 
vascular remnant at the same level, par­
ticularly in young adults. Such evidence 
could easily be overlooked if the ulcer was 
associated with marked scarring and local 
peritonitis.
Photographs were by Lois Lines. We thank 
Dr. M.D. Silver for a critical review of the 
manuscript.
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FIG. 2—Case 2. (a) Gross view of ileal segment shows ulcer (arrow) at junction of dilated 
proximal (left) and normal-diameter bowel, (b) Ulcer has floor of granulation tissue (above) 
and scar that extends to true muscle coat (below); hypertrophied nerves of submucosal plexus 
are prominent (arrowheads, central one overlying lymphoid patch) but ganglion cells are present 
in normal numbers (hematoxylin and eosin, original magnification x 82).
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B. fragilis, the most prevalent anaerobe in intra-abdominal infections, 
was responsible for up to 60% of mortalities in patients with B. fragilis 
bacteremia when inappropriate treatment was given1. And recent 
North American studies show23 B. fragilis is becoming resistant to 
newer antibiotics such as clindamycin or cefoxitin.
No proven resistance to metronidazole
Flagyl 500 Inj. (metronidazole) remains unaffected by B. fragilis 
resistance23. Flagyl 500 Inj. is active, regardless of bacterial concentra­
tion or growth stage4-5. It has an excellent record of safety, and it is 
compatible with most antibiotics6 used for aerobic coverage in intra­
abdominal and pelvic surgery.
Average resistance Clindam ycin C efoxitin M oxalactam M etron idazo le
B. fragilis 4.8% 8.8% 17.9% 0%
Whenever B. fragilis cannot be ruled out
FLAGYL 500
metronidazole
a selective anaerobicide
RHONE POULENC PHARMA Inc ------
8580 Esplanade 
Montreal, Quebec 
^authorized user
Whenever B. fragilis cannot 
be ruled out
FLAGYL 5 0 0
(metronidazole)
a selective anaerobicide
Therapeutic Classification
Antibacterial-Antiprotozoal
Actions
Flagyl (metronidazole) is bactericidal against 
anaerobic bacteria, it exerts trichomonacidal 
activity and is also active against Giardia 
lamblia and Entamoeba histolytica. Its exact 
mechanism of action has not been entirely 
determined as yet. It has been proposed that 
an intermediate in the reduction of metronidazole, 
produced only in anaerobic bacteria and 
protozoa is bound to deoxyribonucleic acid 
and proteins, and inhibits subsequent nucleic 
acid synthesis.
INDICATIONS AND CLINICAL USES 
Bacterial infections
The treatment of serious anaerobic abdominal 
infections due to susceptible anaerobic bacteria, 
such as Bacteroides fragilis (and other species 
of Bacteroides), Clostridium, Fusobacterium, 
Peptococcus, and Peptostreptococcus species. 
Culture and susceptibility studies should be 
performed to determine the causative organisms 
and their susceptibility to metronidazole.
Based on clinical judgment and anticipated 
bacteriological findings, therapy may be 
started while awaiting the results of these 
tests.
In mixed aerobic and anaerobic infections, 
consideration should be given to the con­
comitant administration of an antibiotic 
appropriate for the treatment of the aerobic 
component of the infection. (See Warnings). 
Flagyl (metronidazole) has also been used in 
the treatment of a small number of cases of 
brain or lung infections (some with abscesses) 
caused by anaerobic bacteria.
CONTRAINDICATIONS
Flagyl (metronidazole) is contraindicated in 
patients with a prior history of hypersensitivity 
to metronidazole or other nitroimidazole 
derivatives.
Flagyl should not be administered to patients 
with active neurological disorders or a history 
of blood dyscrasia, hypothyroidism and 
hypoadrenalism.
Warnings
Flagyl (metronidazole) has no direct activity 
against aerobic or facultative anaerobic bacteria. 
In patients with mixed aerobic-anaerobic 
infections appropriate concomitant antibiotics 
active against the aerobic component should 
be considered.
Known or previously unrecognized moniliasis 
may present more prominent symptoms after 
treatment with Flagyl.
Studies in rats and mice have provided some 
evidence that metronidazole may cause tumors 
in these species when administered orally for 
a long period at high doses. The relevance of 
these findings in humans is not known.
Severe neurological disturbances (i.e. convulsive 
seizures and peripheral neuropathy) have 
been reported in patients treated with Flagyl 
(administered orally or intravenously). These 
have been observed very infrequently.
Precautions
Patients taking Flagyl (metronidazole) should 
be warned against consuming alcohol, because 
of a possible disulfiram-like reaction. For the 
same reason, patients receiving Flagyl should 
not be administered disulfiram concomitantly. 
Transient eosinophilia and leukopenia have 
been observed during treatment with Flagyl. 
Regular total and differential leukocyte counts 
are advised if administration for more than
10 days or a second course of therapy is 
considered to be necessary.
Metronidazole crosses the placental barrier. 
Although Flagyl has been given to pregnant 
women without apparent complication, it is 
advisable that oral administration be avoided 
in pregnant patients and Flagyl be withheld 
during the first trimester of pregnancy. In 
serious anaerobic infections, if the adminis­
tration of Flagyl to pregnant patients is 
considered to be necessary, its use requires 
that the potential benefits be weighed against 
the possible risks to the fetus.
Metronidazole is secreted in breast milk in con­
centrations similar to those found in plasma. 
Intravenous or oral administration of Flagyl 
should be avoided in the nursing mother. 
Metronidazole has been reported to potentiate 
the anticoagulant effect of warfarin resulting 
in a prolongation of prothrombin time. This 
possible drug interaction should be con­
sidered when Flagyl is prescribed for patients 
on this type of anticoagulant therapy.
Clinical experience in children is very limited. 
The monitoring of this group of patients is 
particularly important. The safety and effec­
tiveness of intravenous Flagyl in children has 
not been established.
A rare case of reversible but profound 
neurological deterioration has been reported 
following a single oral dose of Flagyl; it is 
therefore advisable that a patient taking 
Flagyl for the first time not be left unattended 
for a period of two hours. The appearance of 
abnormal neurologic signs demands prompt 
discontinuation of Flagyl therapy and, when 
severe, immediate medical attention. Gastric 
lavage may be considered if no more than 
two or three hours have elapsed since 
administration of the drug.
Treatment with Flagyl should be discontinued 
if ataxia or any other symptom of CNS 
involvement occurs.
Patients with severe hepatic disease metabolize 
metronidazole slowly with resultant 
accumulation of metronidazole and its 
metabolites in the plasma. Accordingly, for 
such patients, doses of Flagyl below those 
usually recommended should be 
administered and with caution. The 
determination of serum glutamic oxaloacetic 
transaminase (SGOT) by the Technicon SMA 
12/60 system in blood samples from patients 
receiving Flagyl may give abnormally low 
values. This abnormality is artifactual and 
caused by the absorption of metronidazole at 
the wavelength where the enzymatic reaction 
is monitored spectrophotometrically.
Adverse reactions
Gastrointestinal: diarrhea, nausea, vomiting, 
anorexia, epigastric distress, dyspepsia, 
constipation.
Mouth: furred tongue, dry mouth, unpleasant 
metallic taste.
Hematopoietic: transient eosinophilia or 
leukopenia.
Dermatologic: rash and pruritus. 
Cardiovascular: palpitation and chest pain. 
Central Nervous System: convulsive 
seizures, peripheral neuropathy, transient 
ataxia, dizziness, drowsiness, confusion, 
insomnia and headache.
Peripheral neuropathies have been reported 
in a few patients on moderately high to 
high-dose prolonged oral treatment with 
metronidazole. It would appear that the 
occurrence is not directly related to the daily 
dosage and that an important predisposing 
factor is the continuation of oral and/or I.V. 
medication for several weeks or months.
Profound neurological deterioration, within 2 
hours after Flagyl administration has been 
reported. The occurrence is not directly 
related to the dosage level.
Metabolic: An antithyroid effect has been 
reported by some investigators but three 
different clinical studies failed to confirm this. 
Local Reactions: Thrombophlebitis has 
occurred with I.V. administration.
Other: Proliferation of Candida albicans in 
the vagina, vaginal dryness and burning; 
dysuria; occasional flushing and headaches, 
especially with concomitant ingestion of 
alcohol; altered taste of alcoholic beverages. 
Darkening of the urine has been reported. 
This is probably due to a metabolite of 
metronidazole and seems to have no clinical 
significance.
SYMPTOMS AND TREATMENT OF
OVERDOSAGE
Symptoms
Massive ingestion may produce vomiting and 
slight disorientation.
Treatment
There is no specific antidote. Early gastric 
lavage may remove a large amount of the 
drug; otherwise, symptomatic treatment.
DOSAGE AND ADMINISTRATION 
Treatment of anaerobic infections
Treatment should be initiated by the I.V. 
route. Oral medication may be substituted 
when it is feasible and/or practical. Duration 
of therapy depends upon clinical and 
bacteriological assessment. Treatment for 
seven days should be satisfactory for most 
patients. However in cases where infection 
sites cannot be drained or which are liable to 
endogenous recontamination by anaerobic 
pathogens, a longer treatment may be 
required.
I.V. Administration
100 mL (500 mg) by intravenous infusion 
every 8 hours. The injection should be 
infused intravenously at the rate of 5 mL per 
minute.
Flagyl Injection is compatible in a volume 
ratio of 1:5 with normal saline, dextrose- 
saline, dextrose 5 per cent w/v or potassium 
chloride injections (20 mmol and 40 mmol). 
These admixtures will remain stable for a 
period of 24 hours when kept in the dark or 
in combined daylight and artificial light. Not 
to be mixed with sodium lactate injection 
5% w/v, or dextrose injection 10% w/v.
AVAILABILITY
Injection 0.5% w/v Viaflex' plastic bags of 
100 mL (500 mg) for i.v. infusion.
'Trademark of Baxter Travenol Laboratories Inc.
Complete information available on 
request.
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Effects of Cod-Liver Oil on Intimal Hyperplasia 
in Vein Grafts Used for Arterial Bypass
Cod-liver oil rich in eicosapentaenoic 
acid, an unsaturated fatty acid, has been 
shown to inhibit platelet aggregation. To 
determine the effect of this acid on vein- 
graft intimal hyperplasia, 46 segments of 
undistended external jugular vein were 
interposed between the bilaterally 
divided femoral arteries of 26 mongrel 
dogs. The animals received a 2 %  
cholesterol diet for 1 week before and 6 
weeks after the operation. Eight control 
animals received the diet alone, eight 
received cod-liver oil containing 1.8 g of 
eicosapentaenoic acid daily, for 1 week 
before and 6 weeks after operation, 
and seven animals received 1.8 g of 
eicosapentaenoic acid daily for 6 weeks 
after operation. Intimal thickness was 
measured at 6 weeks with a Zeiss com­
puterized interactive image analysing 
system from multiple cross-sections of 
vein graft; 3 9 5±10 measurements were 
made from each graft. The intima meas­
ured 4 ± 0 .2  fitn (SEM) before implanta­
tion and increased to 8 3 + 1 0  fim in the 
controls. Eicosapentaenoic acid 
administered before and after operation 
reduced intimal hyperplasia to 24 + 2.5 
/im (p <0.0011 and to 3 0 ± 5  jtm in 
animals receiving eicosapentaenoic acid 
after operation only (p < 0.001). These 
results indicate that the acid inhibits 
intimal hyperplasia of canine vein grafts 
but that it is more effective when 
given before operation (p < 0 .01).
L'huile de foie de morue qui est riche en 
acide eicosapentaenoique, un acide gras
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insature, inhibe I'agregation plaquettaire. 
Afin de constater I'effet de cet acide sur 
I'hyperplasie de I'intima des greffes vei- 
neuses, on a interpose 46 segments de 
veines jugulaires externes non distendues 
entre les arteres femorales bilateralement 
divisees de 26 chiens batards. Les ani- 
maux ont recu un regime alimentaire 
contenant 2 %  de cholesterol a partir 
d'une semaine avant I'operation jusqu'a 
la 6e semaine qui a suivie. Huit animaux 
temoins ont regu la diete seule, huit ont 
recu de l'huile de foie de morue renfer- 
mant 1.8 g d'acide eicosapentaenoique 
quotidiennement pendant la meme 
periode, et sept animaux ont recu une 
dose quotidienne de 1.8 g d'acide eico­
sapentaenoique apres I'operation seule- 
ment. L'epaisseur de I'intima a ete mesu- 
ree apres la 6e semaine a I'aide d'un 
systeme Zeiss d'analyse interactive des 
images par ordinateur sur des coupes 
multiples des greffons veineux;
395 ± 1 0  analyses ont ete faites sur 
chaque greffe. L'intima qui mesurait 
4 ± 0.2 /tm (±  ET) avant la greffe a 
augmente a 83 ± 10 /im chez les 
temoins.
L'acide eicosapentaenoique administre 
avant et apres I'intervention a reduit 
I'hyperplasie de I'intima a 24 ± 2.5 /*m 
(p <  0.001) et, quand il a ete administre 
apres I'operation seulement, a 30 ± 5 
/*m (p <  0.001). Ces donnees indiquent 
que l'acide eicosapentaenoique inhibe 
I'hyperplasie de I’intima dans les greffons 
de veines canines mais qu'il est plus effi- 
cace quand le traitement commence 
avant I'operation.
Cod-liver oil is rich in the unsaturated 
fatty acid eicosapentaenoic acid.12 Find­
ings o f recent investigations3,4 indicate 
that increased dietary intake o f eicosapen­
taenoic acid results in decreased platelet 
aggregation and total platelet counts. The 
potential for eicosapentaenoic acid to 
inhibit platelet aggregation prompted this 
study to determine whether it could be 
used to prevent platelet-mediated intimal
hyperplasia in autogenous vein grafts 
used for arterial bypass.
Material
Twenty-three adult mongrel dogs, 
weighing between 25 and 30 kg, were 
divided into three groups. The animals 
were fed a 2% cholesterol diet (IC N  
Nutritional Biochemicals, Cleveland, 
Ohio) that was started 1 week before 
operation and continued for the duration 
o f the study. Eight animals served as con­
trols (group 1) and received the lipid- 
supplemented diet alone. Eight animals 
also received cod-liver-oil capsules, con­
taining 1.8 g o f eicosapentaenoic acid 
daily for 1 week before and 6 weeks after 
operation (group 2); a further seven 
animals received the diet and 1.8 g o f 
eicosapentaenoic acid daily but only after 
the operation (group 3).
Operative Protocol
Preoperative sedation consisted o f 1 
mL o f Innovar, containing fentanyl 
citrate (0.4 mg/mL) and droperidol (20 
mg/mL). Anesthesia was induced and 
maintained with sodium pentobarbital (3 
mg/kg) and the animals were ventilated 
with a pressure-regulated ventilator.
The femoral arteries were exposed 
bilaterally and a segment o f  autogenous 
external jugular vein was harvested from 
the neck, using sterile technique. A  small 
segment o f  external jugular vein was 
immediately fixed in formaldehyde for 
later examination under the light micro­
scope. A fter the systemic administration 
o f heparin (2 mg/kg), undistended 2.5-cm 
segments o f  external jugular vein were 
interposed between bilaterally divided 
femoral arteries. The anastomoses were 
completed with running 6-0 Prolene, 
using optical magnification. Hepariniza­
tion was then reversed with protamine 
sulfate and the incisions were closed.
The animals were anesthetized 6 weeks 
later and the vein grafts were harvested 
and fixed in formaldehyde.
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Analysis of Vein-Graft 
Intimal Hyperplasia
Cross-sections of the autogenous vein 
grafts were sampled at 2-mm intervals 
along the entire length of each graft. The 
cross-sections were stained with hematox­
ylin and eosin and Masson stains. Intimal 
thickness of each vein graft was measured 
from multiple cross-sections using a Zeiss 
computerized interactive image analysing 
system. This system comprises a com­
puter, a Zeiss microscope and a 12-inch 
television screen. Slides are projected on 
the screen and a mobile cursor, connected 
to the computer, is used to measure 
intimal thickness in micrometres. Meas­
urements were made at 100-^m intervals 
around the circumference of each cross- 
section. The resolution of the measuring 
equipment was in the range of ± 0.52 tun.
Hematologic and Biochemical Analyses
Serum cholesterol and hemoglobin 
levels, the hematocrit, total platelet count, 
and prothrombin, partial thromboplastin 
and bleeding times were all measured 
before the 2% cholesterol diet was 
started, while the animals were receiving 
the lipid-supplement diet before operation 
and at 2 and 4 weeks after autogenous 
vein implantation.
Student’s /-test and the F distribution 
were used for statistical comparisons. 
Results are reported as the arithmetic 
mean with corresponding standard error.
Results
Lipid supplementation caused a simi­
lar weight gain in all three groups and 
resulted in an overall increase in total 
body weight of 3.5±0.4 kg (p<0.01). 
The baseline serum cholesterol level was 
4.6 ±0 .4  mm/L and the level increased 
similarly in all groups: to 8.3 ± 0.4 mm/L 
in group 1, 7.1+0.5 mm/L in group 2 
and 6.6±0.5 mm/L in group 3 (p<0.01). 
The hemoglobin and hematocrit values, 
the bleeding, prothrombin and partial 
thromboplastin times and the total plate­
let count were unchanged throughout the 
study.
Intimal Thickness
Examination of vein-graft cross- 
sections under the light microscope before 
implantation demonstrated that the 
intima was intact and had not been 
damaged during harvesting. Statistical 
comparison of individual cross-sections 
of vein graft demonstrated that intimal 
thickness as determined with a Zeiss com­
puterized microscope did not vary signifi­
cantly along the entire length of the graft 
and that any one section was representa­
tive of the degree of intimal hyperplasia. 
Furthermore, there was no statistical
difference in mean intimal thickness in 
vein grafts harvested from the right and 
left extremities. Measurements (395 ± 10 
per graft) of intimal thickness are 
represented diagrammatically in Fig. 1. 
Intimal thickness before implantation 
measured 4 ±0.2 ;tm; this increased to 
83 ±10 fim at 6 weeks in group 1. In 
group 2, there was a smaller increase in 
intimal thickness (24±2^m ) (p<0.001). 
Similarly in group 3, the increase in 
intimal thickness was smaller than in con­
trol animals (30 ± 5 jim) (p < 0.001). 
Although the administration of eico- 
sapentaenoic acid resulted in a lesser 
degree of vein-graft intimal hyperplasia 
when given either before and after or only 
after arterial bypass, there was less vari­
ance in mean intimal thickness when cod- 
liver oil was administered both before and 
after implantation (p<0.01, F distri­
bution).
Vein-graft cross-sections are illustrated 
in Fig. 2. The marked increase in thick­
ness in control animals (Fig. 2A) is in con­
trast to that in animals receiving eicosa- 
pentaenoic acid before and after (Fig. 2B) 
or only after arterial reconstruction (Fig. 
2C).
Discussion
Epidemiologic studies5'6 indicate that 
Greenland Eskimos have a much lower 
prevalence of atherosclerotic heart disease 
than the non-Eskimo North American 
population. Subsequent clinical investi­
gations1’2 have shown that this finding is 
related to the Eskimo diet that is rich in 
marine oils containing the unsaturated 
fatty acid, eicosapentaenoic acid. Similar
FIG. 1—Intimal thickness measured in 
micrometres with corresponding standard error 
of mean (395 ±10 measurements per graft) for 
three groups of dogs: group 1 (controls) that 
received only lipid-supplemented diet, group 
2 (EPA-B) animals that received eicosapen­
taenoic acid before and after operation and 
group 3 (EPA-A) that received eicosapen­
taenoic acid after operation only.
epidemiologic observations have been 
made in other parts of the world. The 
prevalence of atherosclerotic heart disease 
is lower on the island of Okinawa and in 
Japanese fishing villages where fish con­
stitute a large part of the diet.7 Krom- 
hout and colleagues8 have just concluded 
a 20-year prospective study on heart dis­
ease in the town of Zutphen in the Nether­
lands. They observed an inverse relation 
between dietary consumption of fish oil 
and the 20-year death rate from coronary 
artery disease.
High platelet counts and elevation of 
serum lipid levels have been implicated in 
the pathogenesis of atherosclerosis.9 
Marine oils, rich in the unsaturated fatty 
acid eicosapentaenoic acid, have been 
shown to inhibit platelet aggregation and 
reduce total platelet counts.3'4 Also, 
increased dietary intake of eicosapen­
taenoic acid reduces serum lipid levels in 
normolipidemic subjects and in patients 
with hyperlipidemias.10,11 The effects of 
marine oil on platelet function and serum 
lipid values may explain the lower fre­
quency of coronary artery disease in 
populations in which there is a high daily 
intake of fish.
FIG. 2—Vein-graft cross-sections. (A) Typi­
cal appearance of intima in vein graft from 
control dog, receiving lipid supplementation 
only. Intimal thickening after implantation is 
reduced when eicosapentaenoic acid is 
administered (B) before or (C) after operation 
(hematoxylin and eosin, original magnification 
X 250).
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Experimental catheter abrasion of the 
arterial intima causes fibromuscular 
intimal hyperplasia and the formation of 
an early atherosclerotic plaque in animals 
receiving a lipid-supplemented diet. In 
contrast, the intimal proliferative 
response is reduced and early athero­
sclerotic lesions fail to develop in animals 
with platelet deficient serum.12 Similar 
histologic features are present in vein 
grafts used for arterial reconstruction. 
Fibromuscular intimal hyperplasia is 
present within 6 months and typical 
atherosclerotic lesions have been observed 
in vein grafts removed at autopsy many 
years after operation.13-15 Metke and 
colleagues16 have demonstrated that 
antiplatelet drug regimens reduce intimal 
hyperplasia in canine autologous vein 
grafts and, more recently, Chesebro and 
associates17 have shown that platelet 
inhibition improves long-term patency in 
vein grafts used for myocardial revas­
cularization, thus establishing a link 
between platelets and the development of 
fibromuscular intimal hyperplasia.
The findings of experimental studies 
and clinical trials indicate that eicosapen- 
taenoic acid inhibits platelet aggregation 
by reducing the platelet membrane 
production of proaggregatory prostaglan­
din thromboxane A2.18-20 Arachidonic 
acid is the precursor for platelet 
prostaglandin biosynthesis and is con­
verted by platelet membranes to proag­
gregatory thromboxane A2. Eicosapen- 
taenoic acid competes with arachidonic 
acid for the enzyme cyclo-oxygenase and 
is metabolized by platelet membranes to 
a weakly aggregatory prostanoid throm­
boxane A 3,21 whereas blood vessels 
metabolize eicosapentaenoic acid to 
prostacyclin I3.22 The effects of increased 
dietary intake of eicosapentaenoic acid on 
platelet aggregation and more recent 
reports demonstrating the effectiveness of 
antiplatelet drug regimens on the reduc­
tion of intimal hyperplasia suggest that 
eicosapentaenoic acid might be used to 
prevent intimal hyperplasia in veins used 
for arterial reconstruction.
We have shown previously23 that a 
high cholesterol diet accelerates intimal 
hyperplasia in canine autologous vein 
grafts and we used the same model in this 
study to determine the effects of 
eicosapentaenoic acid on vein-graft 
intimal hyperplasia. Our data show that 
eicosapentaenoic acid reduces intimal 
hyperplasia when given either before or 
after operation, but the unsaturated fatty 
acid is less effective when administered 
following arterial bypass. This observa­
tion is in keeping with those of previous 
studies.24
Although this study is only prelimi­
nary, it suggests that cod-liver oil reduces 
canine vein-graft intimal hyperplasia and 
that further studies are needed to deter­
mine whether eicosapentaenoic acid may 
be used to improve long-term graft 
patency following arterial reconstruction.
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inflammation subsides.
SUPPOSITORIES: Insert 1 suppository in the morn­
ing and 1 suppository at bedtime and after each 
bowel movement. Continue this treatment until 
the acute phase of pain and discomfort passes 
and the inflammation subsides.
SUPPLIED: Ointment: Available in 15 g and 30 g 
tubes with a plastic applicator. Suppositories: 
Available in boxes of 12 and 24 suppositories.
INGREDIENTS: Suppositories Ointment
Zinc Sulfate
Monohydratef 10 mg 0.5%
Hydrocortisone
Acetate 10 mg 0.5%
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cleansing pad for hemorrhoids, feminine hygiene 
and personal itching problems.
DIRECTIONS: Gently wipe and cleanse affected 
area. For additional relief, apply Tucks for 15-30 
minutes, 3 to 4 times daily.
Soft pads medicated with Hamamelis water 50%, 
glycerin 10%, distilled water, q.s.
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Da lac in C Phosphate S.S.
(clindam ycin phosphate)
Recommended Applications
Action: Clindamycin exerts its antibacterial effect by causing cessation of protein synthesis and also by 
causing a reduction in the rate of synthesis of nucleic acids.
Indications: Dalacin C Phosphate (clindamycin phosphate) is indicated for the treatment of infections 
where the oral route is not indicated or feasible.
Dalacin C Phosphate is indicated in the treatment of serious infections due to sensitive anaerobic 
bacteria, such as Bacteroides species, peptostreptococcus, anaerobic streptococci, Clostridium 
species and microaerophilic streptococci,
Dalacin C Phosphate is also indicated in serious infections due to sensitive Gram-positive organisms 
(staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci) when 
the patient is intolerant of, or the organism resistant to other appropriate antibiotics. 
Contraindications: The use of Dalacin C Phosphate (clindamycin phosphate) is contraindicated in 
patients previously found to be hypersensitive to this compound, the parent compound, clindamycin, or 
clindamycin palmitate. Although cross-sensitization w ith Lincocin® (lincomycin hydrochloride) has 
not been demonstrated, it is recommended that Dalacin C Phosphate not be used in patients who have 
demonstrated lincomycin sensitivity.
Until further clinical experience is obtained, Dalacin C Phosphate is not indicated in the newborn 
(infants below 30 days of age), or in pregnant women.
turnings: Some cases of severe and persistent diarrhea have been reported during or after therapy with 
Dalacin C Phosphate (clindamycin phosphate). This diarrhea has been occasionally associated with 
blood and mucus in the stools and has at times resulted in acute colitis. When endoscopy has been 
performed, some of these cases have shown pseudomembrane formation.
If significant diarrhea occurs during therapy, this drug should be discontinued or, if necessary, 
continued only w ith  close observation. Significant diarrhea occurring up to several weeks post-therapy 
should be managed as if antibiotic-associated.
If colitis is suspected, endoscopy is recommended. Mild cases showing minimal mucosal changes may 
respond to simple drug discontinuance. Moderate to severe cases, including those showing ulceration 
or pseudomembrane formation, should be managed w ith fluid, electrolyte, and protein supplementa­
tion as indicated. Corticoid retention enemas and systemic corticoids may be of help in persistent 
cases. Anticholinergics and antiperistaltic agents may worsen the condition. Other causes of colitis 
should be considered.
Studies indicate a toxin(s) produced by Clostridia (especially Clostridium difficile) may be a principal 
cause of clindamycin and other antibiotic-associated colitis. These studies also indicate that this 
toxigenic Clostridium is usually lensitive in-v itro  to vancomycin. When 125 mg to 500 mg of vanco­
mycin were administered orally four times a day for 5 -1 0  or more days, there was a rapid observed 
disappearance of the toxin from faecal samples and a coincidental recovery from the diarrhea.
Is should be noted that serious relapses have occurred up to one month after apparently successful 
treatment. A relatively prolonged period of continuing observation is therefore recommended. 
Precautions: Dalacin C Phosphate (clindamycin phosphate), like any drug, should be prescribed with 
caution in atopic individuals.
Dalacin C Phosphate must be diluted for intravenous administration. (See Dosage and Administration) 
The use of antibiotics occasionally results in overgrowth of nonsusceptible organisms - particularly 
yeasts. Should superinfections occur, appropriate measures should be taker, as indicated by the 
clinical situation.
As w ith  all antibiotics, perform culture and sensitivity studies in conjunction with drug therapy. 
Since abnormalities of liver function tests have been noted occasionally in animals and man, periodic 
liver function tests should be performed during prolonged therapy. Blood counts should also be 
monitored during extended therapy.
Dalacin C Phosphate may be used in anuretic patients. Since the serum half-life of clindamycin in 
patients w ith impaired hepatic function is greater than that found in normal patients, the dose of 
Dalacin C Phosphate should be appropriately decreased. Hemodialysis and peritoneal dialysis are not 
effective means of removing the compound from the blood. Periodic serum levels should be determined 
in patients w ith  severe hepatic and renal insufficiency.
Adverse Reactions: Local.
(a) Intramuscular Injections: Of 404 patients treated w ith  Dalacin C Phosphate (clindamycin phos­
phate) intramuscularly (with a solution containing 150 mg/mL), six (1.5%) demonstrated local 
reactions as follows: Two complained of pain at the injection site, two demonstrated induration at the 
injection site and two developed sterile abscesses.
(b) intravenous Infusions: Of 192 patients treated w ith Dalacin C Phosphate by intravenous infusion, 
14 (7.3%) demonstrated local reactions. Eleven patients developed superficial thrombophlebitis and 
one patient developed both superficial and deep thrombophlebitis. The majority of these cases 
developed in conjunction with the use of indwelling I.V. catheters and it is d ifficult to know how much 
the drug contributed to the irritation. Two patients developed localized erythema, swelling and pain at 
the site of the infusion.
Systemic Side Effects: Twenty-eight patients of 596 treated w ith Dalacin C Phosphate (clindamycin 
phosphate) by either the intramuscular or intravenous routes developed systemic side effects as 
follows:
Number o f Patients
Rash.................................................................................................................................................................. 7
U rtica r ia ..........................................................................................................................................................  1
Pruritus.............................................................................................................................................................  1
Fever, Leucocytosis ....................................................................................................................................  1
Nausea, w ith or w ithout vo m itin g ............................................................................................................. 1
Diarrhea (See also under “Warnings” ) ....................................................................................................... 4
Hypotension ...................................................................................................................................................  1
Hypertension...................................................................................................................................................  1
Shortness of Breath ....................................................................................................    1
Superin fec tion ".............................................................................................................................................. 4
Cardiac arrest”  ...........................................................................................................................................  1
Bad and bitter taste in m ou th ...................................................................................................................... 5
" Superinfection is a complication of antibiotic therapy in general and is not necessarily a true 
side effect of clindamycin phosphate.
■* Due to underlying myocarditis in this patient.
Clinical anil Laboratory Findings: Patients treated during clinical trials of Dalacin C Phosphate 
(clindamycin phosphate) were followed with clinical laboratory tests, including complete hematology, *  *  
urinalysis and liver and kidney function tests. Some of these tests were abnormal initially and returned 
to normal during therapy w ith Dalacin C Phosphate, while others were normal initially and became 
abnormal during therapy. Overall evaluation of clinical laboratory values in these patients does n o t' 
indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic, hepatic or renal 
systems. Transient elevations of serum transaminases have occurred in some patients, but other lived '  J 
function tests (alkaline phosphatase, serum bilirubin) have not shown any tendency to increase and 
there have not been clinical signs of drug-induced hepatic toxicity. e —
Symptoms sod Trratmmt of Overdossgo: No cases of overdosage have been reported. No specific antidote 
is known. Doses as high as 1200 mg every six hours (4800 mg/day) by infusion for five days have been •< 4 
given without adverse effects,
DOSAGE AND ADMINISTRATION ,
Adults
Intramuscular Injection: 600 mg/day in 2 equal doses. d *  ‘
Moderately severe infections: 600 to 1200 mg/day in 2 or 3 equal doses.
Severe infections: 1200 to 2400 mg/day in 2 .3  or 4 equal doses. Intramuscular injections of more than ~~ 
600 mg into a single site are not recommended.
Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) must be diluted prior to I.V. * 
administration to a dilution of 300 mg in 50 ml of diluent (6 mg/m l) or more, and infused in not less 
than 10 minutes. Administration of more than 1200 mg in a single 1 hour infusion is not recommended * —■ 
Dalacin C Phosphate should not be injected intravenously undiluted as a bolus.
Moderately severe infections: 900 to 1800 mg/day by continuous drip or in 2 or 3 equal doses, eactt 4  * 
infused over 20 minutes or longer.
Severe infections: 1800 to 2700 mg/day by continuous drip or in 3 or 4 equal doses, each infused over *«
20 minutes or longer. In life-threatening infections, doses of 2700 to 4800 mg/day by continuous drip 
or in 3 or 4 equal doses each infused over 20 minutes or longer may be given, .. ,
Dilution and Infusion rites:
Dose Diluent Time * <4
300 mg 50 ml 10 min.
600 mg 100 ml 20 min. 4 ♦ ‘
900 mg 150 ml 30 min.
1200 mg 200 ml 45 min.
Alternatively, drug may be administered in the form of a single rapid infusion of thefirst dose followed
by continuous I.V. infusion as follows: , 1
To maintain serum Rapid Maintenance + 1
clindamycin levels infusion rate infusion rate
Above 4 mcg/ml 10 mg/min. for 30 min. 0.75 mg/min. 4
Above 5 mcg/ml 15 mg/min. for 30 min. 1.00 mg/min.
Above 6 mcg/ml 20 mg/min. for 30 min. 1.25 mg/min. 4  *
Children: (Over one month of age)
Intramuscular injection: 10 to 15 mg/kg/day in 2, 3 or 4 equal doses.
Moderately severe infections: 15 to 20 mg/kg/day in 3 or 4 equal doses.
Severe infections: 20 to 30 mg/kg/day in 3 or 4 equal doses. 1
Intravenous Administration:
Moderately severe infections: 15 to 25 mg/kg/day by continuous drip or in 3 or 4 equal doses, each” ”* ’  
infused over 20 minutes or longer. In severe infections, it is recommended that children be given no less 
than 300 mg/day regardless of body weight. (Dilute Dalacin C Phosphate Sterile Solution in the same» 
manner as for adults.)
Dilution and Compatibility: 4
4 ml (600 mg) Dalacin C Phosphate when diluted w ith  1000 ml of the following commonly used in­
fusion solutions was found to be physically compatible and demonstrated no significant change in pH 4 
or antimicrobial potency over a period of 24 hours:
Sodium chloride injection
Dextrose 5% in water '
Dextrose 5% in saline 
Dextrose 5% in Ringer’s Solution
Dextrose 5% in half-strength saline plus 40 mEq potassium chloride
Dextrose 2%% in lactated Ringer’s Solution (Hartmann’s Solution) . -
Dalacin C Phosphate was not stable when added to Dextrose 5% in water plus vitamins. Therefore it is 
not recommended that Dalacin C Phosphate be mixed w ith  any infusion solution containing B vitamins -  >  
Supplied:
Dalacin C Phosphate contains the following per ml of sterile solution: j
Clindamycin phosphate equivalent to clindamycin base 150 mg
Benzyl alcohol 5 mg ^
Disodium edetate 0.5 mg '
Water for injection q.s.
When necessary the pH is adjusted w ith sodium hydroxide and/or hydrochloric acid to maintain a pH ^  
range of 5.5 to 7.0.
Dalacin C Phosphate is available in 2 ml and 4 ml ampoules.
NOTE: Do not store below 15°C.
Product Monograph available upon request. CE 1377.1C
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Right Hemothorax: an Unusual Presentation 
of Ruptured infrarenal Abdominal Aortic Aneurysm
The authors describe what they believe 
is the first reported case of rupture of an 
infrarenal abdominal aortic aneurysm into 
the right pleural cavity. A  75-year-old 
woman presented simultaneously with 
two common causes of severe abdomi­
nal pain and hypotension: perforated 
duodenal ulcer and ruptured abdominal 
aortic aneurysm. The absence of an 
infrarenal retroperitoneal hematoma 
delayed the diagnosis of rupture of the 
abdominal aortic aneurysm and the ter­
minal event was exsanguination into the 
right pleural cavity through an erosion in 
the right hemidiaphragm.
Les auteurs ddcrivent ce qu'ils croient 
etre le premier cas rapporte de rupture 
d'un andvrisme sous-renal de I'aorte 
abdominale dans la cavite pleurale droite. 
Une femme de 75 ans a ete vue prdsen- 
tant simultan6ment deux causes frequen- 
tes de douleur abdominale intense et 
d'hypotension: un ulcdre perform du duo­
denum et une rupture d'un an6vrisme de 
I'aorte abdominale. L'absence d'un 
hematome retroperitoneal sous-renal a 
retarde le diagnostic d'anevrisme rupture 
et Tissue finale a ete I'exsanguination 
dans la cavite pleurale droite £ travers 
une erosion dans I'hemidiaphragme droit.
Infrarenal abdominal aortic aneurysms 
usually rupture into the retroperitoneal 
space, less commonly into the peritoneal 
cavity and rarely into adjacent structures 
such as the inferior vena cava, the left 
renal vein and the gastrointestinal tract. 
Massive left hemothorax has been found 
at autopsy in three patients with ruptured 
abdominal aortic aneurysm s.1 This 
report describes a case of secondary rup-
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ture of an infrarenal abdominal aortic 
aneurysm into the right pleural cavity.
Case Report
A 75-year-old woman was admitted for 
investigation of persistent abdominal pain radi­
ating to the back without associated gastroin­
testinal or constitutional symptoms. She had 
had the symptoms for 2 weeks. Her medical 
history included hypertension but was other­
wise non-contributory.
The only positive finding on physical exami­
nation was tenderness on deep palpation of the 
lower abdomen. The leukocyte count was 19.7 
x 109/L . A chest film showed a left upper 
lobe infiltrate; the abdomen appeared 
normal. The urine contained pus that grew 
Escherichia coli on culture. Urinary tract infec­
tion and a lung infiltrate of unknown cause 
were diagnosed. Ampicillin (1 g every 6 hours) 
was given intravenously.
During the first hospital week, the patient’s 
abdominal pain persisted and she experienced 
anorexia and nausea. The hemoglobin value 
remained at 13 g/L, but the leukocyte count 
gradually increased to 21.6 x 109/L despite 
ampicillin therapy. Ultrasonography of the 
abdomen revealed a 4 x 5-cm abdominal aor­
tic aneurysm surrounded by what was thought 
to be intraperitoneal fluid or, less likely, fluid 
leaking from the aneurysm.
Severe epigastric pain radiating to the back 
and clinical shock developed, so emergency 
laparotomy was done. A large perforated duo­
denal ulcer with purulent peritoneal fluid was 
found; an infrarenal abdominal aortic 
aneurysm was noted, but there was no blood- 
staining of the retroperitoneal tissues to sug­
gest rupture. The ulcer was oversewn with an 
omental patch.
Postoperatively, massive fluid administra­
tion was required to maintain normal blood 
pressure and urine output. A right pleural effu­
sion developed and 6 days after operation 300 
mL of sanguineous fluid with a hematocrit of 
8% was removed at thoracentesis. Thrombotic 
occlusion of the common iliac veins and the 
infrarenal inferior vena cava was demonstrated 
by venography. Systemic heparinization gave 
transient improvement in her respiratory status.
Eight days after operation the hematocrit fell 
from 34% to 29% and the patient became 
hypotensive and hypoxemic. She was placed 
on cardiopulmonary bypass with a presump­
tive diagnosis of pulmonary embolism. The 
pulmonary artery was free of clot, but profuse 
bleeding into the right pleural cavity was noted 
from a defect in the posteromedial aspect of 
the right hemidiaphragm. Laparotomy was
performed, but the patient died in the operat­
ing room.
At autopsy, a rupture of the anterolateral 
wall on the right side of an infrarenal abdomi­
nal aortic aneurysm was found, with a defect 
in the aorta measuring 4 x 5 cm and sur­
rounded by blood clot (Fig. 1). There was no 
free blood in the peritoneal cavity or in the 
lesser sac, and the retroperitoneal tissues 
inferior to the aneurysm were not blood­
stained. A large collection of blood had tracked 
superiorly from the point of aortic rupture, 
from the superior pole of the right kidney to 
the costal attachments of the right hemidi­
aphragm and through a necrotic tear in this 
structure into the right pleural cavity. Complete 
thrombosis of the iliac veins and the inferior 
vena cava was encountered up to the level of 
the adjacent ruptured aneurysm, but the 
suprarenal and thoracic inferior vena cava and 
the pulmonary arteries were free of clot. Apart 
from the previously patched duodenal ulcer 
and small splenic and right renal infarcts, no 
other abnormalities were noted.
Discussion
The natural history of an abdominal 
aortic aneurysm terminates in its rupture. 
The size of the aneurysm correlates well 
with the risk o f rupture, small aneurysms 
less than 5 cm in diameter carrying a low 
risk.1 In 17% o f autopsy cases the 
aneurysm has been found to rupture into 
the peritoneal cavity and in 82% of cases 
into the retroperitoneum2 where the 
blood dissects caudally to the pelvis, 
producing a large hematoma that has 
a tamponade effect on the ruptured 
aneurysm. Other sites o f  rupture of 
infrarenal adominal aortic aneurysms
FIG. 1—Lower arrow marks site of aortic 
rupture. Upper arrow shows erosion of right 
hemidiaphragm allowing blood to enter right 
pleural cavity.
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have been described, such as into the 
inferior vena cava,3 4 the left renal vein,5 
an anomalous renal vein6 and the gas­
trointestinal tract7'8 where the duodenum 
(especially the third part) is the organ 
most commonly involved. Secondary rup­
ture of an infrarenal abdominal aortic 
aneurysm into the left pleural cavity was 
found in three cases of a large autopsy 
series,1 but to our knowledge no case of 
rupture of an infrarenal aortic aneurysm 
into the right pleural cavity has previously 
been reported.
The coexistence of perforated peptic 
ulcer and ruptured abdominal aortic 
aneurysm in this elderly woman is 
interesting and unusual. The proportion 
of abdominal aortic aneurysms is higher 
in men than in women by a ratio of 
approximately 10 to l .9 Although the 
rate of peptic ulcer disease in the general 
population is estimated to be between 5% 
and 15%,10 this disease has been found 
at autopsy in 22.6% of those with an 
abdominal aortic aneurysm.11 In the lat­
ter series, however, an important associ­
ation between abdominal aortic aneurysm 
and peptic ulcer was noted in men, but 
not in women.
Although it is impossible to determine 
the exact time of initial rupture of the 
abdominal aortic aneurysm in our 
patient, retroperitoneal rupture was most
likely present at the time of admission but 
remained clinically silent because of the 
tamponade effect of the hematoma. Con­
comitantly, the patient had an active pep­
tic ulcer that was aggravated by the stress 
of a ruptured aneurysm and perforated 
intraperitoneally. Rupture of the abdomi­
nal aortic aneurysm was missed at 
laparotomy because the perianeurysmal 
hematoma dissected superiorly rather 
than inferiorly. Postoperatively, the 
blood tracked into the pleural space 
through a diaphragmatic defect, resulting 
in an initial small right hemothorax which 
was drained 2 days before the patient 
died. Associated with this initial 
hemothorax was thrombosis of the deep 
pelvic veins and the inferior vena cava by 
the expanding retroperitoneal aneurysm. 
This angiographically demonstrated 
thrombosis together with the persistent 
severe hypoxemia led to the decision to 
heparinize the patient systemically 
because of presumed pulmonary embo­
lism. Unfortunately, this transformed the 
initial minimal bleeding into uncontroll­
able hemorrhage into the right pleural 
space, causing the patient’s death.
This case illustrates the fact that rup­
tured abdominal aortic aneurysm may 
occur simultaneously with other life- 
threatening lesions, including perforated 
peptic ulcer. Thus, when a patient with
PARKE-DAVIS
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a known abdominal aortic aneurysm 
presents with abdominal pain and 
hypotension, rupture must definitely be 
ruled out even when the patient’s condi­
tion can be explained by other abdomi­
nal disease.
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Contribution of Immunohistochemistry to the 
Diagnosis of Breast Cancer in Men
In men with advanced carcinoma of the 
prostate who have a breast tumour, it is 
often difficult to distinguish a primary 
from a secondary breast lesion. The 
authors describe the case of a 72-year- 
old man who presented with a poorly 
differentiated carcinoma in one breast 
after receiving estrogen therapy for dis­
seminated prostatic cancer. Application 
of the unlabelled antibody peroxidase- 
antiperoxidase immunohistochemical 
method demonstrated prostate-specific 
antigen in the tumour cells, thus estab­
lishing the secondary origin of the lesion. 
Five controls — men with primary breast 
cancer — when tested by the same 
method did not have this marker. The 
authors conclude that in this clinical con­
text, prostate-specific antigen is a useful 
marker of breast cancer in men.
Chez I'homme qui souffre d'un cancer 
avarice de la prostate et qui presente 
une tumeur du sein, il est souvent diffi­
cile de distinguer une lesion mammaire 
primitive d'une lesion secondaire. Les 
auteurs decrivent le cas d'un homme de 
72 ans chez qui on a constate un cancer 
du sein mal differencie apres qu'il eut 
recu un traitement aux oestrogenes pour 
un cancer prostatique dissemine. L'utili- 
sation d'une methode immunohistochimi- 
que mettant en oeuvre un syst&me 
peroxydase-anticorps antiperoxydase non 
marque a demontre I'existence d'un anti­
gene prostatique specifique dans les cel­
lules tumorales, etablissant ainsi I'origine 
secondaire de la lesion. Cinq sujets
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temoins, des hommes souffrant d'un 
cancer mammaire primitif, n'ont pas 
montrS la presence de ce marqueur 
lorsqu'ils ont ete soumis au meme test. 
Les auteurs concluent que dans ce con- 
texte clinique, I'antigdne prostatique spe­
cifique est un marqueur utile pour le can­
cer mammaire chez I'homme.
Primary carcinoma of the breast is rare 
in men, compared with women, the ratio 
being 1:100. Secondary carcinoma or 
metastasis to the breast in both men and 
women is also uncommon. It may arise 
from prostatic carcinoma, malignant 
melanoma, lymphoma or renal cell can­
cer. In a patient with prostatic carcinoma 
and a tumour mass in the breast, there is 
often controversy as to whether the lat­
ter is a true metastasis or a primary breast 
carcinoma induced by estrogen therapy.1 
We report the case of a man with 
undifferentiated metastatic carcinoma to 
the breast from a carcinoma of the 
prostate. The breast lesion was identified 
by immunohistochemistry.
Case Material
A 72-year-old man presented with con­
stipation 6 years before the present admis­
sion. At that time, needle biopsy of the 
prostate showed a poorly differentiated 
adenocarcinoma involving striated mus­
cle (stage D). The acid phosphatase level 
was 7.51 IU/L (normal 0 to 11.0 IU/L). 
He took ethinyl estradiol, 0.05 mg twice 
daily until 1 year before the present 
admission and also underwent bilateral 
orchiectomy and three separate trans­
urethral prostate resections. Six months 
earlier an intravenous pyelogram showed 
bilateral hydronephrosis and hydroureter. 
Skeletal roentgenograms showed blastic 
lesions in the right sacroiliac joint and left innominate bone.
Physically the patient was an elderly 
man who had bilateral gynecomastia and 
a firm mass (approximately 2.0 cm in 
diameter) in the upper, outer quadrant of 
the left breast with no skin retraction. On 
rectal examination the prostate was uni­
formly enlarged. A left breast biopsy was 
performed under general anesthesia. The 
breast tissue was fixed in buffered forma­
lin and processed for light microscopy 
and for immunohistochemistry to deter­
mine the presence of prostate-specific 
antigen. The immunohistochemical 
method used was the PAP immunoperox- 
idase technique described previously.2 
The primary antibody was obtained from 
Dako Corporation (Cedarlane Laborato­
ries, Hornby, Ont.). Breast tissue from 
five men with primary breast carcinoma 
was stained simultaneously for the 
presence of prostate-specific antigen. Two 
cases of prostate carcinomas were used as 
a positive control.
A portion of the breast tumour was 
quickly frozen in liquid nitrogen and exa­
mined for the presence of estrogen and 
progesterone receptors as described previ­
ously.3,4
Pathological Findings
Microscopically, the biopsy material 
from the breast lesion contained sheets, 
nests and, in focal areas, “ Indian files” 
of a poorly differentiated tumour 
infiltrate in a fibrous stroma (Fig. 1). 
Rare tumour nests showed poorly defined 
glands. The cells had a thin eosinophilic 
cytoplasm with indistinct borders. The 
nuclei were dark and uniformly stained. 
Most cells had one prominent eosinophilic 
nucleolus.
When the immunoperoxidase tech­
nique was used to demonstrate the 
presence of prostate-specific antigen, the 
cytoplasm of many tumour cells was 
strongly stained (Fig. 2), but the residual 
breast ducts did not stain.
The tissue from the five control 
primary breast cancers showed no stain­
ing for prostate-specific antigen.
Estradiol and progesterone binding 
were both negative in our case.
Discussion
The presence of prostate-specific anti­
gen in many cells of this otherwise poorly 
differentiated male breast cancer led us
VOLUME 29, NO. 2, M ARCH 1986 /  THE CANADIAN JOURNAL OF SURGERY 135
to conclude that it represented a metasta­
sis of prostate carcinoma. The usefulness 
and the specificity of prostate-specific 
antigen in this context are supported by 
the observation that the marker was 
absent in all control cases of primary 
breast carcinoma that we studied simul­
taneously.
The sensitivity of prostate-specific anti­
gen as a marker of prostate cancer was 
documented as being 100% in a study of 
primary and metastatic prostate carci­
nomas with no positive staining in the 
other tissues tested.s However, extremely 
poor differentiation of prostatic carci­
noma can occasionally lead to negative 
results, as shown in a report6 describing 
the absence of prostate-specific antigen 
marker in cases of prostate carcinomas 
with Gleason’s grades7 higher than 9.
The case described in this report illus­
trates a common problem in the patho­
logical diagnosis of a breast tumour in a 
man known to have a prostate carcinoma.
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FIG. 1—Normal mammary duct surrounded by fibrous stroma with tumour cells, which 
are organized in upper field and are scattered in lower field (hematoxylin and eosin, original 
magnification x 10).
FIG. 2—Strong staining for prostate-specific antigen in cytoplasm of some tumour cells 
(arrows) (immunoperoxidase, counterstained with hematoxylin, original magnification x 25).
Most of these patients receive long-term 
treatment with estrogenic hormones and 
consequently are at increased risk for the 
development of a primary breast carci­
noma. In cases in which the differentia­
tion of the breast tumour is poor, the 
usual morphologic criteria may lead to 
ambiguity in distinguishing between the 
primary or secondary nature of the lesion. 
This ambiguity and the difficulties in 
making a correct diagnosis by the usual 
methods have been discussed by McDivitt 
and colleagues,8 who concluded that 
many so-called primary breast cancers in 
men receiving estrogens for prostate car­
cinoma actually represent metastatic 
growth into the mammary ducts, giving 
the appearance of a primary breast lesion.
We believe that by testing this lesion 
immunohistochemically for the presence 
of prostate-specific antigen, most cases 
can be classified as secondary or primary 
tumours, depending on the presence or 
absence of the marker. With proper iden­
tification of the biopsy material, patients 
can be spared unnecessary surgery.
We thank Robert Sawka and Matilda 
Cheung for technical assistance and Grace 
Pawelec for typing the manuscript.
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COLON AND RECTAL SURGERY. Marvin
L. Corman. 784 pp. Iilust. J.B. Lippincott
Company, Philadelphia, 1984. $85. (US).
ISBN 0-397-50647-3.
Ordinary surgical mortals like me have their 
sense of inadequacy reinforced by a book like 
this. It is a single-author effort and Dr.Cor­
man must have devoted a vast amount of 
energy to this project over many years. As I 
read through the book I found that my initial 
prejudices and expectations about one author’s 
personal dogma were completely unfounded. 
In many ways this book is a personal statement 
by the author, but it becomes clear that not 
only is he a man of enormous personal 
experience in the field but also who has a great 
breadth of understanding and insight.
The book is remarkable from many aspects. 
It is a textbook of diseases of the colon, rec­
tum and anus, and it also succeeds, as few 
books do, in being a surgical textbook of such 
diseases. The illustrations by Lois Barnes are 
outstanding and generous to a fault. She has 
the knack of setting an uncluttered stage and 
then focusing the viewer’s attention on the 
point to be made. There is hardly a page 
without visual amplification of the text in the 
form of diagrams, photographs, tables and 
histologic photomicrographs. The text is clear 
and concise and the author usually makes it 
quite clear whether he is expressing personal 
views, literature consensus or another 
individual’s treasured opinion. He takes a very 
balanced approach to controversial areas and 
the reader is left feeling well informed on the 
various sides of such issues.
A serious test of any book is for a reader 
to turn to an area of personal interest and to 
see by how much the author is in agreement 
or otherwise. For example, I went to the sec­
tion dealing with alternative operative 
approaches to cancer of the rectum and I was 
not disappointed. The author discusses all the 
recommended approaches but he puts every­
thing into perspective with a level-headed dis­
cussion of indications and complications. The 
reader will also find up-to-date discussions of 
modern concepts in inflammatory bowel dis­
ease and newer operative techniques such as 
sphincter-saving procedures, pelvic pouches 
and Koch pouches. Each chapter is exhaus­
tively indexed and this book could form the 
basis of an entire libfary on the subject.
In summary, I have been unstinting in my 
admiration for this book, first because it is very 
good and second because of the personal stamp 
of the author. This book talks directly to 
general surgeons, specialist colorectal surgeons 
and surgical trainees, and they will recognize 
a wealth of experience and good judgement 
behind it.
Charles J. W right , mb, m sc , frcsc,
FRCS, FRCS(EDIN)
Professor of Surgery,
University of Saskatchewan,
Saskatoon, Sask.
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PRINCIPLES OF FRACTURE MANAGE­
MENT. Edited by C.S.B. Galasko. 234 pp.
Iilust. Churchill Livingstone, Edinburgh;
Academic Press Canada, Don Mills, Ont.,
1984. $47 .75 , paperbound. ISBN
0-443-02508-8.
A volume this size is obviously not intended 
to describe every fracture. It is, however, an 
up-to-date reminder of the well-proven basics 
of fracture treatment and of more recent 
developments. The general outline of fracture 
management is supplemented in each chapter 
by an extensive bibliography.
The first chapter on the biology of fracture 
repair by S.M.L. Nade details the sequence of 
events involving soft tissue and bone, includ­
ing the extent of necrosis of bone ends and 
fragments in fractures. The similarities and 
differences of healing fractures in cancellous 
and cortical bone are outlined. Nade correctly 
points out that angulation in a growing bone 
may be corrected but that joint malalignment 
at bone ends and rotation errors may not. The 
biologic advantages of loose-fitting intramedul­
lary nails and the extent of injury to the 
diaphyseal blood supply by reaming and tight- 
fitting nails are mentioned. Stable but not rigid 
fixation appears to be a worthy goal to pro­
mote union without osteopenia. “By and large 
treatment by closed methods, skilfully applied, 
causes less interference with the normal 
mechanism of bone healing than any other 
method.”
The second chapter, a prolonged description 
of self-evident factors in manipulation and cast 
immobilization of fractures, is made worth­
while by a careful description of the compli­
cations associated with this method of 
treatment.
The correct use of skeletal traction in the 
treatment of fractures of the femur and 
humerus is the treatment of choice in some cir­
cumstances. The use of the halo body cast is 
adequately explained but I was surprised to see 
odontoid fractures being treated by traction for 
12 weeks.
The chapter on fracture bracing by J. Angel 
details the techniques required and summarizes 
the results that proponents of this method have 
achieved.
The section on fixation of fractures without 
rigidity outlines conditions for which less-than- 
rigid fixation is expected to succeed. When 
rigid fixation is impossible, the judicious use 
of a small intramedullary nail, Kirschner wire 
or transfixion frame may allow satisfactory 
healing of fractures, and several examples are 
illustrated. Conditions in which unintentional 
lack of rigidity is liable to occur are also illus­
trated.
J. Rush prefers early closed intramedullary 
nailing of the fractures of the femur over 
delayed or open nailing since the risk of infec­
tion is lower and the periosteal blood supply 
is protected. Use of cross screws in either or 
both ends of a fenestrated nail avoids short­
ening of comminuted fractures and controls 
rotation in fractures nearer bone ends. The 
cross-pin method is not mentioned for treat­
ing tibial fractures.
C.E. Ackroyd provides a scholarly, well- 
documented explanation of the advantages and 
shortcomings o f and indications for rigid inter­
nal fixation. The alternative of external frame 
fixation in compound fractures is encouraged. 
Guidelines based on the patient’s status and 
future requirements, on the fracture itself, and 
on the experience and available surgical facil­
ities are set out in detail. The author points out 
that modern functional nonoperative methods 
have such great advantages in treating tibial 
fractures that rigid internal fixation should be 
used only for special cases. Causes of unsta­
ble and inadequate fixation and its diagnosis 
and management are also outlined.
The chapter on external fixation by D. 
Court-Brown and S.P.F. Hughes reports valu­
able firsthand experience in the design and use 
of single-bar and frame fixation. They correctly 
emphasize that its use should be discontinued 
as soon as its primary objective of preventing 
pin loosening has been achieved.
A pioneer in his field, R.O. Becker gives a 
detailed description of the historical evolution 
and the theory behind electrical stimulation of 
tissue for repair and regeneration. He feels it 
is precedent to limit the use of all electrical 
stimulation techniques to ununited fractures 
that have proved refractory to standard ortho­
pedic treatment and to avoid its use in preg­
nant women.
Galasko sets out the conditions of success­
ful treatment and the pitfalls of uncomplicated 
fractures in almost all areas o f the skeleton. 
The compilation of no less than 120 references 
relevant to the problems discussed makes fur­
ther detailed study easier wherever a good 
reference library is available.
The final chapter on the treatment o f com­
plicated fractures gives excellent guidelines for 
treating minor, moderate and severe compound 
fractures. The role an orthopedic surgeon may 
play when dealing with visceral injuries and 
damage to nerves and vessels is adequately dis­
cussed. Management of multiple injuries and 
the complications of pathologic fracture are 
well summarized and again a generous biblio­
graphy reinforces the author’s opinion.
Although it is the work of 12 writers, the 
book’s style is uniformly clear and readable. 
It is an up-to-date reminder of the well-proven 
principles of fracture treatment and of more 
recent developments. Its reading would also be 
an invaluable preparation for a fellowship oral 
examination.
J.P. M orea u , m d , frcsc, facs
Chief of Orthopedic Surgery,
Edmonton General Hospital,
11111 Jasper Ave.,
Edmonton, Alta.
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(^ Mefoxin
(sterile cefoxitin sodium, Frosst Std.)
ANTIBIOTIC
ACTION
in  v itro  stud ies dem onstra te  that the 
bactericidal action of cefoxitin, a cephamycin 
derived from cephamycin C, results from the 
inhibition of bacterial cell wall synthesis. 
Evidence suggests that the methoxy group in 
the l a  pos ition  is respons ib le  fo r the 
resistance of cefoxitin to degradation by 
bacterial beta-lactamases.
INDICATIONS AND CLINICAL USES
TREATMENT
The treatment of the following infections when 
due to susceptible organisms:
1 - In tra-abdom ina l in fec tions such as
peritonitis and intra-abdominal abscess
2 - G yne co log ica l in fe c tio n s  such as
endometritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and 
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t infections caused by
Staphylococcus aureus 
1 - Soft tissue infections such as cellulitis, 
abscesses and wound infections 
Appropriate culture and susceptibility studies 
should be performed to determ ine the 
susceptibility of the causative organism(s) to 
MEFOXIN*. Therapy may be started while 
awaiting the results of these tests, however, 
modification of the treatment may be required 
once these results become available. 
O rganism s pa rticu la rly  appropria te  fo r 
therapy with MEFOXIN* are:
Gram positive
Staphylococci, penicillinase producing and 
non-producing
Streptococci excluding enterococci 
Gram negative (beta-lactamase producing 
and non-producing strains)
E. coli
K l e b s i e l l a  s p e c ie s  ( in c lu d in g  K. 
pneumoniae)
Proteus, indole positive and negative 
Haemophilus influenzae 
Providencia species 
Anaerobes 
Bacteroides fragilis
MEFOXIN* may also be appropriate for the 
treatment of infections involving susceptible 
strains of both aerobic and anaerobic bacteria. 
Clinical experience has demonstrated that 
MEFOXIN* can be administered to patients 
who are also rece iv ing  c a rb e n ic ill in ,  
gentamicin, tobramycin, or amikacin (see 
PRECAUTIONS and ADMINISTRATION). 
Intravenous Administration 
The intravenous route is preferable fo r 
p a t ie n ts  w ith  b a c te re m ia , b a c te r ia l 
septicemia, or other severe or life-threatening 
infections, or for patients who may be poor 
risks because of lowered resistance resulting 
from  such d e b ilita t in g  c o n d it io n s  as 
malnutrition, trauma, surgery, diabetes, heart 
failure, or malignancy, particularly if shock is 
present or impending.
PROPHYLACTIC USE
MEFOXIN* may be administered periopera- 
tively (preoperatively, intraoperatively and 
postoperatively) to patients undergoing 
vaginal or abdominal hysterectomy and 
abdominal surgery when there is a significant 
risk of postoperative infection or where the 
occurrence of postoperative infection is 
considered to be especially serious.
In patients undergoing cesarean section, 
intraoperative (after clamping the umbilical 
cord) and postoperative use of MEFOXIN* 
may reduce the incidence of surgery related 
postoperative infections.
Effective prophylactic use depends on the 
time of administration. MEFOXIN* usually 
should be given one-half to one hour before 
the operation. Prophylactic administration 
should usually be stopped within 12 hours. It 
has been generally reported that continuing 
adm inistration of any an tib io tic  beyond 
*®Trademark
24 hours fo llow ing surgery increases the 
possibility of adverse reactions but, in the 
majority of surgical procedures, does not 
reduce the incidence of subsequent infection. 
If signs of postsurgical infection should 
appear, specimens for culture should be 
obtained for identification of the causative 
organism(s) so that appropriate therapy may 
be instituted.
CONTRAINDICATIONS
MEFOXIN* is contraindicated in persons who 
have shown hypersensitivity to cefoxitin or to 
the cephalosporin group of antibiotics. 
WARNINGS
Before therapy with MEFOXIN* is instituted, 
careful inquiry should be made to determine 
whether the patient has had previous hyper­
s e n s it iv ity  re a c t io n s  to  M EFO X IN *, 
cephalosporins, penicillins or other drugs. 
MEFOXIN* should be given with caution to 
penicillin-sensitive patients.
There is some clinical and laboratory evidence 
of partia l c ro ss -a lle rg e n ic ity  between 
cephamycins and the other beta-lactam 
antibiotics, penicillins and cephalosporins. 
Severe reactions (including anaphylaxis) have 
been reported  w ith  most beta-lactam  
antibiotics.
Pseudomembranous colitis has been reported 
with virtually all antibiotics. This colitis can 
range from mild to life threatening in severity. 
Antibiotics should therefore be prescribed 
with caution in individuals with a history of 
gastrointestinal disease, particularly colitis. It 
is important to consider a diagnosis of 
pseudomembranous colitis in patients who 
develop diarrhea in association with antibiotic 
use. While studies indicate that a toxin 
produced by Clostrid ium  diffic ile  is one 
primary cause of antibiotic-associated colitis, 
other causes should also be considered.
Any patient who has demonstrated some form 
of allergy, particularly to drugs, should receive 
antibiotics including MEFOXIN* with caution. 
If an allergic reaction to MEFOXIN* occurs, 
adm in is tra tion  o f the drug should be 
d iscontinued. Serious hypersens itiv ity  
reactions may requ ire  trea tm ent w ith 
epinephrine and other emergency measures. 
PRECAUTIONS
The total daily dosage should be reduced 
when MEFOXIN* is administered to patients 
with transient or persistent reduction of 
urinary output due to renal insufficiency (see 
DOSAGE AND ADMINISTRATION) because 
high and p ro longed  serum a n tib io tic  
concentrations can occur from usual doses.
In patients treated with MEFOXIN* a false­
positive reaction to glucose in the urine may 
occur with Benedict’s or Fehling’s solutions 
but not with the use of specific glucose 
oxidase methods.
Using the Jaffe Method, falsely high creatinine 
values in serum  may occu r if  serum 
concentrations of cefoxitin exceed 100 j/g/mL. 
Serum samples from patients treated with 
MEFOXIN* should not be analyzed for 
creatinine if withdrawn within two hours of 
drug administration.
Increased nephrotoxicity has been reported 
following concom itant administration of 
c e p h a lo s p o rin s  and a m in o g ly c o s id e  
antibiotics.
The safety of MEFOXIN* in the treatment of 
infections during pregnancy has not been 
es tab lished . If the  a d m in is tra tio n  of 
MEFOXIN* to pregnant patients is considered 
necessary, its use requires that the anticipated 
benefits be weighed against possible hazards 
to the fetus. Reproductive and teratogenic 
studies have been performed in mice and rats 
and have revealed no evidence of impaired 
fertility or harm to the fetus due to MEFOXIN*. 
Cefoxitin has been observed in the milk of 
nursing mothers receiving the drug.
Prolonged use of MEFOXIN* may result in the 
overgrowth of non-susceptible organisms. 
Repeated evaluation of the patient’s condition 
is essential and if super-infection occurs 
during therapy, appropriate measures should 
be taken. Should an organism become 
resistant during antibiotic therapy, another 
antibiotic should be substituted.
In children 3 months of age or older, higher 
doses of MEFOXIN* (100mg/kg/day and 
above) have been associated w ith  an 
increased incidence of eosinophilia and 
elevated SGOT.
ADVERSE REACTIONS
MEFOXIN* is generally well tolerated. Adverse 
reactions rare ly  required cessation of 
treatment and usually have been mild and 
transient.
Local Reactions
T h ro m b o p h le b it is  has occu rred  w ith 
intravenous administration. Some degree of 
pain and tenderness is usually experienced 
after intramuscular injections using water. 
Induration has occasionally been reported. 
Allergic
M aculopapular rash, urticaria, pruritus, 
eosinophilia, fever and otherallergic reactions 
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can 
appear during or after antibiotic treatment. 
Nausea and vomiting have been reported 
rarely.
Blood
T ra n s ie n t e o s in o p h ilia , leu ko p en ia , 
neutropenia, hemolytic anemia, and thrombo- 
cy to p en ia  have been reported. Some 
individuals, particularly those with azotemia, 
may develop positive direct Coombs tests 
during therapy with MEFOXIN*.
Liver Function
Transient elevations in SGOT, SGPT, serum 
LDH, and serum alkaline phosphatase have 
been reported.
Kidney
Elevations in serum creatinine and/or blood 
urea nitrogen levels have been observed. As 
with the cephalosporins, acute renal failure 
has been reported rarely. The role of 
MEFOXIN* in changes in renal function tests 
is d i f f ic u l t  to  assess, s ince fa c to rs  
predisposing to prerenal azotemia or to 
impaired renal function have often been 
present.
TREATMENT OF OVERDOSE
Other than general supportive treatment, no 
specific antidote is known. MEFOXIN* can be 
eliminated by dialysis in patients with renal 
insufficiency.
DOSAGE AND ADMINISTRATION
MEFOXIN* may be administered in tra­
venously or intramuscularly when required. 
(See complete monograph for full details on 
ADMINISTRATION and RECONSTITUTION.) 
TREATMENT DOSAGE 
Adults
The usual adult dosage is 1 g or 2g of 
MEFOXIN* every 6 to 8 hours. Dosage and 
route of administration should be determined 
by severity of infection, susceptibility of the 
causative organisms, and condition of the 
patient. The usual adult dosages are shown in 
the Table below.
Usual Adult Dosage
Type o f Daily  
of infection Dosage
Frequency  
and Route
Uncomplicated 
forms* o f in ­
fections such as 
pneumonia, 
urinary tract 
infection, soft 
tissue in fection
3-4 g 1 g every 6-8 h 
I.V. or I.M.
Moderately 
severe or severe 
in fections
6-8 g 1 g every 4 h 
or
2 g every 6-8 h I.V.
Infections 
com m only 
needing anti­
biotics in higher 
dosage (e.g. gas 
gangrene)
12 g 2 g every 4 h
or
3 g every 6 h I.V.
'I n c lu d in g  p a t ie n ts  
a b s e n t o r  u n lik e ly
in w h o m  b a c te re m ia  is
Therapy may be started while awaiting the 
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic 
streptococcal infections should be maintained 
for at least 10 days to guard against the risk of 
rheumatic fever or glomerulonephritis. In 
staphylococcal and other infections involving 
a collection of pus, surgical drainage should 
be carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN* may be used in patients with 
reduced renal function but a reduced dosage
should be employed and it is advisable to 
m onitor serum levels in patients w ith severe 
impairment.
In adults w ith renal insufficiency, an initial 
loading dose of 1 g to 2 g should be given. 
A f te r  a lo a d in g  d o se , th e  fo l lo w in g  
recommendations fo r maintenance dosage 
may be used as a guide:
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RENAL CREATININE
FUNCTION CLEARANCE DOSE FREQUENCY
mL/m in
Mild
impairment 50-30 1-2 g every 8-12 h
Moderate
impairment
Severe
29-10 1-2 g every 12-24 h
impairment 9-5 0.5-1 g every 12-24 h
Essentially 
no function <5 0.5-1 g every 24-48 h
In the patient undergoing hemodialysis, the 
loading dose of 1 - 2 g should be given after 
each hemodialysis, and the maintenance dose 
should be given as indicated in the Table 
above.
Neonates (Including Premature Infants), 
Infants and Children (See WARNINGS for 
Neonates under ADMINISTRATION in the 
complete monograph.)
Premature Infants 
with Body Weights 
Above 1500 g 20-40 m g /k g  every 12 h I V.
Neonates
0 - 1 week o f age
1- 4 weeks o f age
20-40 m g /k g  every 12 h I.V. 
20-40 m g /k g  every 8 h I.V.
Infants
1 m on th  to  2 years 
o f age
20-40 m g /k g  every 6 h or 
every 8 h I.M. o r I.V.
Children 20-40 m g /k g  every 6 h or 
every 8 h I.M. o r I.V.
In severe infections, the tota l daily dosage in 
in fa n ts  and ch ild ren  may be increased to 
200 m g/kg, but not to  exceed 12 g per day. 
MEFOXIN” is not recommended for the ther­
apy of meningitis. If meningitis is suspected, 
an appropriate antibiotic should be used.
A t p resen t the re  is in s u ff ic ie n t da ta  to 
recommend a specific dosage fo r children 
with impaired renal function. However, if the 
administration of MEFOXIN* is deemed to be 
essential the dosage should  be m odified 
consis ten t w ith  the recom m endations for 
adults (see Table above).
PROPHYLACTIC USE
For p rophylactic use, a three-dose regimen of 
MEFOXIN is recommended as follows: 
Vaginal or abdominal hysterectomy and 
abdominal surgery
2 g a d m in is te re d  in t r a m u s c u la r ly  or 
in t r a v e n o u s ly  ju s t  p r io r  to  s u rg e ry  
(approximately one-half to one hour before 
initial incision).
The second and th ird 2g  doses should be 
administered at 2 -6hour intervals after the 
initial dose.
Cesarean Section
The firs t dose of 2 g should be administered 
intravenously as soon as the um bilical cord 
has been clamped. The second and third 
2 g doses should be given intravenously or 
intramuscularly four hours and eight hours 
after the first dose.
AVAILABILITY
MEFOXIN” (sterile cefoxitin sodium, Frosst 
Std.) is supplied as sterile powder in boxes of 
10 vials:
No. 3356 1 g cefoxitin as sodium salt 
No. 3357 2 g cefoxitin as sodium salt
Storage
MEFOXIN* in the dry state should be stored 
below 30° C.
PRODUCT MONOGRAPH AVAILABLE 
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GENERAL SURGEON: ON
Required for surgical group.
Full-time employment (Toronto 
ar ea)
Ideal working conditions.
All replies will be treated in con­
fidence.
Reply:
Box S112 CJS
-S 8 6 -1 1
ICU RESEARCH FELLOW: -  Ewart Angus Inten- 
sive Care Unit, The Wellesley Hospital. Available 
July 1, 1986 for a onfe year period in an academic 
Medical-Surgical Unit. Research areas include clin­
ical epidemiology of ICU care, nutrition and 
respiratory muscle physiology. Reply to: Dr. I.M. 
Fraser, Director EAICU, 247 The Jones Bldg., 160 
Wellesley St. E., Toronto, ON M4Y 1J3 (416) 
926-7747. -S 8 6 -04
HEAD OF SURGERY, REGINA: SK -  The College 
of Medicine, University of Saskatchewan, invites 
applications for the position of Head of the Regi­
na section, Department of Surgery. The success­
ful candidate will also be Head of the Department 
of Surgery at the Plains Health Centre in Regina, 
and w ill be responsible for the undergraduate and 
postgraduate teaching programs there. The aca­
demic rank w ill be commensurate with the suc­
cessful candidate's qualifications and experience. 
In accordance w ith Canadian immigration require­
ments, this advertisement is directed to Canadi­
an citizens and permanent residents. Interested 
candidates should send a letter of application, cur­
riculum vitae and the names of three referees to: 
Dr. C.J. Wright, Department of Surgery, Univer­
sity Hospital, Saskatoon, SK S7N 0W0. Closing 
date for applications is April 15, 1986.-S86-13
ADVANCES AND CONTROVERSIES IN VASCU­
LAR SURGERY -  1986: -  May 27, 28. The Con­
ference will be held at Mount Sinai' Hospital, 
Toronto, Ontario and will be of interest to vascu­
lar and general surgeons. Category One AM A 
credits. For further information contact: Continu­
ing Education, University of Toronto, Room 116, 
FitzGerald Building 150 College St., Toronto, ON 
M5S 1A8. Tel.: (416) 978-2718. -S86-10
TRANSPLANTATION SURGEON: ON -  The
University of Toronto seeks a surgeon to direct its 
multiorgan transplant program at one of its univer­
sity based hospitals. Full training in general sur­
gery plus formal clinical training in multiorgan 
transplantation surgery is required. The success­
ful candidate w ill also be expected to have ob­
tained research training which will enable him/her 
to  conduct an independent research program and 
interact w ith  other faculty in the areas of trans­
plant immunology and infectious diseases relat­
ed to  transplantation. This w ill be an annual ap­
pointment, at the rank of Assistant Professor. 
Salary to  commensurate w ith qualifications and 
experience. Qualifications: MD, FRCSC. Effective 
date of appointment: Open. Closing date o f appli­
cations: February 28, 1986. Enquiries, curriculum 
vitae and three letters of reference should be sent 
to : Dr. R.M. Stone, Surgeon in Chief, Toronto 
Western Hospital, 399 Bathurst St., Toronto, ON 
M5T 2S8. In accordance w ith  Canadian Immigra­
tion requirements, this advertisement is directed 
to  Canadian citizens and permanent residents.
-S86-03
5lO M t
P.0. BOX 1005, POINTE-CLAIRE 
DORVAL, QUEBEC H9R 4P8
PROFESSOR OF SURGERY (OPHTHALMOLO­
GY): NF — Applications are invited for the po­
sition of Professor of Surgery (Ophthalmology) 
in the Medical School, Memorial University of 
Newfoundland. The successful candidate for 
th is  appointment w ill also act as chief o f the 
clinical ophthalmology services in the Health 
Sciences Centre, St. John's. The medical 
school and hospital have targeted ophthalmol­
ogy as an area of high priority for academic 
and clinical development. The post would be 
o f particular interest to a physician who w ish­
es to  plan and oversee the expansion o f a 
university based ophthalmology service in clin­
ical, teaching and research areas. Interested 
physicians who would like to make application 
or to  seek further information should contact 
the Chairman of the Search Committee: Wil­
liam Pryse-Phillips, MD, FRCP, FRCPC, Health 
Sciences Centre, Memorial University of New­
foundland, St. John's NF A1B 3V6. —S86-09
CERTIFIED OBSTETRICIAN/GYNECOLOGIST: YK
— (Permanent position to  commence immediate­
ly but short term locums will be accepted.) Re­
quired to join ten family physician group located 
in Whitehorse, servicing a population of 25 000 
including 27 doctors. Must have LMCC and Cana­
dian fellowship. Colposcopy and ultrasound a 
definite asset. Excellent location for someone who 
enjoys the outdoors. A ttractive northern fee 
schedule. Please write complete resume, or te le­
phone: J.L. Pollock, Business Manager, W hite­
horse Medical Services Limited, 406 Lambert St., 
Whitehorse, YK Y1A 1Z7. Tel.. (403) 667-4421.
-S 8 6 -0 8
ALBERTA CHILDREN S HOSPITAL 
CHILD HEALTH CENTRE
PAEDIATRIC
SURGEON
Alberta Children's Hospital, 
Calgary, invites applica­
tions from paediatric 
general surgeons. Both ge­
ographic full-time and clin­
ical affiliation with the 
University of Calgary Med­
ical School available.
Candidates should be eligi­
ble for certification by the 
Royal College of Physicians 
and Surgeons of Canada 
and for licensure by the 
College of Physicians and 
Surgeons of Alberta. 
Interested surgeons are re­
quested to submit a curric­
ulum vitae and the names 
of three references to: 
Please apply to:
Dr. S.T. Myles 
Chief of Staff — Surgery 
Alberta Children’s Hospital 
1820 Richmond Road S.W.
Calgary, Alberta 
T2T 5C7
Orthopedic Surgeons
OUTSTANDING PRACTICE 
OPPORTUNITIES 
Midwest U.S.A.
You know what Humana stands for: quality health care 
that’s second to none. That’s exactly why we are assisting 
these private practice physicians in their search for new 
associates.
One practice opportunity is to join a board certified Ortho­
pedic Surgeon with a successful, state-of-the-art Ortho­
pedic and Sports Medicine practice. Training in hand 
surgery is strongly preferred, however this physician will 
assist financially with a hand fellowship. The second 
practice opportunity is to join a multi-specialty group. 
Both practices are affiliated with a ten-year-old, ultra­
modern Humana hospital located in the midwest. The 
hospital is already equipped for orthopedic surgery and 
will purchase any additional equipment that is required.
For specific information, send your curriculum vitae or 
call: John Hollander, Director o f Professional Relations, 
Humana Inc., Dept. Z-3, The Humana Building, 500 
West Main, Louisville, KY 40201-1438. COLLECT: 
502/580-3559.
CHAIRMAN, 
DEPARTMENT OF 
INTENSIVE CARE
The General Hospital, St. John's, Newfoundland is 
seeking an experienced individual to chair its Depart­
ment of Intensive Care. The unit is located in a modern 
health sciences centre which also houses The Memori­
al University Faculty of Medicine. It accommodates 
both medical and surgical patients.
Applicants should hold a fellowship from the Royal 
College of Physicians and Surgeons of Canada and 
have demonstrated administrative ability.
Details regarding financial arrangements and an ap­
propriate University appointment can be obtained from 
the Chairman of the Search Committee to whom in­
quiries should be addressed:
Dr. David Hawkins 
Health Sciences Centre 
St. John's, Newfoundland 
A1B 3V6
(709) 737-6551 -S86-12
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Hopital General-
St. Boniface-General Hospital
409 Tache Avenue
W INNIPEG, M ANITOBA R2H 2A6
HEAD, DEPARTMENT OF SURGERY 
ST. BONIFACE GENERAL HOSPITAL
The University of Manitoba and St. Boniface General Hospital have 
an opening for this position which includes a geographic full-time ap­
pointment in the Department of Surgery, University of Manitoba and 
provides opportunity for private practice.
The hospital is a fully affiliated teaching hospital of the University 
of Manitoba. Owned and operated by the Grey Nuns of the Province 
of Manitoba, this 850-bed general hospital has ten clinical depart­
ments with geographic full-time heads. In addition to a broad com­
munity base, the hospital provides tertiary care services with 
particular excellence in several areas. The hospital provides major 
services and is the geographic base for the University head of family 
medicine and geriatric medicine. The new Youville Research Institute 
offers ample space and facilities to support major research en­
deavours. The department has twenty faculty members based in fa­
cilities adjacent to the hospital.
The successful candidate will be an outstanding academic surgeon 
with proven clinical and medical leadership qualities who as depart­
ment head will foster excellence in patient care, teaching, and espe­
cially in research. Experience in recruitment and development of 
medical staff will be evident from the curriculum vitae and reference. 
Salary and rank commensurate with experience and ability.
The position is open to both men and women. In accordance with 
Canadian immigration requirements this advertisement is directed to 
Canadian citizens and permanent residents.
Written nominations or applications for the position should be accom­
panied by a curriculum vitae and three references and submitted by 
March 31, 1986 to: Dr. R.J.W. Blanchard —  Chairman, Department 
of Surgery, University of Manitoba, c/o Room A1160, St. Boniface 
General Hospital, 409 Tache Avenue, Winnipeg, Manitoba. R2H 2A6
-S 86-14
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